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ABSTRACT 
	  
    Secreted phosphatidylinositol-specific phospholipase Cs (PI-PLCs) are often virulence 
factors in pathogenic bacteria. Understanding how these enzymes interact with target 
membranes may provide novel methods to control bacterial infections. In this work, two 
typical PI-PLC enzymes, from Bacillus thuringiensis (Bt) and Staphylococcus aureus 
(Sa), were studied and their membrane binding properties were examined and correlated 
with enzymatic activity.  
    BtPI-PLC is kinetically activated by allosteric binding of a phosphatidylcholine (PC) 
molecule. MD simulations of the protein in solution suggested correlated loop and helix 
motions around the active site could regulate BtPI-PLC activity. Vesicle binding and 
enzymatic studies of variants of two proline residues, Pro245 and Pro254, that were 
associated with these motions showed that loss of the correlated motions between the two 
halves of PI-PLC were more critical for enzymatic activity than for vesicle binding. 
Furthermore, loss of enzyme activity could be rescued to a large extent with PC present 
	  in a vesicle. This suggests that binding to PC changes the enzyme conformation to keep 
the active site accessible.  
    SaPI-PLC shows 41.3% sequence similarity with BtPI-PLC but has very different ways 
its activity is regulated. While it is kinetically activated by PC it does not in fact bind to 
that phospholipid. Enzymatic and membrane interaction assays showed that SaPI-PLC 
has evolved a complex, apparently unique way to control its access to PI or GPI-anchored 
substrate. (i) An intramolecular cation-π latch facilitates soluble product release under 
acidic conditions without dissociation from the membrane. (ii) There is a cationic pocket 
on the surface of enzyme that likely modulates the location of the protein. (iii) 
Dimerization of protein is enhanced in membranes containing phosphatidylcholine (PC), 
which acts not by specifically binding to the protein, but by reducing anionic lipid 
interactions with the cationic pocket that stabilizes monomeric protein. SaPI-PLC activity 
is modulated by competition between binding of soluble anions or anionic lipids to the 
cationic sensor and transient dimerization on the membrane depleted in anionic 
phospholipids. This protein also served as a way to test the hypothesis that a cation-π box 
provides for PC recognition site. This structural motif was engineered into SaPI-PLC by 
forming N254Y/H258Y. This variant selectively binds PC-enriched vesicles and the 
enzyme binding behavior mimics that of BtPI-PLC. 
    Itaconic acid (ITA) is a metabolite synthesized in macrophages and related cell lines 
by a cis-aconitate decarboxylase (cADC). cADC activity is dramatically increased upon 
macrophage stimulation. In this work, the cell line RAW264.7 was used to show that 
cADC activity upon stimulation requires de novo protein synthesis. MS analyses of 
	  partially purified RAW264.7 protein extracts from stimulated cells show a large increase 
for immunoresponsive gene 1 protein (IRG1) and siRNA knockdown of the IRG1 
reduces cADC activity upon stimulation. Suspected active site residues of IRG1 were 
identified by mutagenesis studies of the recombinant protein based on a homology 
structure model of fungal cADC. The cloning and overexpression of this enzyme should 
help clarify the cofactor-independent decarboxylation mechanism of this mammalian 
enzyme as well as open up future studies into the specific role of ITA in the mammalian 
immune system and cancers. 
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1.1 Bacterial Phosphatidylinositol-specific Phospholipase C (PI-PLC) 
1.1.1 Phospholipids  
    The bilayer matrix of cellular membranes, formed by amphipathic lipids, enables the 
regulation of cell segregation, cell division, intracellular membrane trafficking, protein 
aggregation and dissociation. Specific lipids also play important roles in signaling 
pathways [1]. There are three major classes of amphipathic lipids: phospholipids, 
glycolipids, and steroids. The lipid composition of different membranes varies throughout 
the cell, but phospholipids are usually the most abundant class, comprising 20-80% of the 
membrane lipid mass [1,2]. In eukaryotic membranes, the major phospholipids are the 
glycerophospholipids: phosphatidylcholine (PC), phosphatidylethanolamine (PE), 
phosphatidylserine (PS), phosphatidylinositol (PI), phosphatidylglycerol (PG) and 
phosphatidic acid (PA) (Fig. 1-1) [2]. Phospholipids are	   composed of a hydrophilic 
headgroup and hydrophobic acyl chains.	   The different polar head groups linked by the 
glycerophosphate moiety generate phospholipids that are either zwitterionic or anionic 
(Fig. 1-1, bottom table).  
    Phospholipids can form a variety of aggregates in aqueous solution (Fig. 1-2) because 
of their amphipathic character [3]. At the air-solution interface, lipids form monolayers 
with the polar headgroups in the aqueous solution and the acyl chains in the more 
hydrophobic air. The structures of phospholipid aggregates differ based on different acyl 
chain lengths and lipid concentrations [4]. For all lipids there is a threshold concentration 
(termed the critical micelle concentration or CMC) below which they exist as monomers 
in the aqueous phase. If the acyl chains are moderately long, the molecules aggregate and 
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form bilayer vesicles. Sizes of vesicles range from 20 nm to 5 µm in diameter. When the 
lipids are hydrated the large vesicles encapsulate many other vesicles. Unilamellar 
vesicles, simpler models for cell membranes, require energy to form from than 
multilamellar vesicles. Small unilamellar vesicles (SUVs) are an easily prepared model 
system that are highly curved with 20–50 nm diameters; these are easily prepared by 
sonication [5]. Many exogenous factors, for example metal ions (Ca2+) or lipid binding or 
cleavage proteins (phospholipase), can trigger vesicle fusion [6]. If acyl chain lengths are 
short (e.g., dihexanoyl-phosphatidylcholine, diC6PC) or the polar head groups are very 
large (e.g., ganglioside GM1) the lipid molecules aggregate to form micelles. Micelles do 
not have an encapsulated aqueous compartment. Both the micelle and vesicle systems are 
widely used as models to study protein-membrane interactions and other cell processes 
that have membrane bound constituents. 
1.1.2 Enzymatic Mechanism of PI-PLCs  	  	  	  	  Phospholipases catalyze the hydrolysis of the four ester linkages of phospholipids to 
generate either two different lipids or a new lipid and a polar molecule. These enzymes 
are classified into four families (PLA, PLB, PLC and PLD) depending on the ester bond 
whose cleavage they catalyze (Fig. 1-3A). PLA1 and PLA2 specifically hydrolyze the 
fatty acyl ester bond at the sn-1 and sn-2 position of the glycerol moiety; PLB enzymes 
possess the ability to sequentially remove both of the sn-1 and sn-2 acyl chains. PLC 
enzymes catalyze the cleavage of glycerophosphate ester bond and PLD cleaves terminal 
phosphodiester bond.  
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Figure 1-1. General phospholipid structure with head group list in bottom table. 
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Figure 1-2.  Different types of phospholipid aggregation at air-solution interface and in 
the solution. 
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    Phosphatidylinositol (PI) is a relatively minor phospholipid component located in the 
cytosolic side of eukaryotic plasma membranes [2]. PI molecules phosphorylated on C3, 
C4 and C5 of the inositol ring, the phosphoinositides (PIPn), are important in signaling 
pathways with several of these specific second messengers [7,8]. Phosphatidylinositol-
specific phospholipase C (PI-PLC) enzymes are a large family of phospholipases that 
specifically catalyze the hydrolysis of polar head group of phosphoinositide substrates. 
The substrates for bacterial PI-PLC enzymes are PI and glycosylphosphatidylinositol 
(GPI), while most mammalian enzymes prefer PIPn over PI. The scheme for bacterial PI-
PLC enzymatic mechanism is shown in Fig. 1-3B. These enzymes use a general acid and 
base mechanism. Bacterial PI-PLC cleaves its substrate via an intramolecular 
phosphotransferase reaction on the PI moiety to form a cyclic inositol phosphate 
molecule (inositol 1,2-cyclic phosphate, cIP) and diacylglycerol (DAG) [9]. The second 
step carried out by the enzyme is a phosphodiesterase reaction that further hydrolyzes the 
water-soluble intermediate cIP to inositol-1-phosphate (I-1-P) [10,11].  
     Bacterial PI-PLC is a virulence factor produced and secreted by many Gram-positive 
bacteria [12], including the pathogens Bacillus cereus, Bacillus thuringiensis, Bacillus 
anthracis, Listeria monocytogenes, Listeria ivanovii, Staphylococcus aureus, Clostridium 
novyi, Rhodococcus equii, and also non-pathogenic species Listeria seeligeri, 
Streptomyces antibioticus, Cytophaga sp., and some strains of lactic acid bacteria (LAB) 
such as Lactobacillus rhamnosus [12-18]. Along with the cleavage of nonphosphorylated 
PI, most of the PI-PLCs secreted by extracellular pathogens (e.g. Bacillus and 
Staphylococcus strains) can also cleave GPI anchors [12] to release proteins that are 
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tethered to the exterior surface of mammalian cell membrane by these anchors. This 
process causes cellular damage and one of the products, DAG, can translocate across the 
bilayer [19] to interfere with intracellular signaling processes [20].  
    B. thuringiensis is an insect pathogen, and earlier work showed that an avirulent 
mutant lacking both the broad range and PI-specific PLC activities was much less potent 
in killing cells [21]. This indicates the PI-PLC enzyme can have significant roles in 
regulating the virulence of pathogens. S. aureus is known to cause a broad range of 
infections in humans and is commonly found in skin infections and abscesses. A S. 
aureus infection can lead to toxemia and lethal bacteremia [20,22]. Secreted S. aureus PI-
PLC may aid in colonization and replication of the microorganism by generating DAG 
from GPI-anchored proteins. The production of this PI-PLC was shown to be up-
regulated upon infection in community-associated methicillin-resistance of this bacterium 
[23]. This kind of PI-PLC usually exhibits significant activity toward PI in an acidic 
environment [24].  
1.1.3 Mammalian and Bacterial PI-PLC Structures 
    At present, there are six families of mammalian PI-PLC enzymes with thirteen distinct 
isoforms: PLC-β(1–4), PLC-γ(1–2), PLC-δ(1,3,4), PLC-ε, PLC-ζ, and PLC-η (Fig. 1-4) [25]. 
These PLC isoforms share four EF-hand motifs (usually associated with specific Ca2+ 
binding), the X and Y catalytic domains, a C-terminal C2 domain for calcium-dependent 
membrane targeting and a N-terminal PH domain (which is not present in PLC-ζ) to 
localize the enzymes to their substrate in the membrane and also to interact with other 
signaling components [26,27].  
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Figure 1-3. The enzymatic mechanism of phospholipases. (A) Cleavage sites for 
phospholipases are indicated. (B) The mechanism of the two sequentially reactions 
catalyzed by bacterial PI-PLC is shown. 
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Figure 1-4. Domain organization of PI-PLC isoforms.  
 
 
 
 
 
 
 
 
 
  
   PH!
           X                     Y!
SH2      SH2      SH3!
PH domain   EF-hands           Catalytic domain             C2 domain      PDZ-binding!
X/Y linker!
CDC25! RA1     RA2!
          !
PLC-β 
(1-4) 
 
 
 
 
 
PLC-γ 
(1, 2) 
 
PLC-δ 
(1, 3, 4) 
 
PLC-ε 
 
 
PLC-ζ 
 
 
PLC-η 
(1, 2) 
 
Bacterial 
PI-PLC           !
	  	  10 
    In contrast to their multi-domain eukaryotic relatives, the bacterial PI-PLCs contain 
only the catalytic domain (homologous to the X-Y domains of mammalian PLC 
enzymes) that is responsible for both catalysis and membrane binding. Although PI-PLC 
catalytic domains are members of the triosephosphate isomerase (TIM) barrel (α/β)8 
superfamily [28,29] they lack a number of hydrogen-bonding interactions between β-
strands, resulting in a relatively open β-barrel [28,29] (Fig. 1-5B). The conserved active 
site is located at the C-terminal end of the β-strands in the barrel [28,29], but most of the 
residues that interact with membranes and control lipid binding in the bacterial enzymes 
are located in the less conserved and more mobile surface helices and loops.  
    The crystal structures of B. thuringiensis PI-PLC (Y247S/251S) and B. cereus PI-PLC 
are almost identical and highly similar to the catalytic domain of PLC-δ1 [28,30]. 
Sequence similarity among the different bacterial PI-PLC enzymes is not exceptionally 
high. For example, S. aureus PI-PLC shows 41.3% identity with B. thuringiensis PI-PLC 
(Fig. 1-5A) in sequence. However, most of the secondary structure superimposes well 
with the Bacillus enzymes. Two key structural features of the bacterial enzymes are short 
helix B (containing Trp47 in Bacillus PI-PLC and Trp45 in S. aureus PI-PLC) and a 
mobile rim loop (containing Trp242 in Bacillus PI-PLC and Phe249 in S. aureus PI-
PLC), both of which have been implicated in membrane binding [31-34]. In S. aureus PI-
PLC, helix B is one residue longer than in the B. cereus structures and has two lysine 
residues to create a more positively charged feature. This can form an extended positively 
charged region when combined with the other positively charged residues in the barrel 
rim. The disposition of the key hydrophobic residue in the mobile rim loop can adopt 
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different orientations. For example, Phe249 in S. aureus PI-PLC is pointed outward and 
toward the membrane interface compared with the homologous side chain (Trp242) in 
Bacillus enzymes. In the latter the tryptophan residues are pointed away from the 
membrane interface. This stresses the flexibility of the rim loop [35].  
1.1.4 Interfacial Activation of Bacterial PI-PLCs 
    The kinetic property ‘interfacial activation’ is observed for many peripheral enzymes, 
including phospholipases. ‘Interfacial activation’ is the sharp increase in enzyme (in this 
case phospholipase) activity when the substrate is presented in an interface as opposed to 
a monomer molecule [36]. For the catalytic process at interfaces, the enzyme in the 
solution initially binds to the interface consisted by aggregated substrate. The interfacial-
associated enzyme likely undergoes some conformational changes that allow substrate to 
bind into the active site. Once the substrate is cleaved, the enzyme releases the products 
to regenerate free enzyme [37]. The overall rate of the catalytic reaction is thus affected 
not only by the kinetics of interfacial catalysis but also by the kinetics of binding between 
enzyme and interface. The concentration of substrate dispersed at an interface is 
characterized by both the bulk concentration and two-dimensional local concentration, 
with the latter often more important for the overall kinetic rate.  
     Several of the bacterial PI-PLC enzymes exhibit a specific interfacial activation by the 
zwitterionic phospholipid PC. The presence of this non-substrate phospholipid leads to PI 
cleavage with an enhanced kcat and reduced apparent Km toward aggregated PI compared 
to monomeric PI [10, 38-41]. Since PI at a surface is a better substrate, the kinetics of 
bacterial PI-PLC enzymes is usually explored in micelle or vesicle systems.   
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Figure 1-5. The comparison of sequences and structures of two typical bacterial PI-PLCs. 
(A) Sequence alignment of B. thuringiensis PI-PLC (Bt) and S. aureus PI-PLC (Sa). 
Active site residues – the two histindines are highlighted in red and other key residues are 
highlighted in yellow for conserved ones and in cyan for less conserved ones. (B) 
Structure of bacterial PI-PLC enzymes: (left) B. thuringiensis PI-PLC (PDB 1PTD) and 
(right) S. aureus PI-PLC (PDB 3V18). The S. aureus structure was obtained at pH 7.4. 
There is a structural change at lower pH values where an intramolecular Phe249 π/His258 
cation latch is formed. 
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    Adding more nonsubstrate lipids dilutes the interfacial substrate concentration. If the 
total concentration of substrate is constant but its surface concentration decreases, 
enzyme specific activity often decreases. This phenomenon is called “surface dilution 
inhibition” [42,43]. The bacterial PI-PLCs also exhibit “scooting mode catalysis”, where 
enzyme completes several rounds of substrate turnover at the substrate interface before 
dissociating from the particle [41]. Scooting mode catalysis becomes more difficult as the 
surface concentration of the substrate decreases. 
    B. thuringiensis PI-PLC, like other PI-PLC enzymes, catalyzes the specific cleavage of 
PI in two steps. The unique property of B. thuringiensis (and B. cereus) enzyme is that 
both of these steps are specifically activated by PI-PLC binding to PC interfaces, either in 
a micelle form or vesicle matrix. Two critical tryptophan residues, Trp47 in the helix B 
region and Trp242 in a disordered loop (Fig. 1-5B, left), are involved in the PC activation 
[31,32]. Considering the homodimer crystal structure of a B. thuringiensis PI-PLC mutant 
(W47A/W242A), the wild-type PI-PLC enzyme was suggested to be activated by 
forming a dimer at PC interface [44]. In the W47A/W242A structure, the major 
contribution to stabilizing the symmetric dimer interface is a central swath of aromatic 
residues (the ‘Tyr strip’ in Fig. 1-5B, left). These side chains are arranged in a quasi-
herringbone pattern. The W47A/W242A dimer structure was only observed in this 
interfacially impaired mutant, so that whether or not the protein does indeed form a dimer 
at membrane surfaces is unclear. Mutagenesis studies of these Tyr residues clearly 
showed a loss of activity and membrane binding affinity [30]. Since initially there was no 
information on where, if at all, a discrete PC molecule would bind to the PI-PLC, the 
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proposed model for interfacial activation of B. thuringiensis PI-PLC suggests that the 
enzyme is a monomer in solution with an intact helix B to ensure Trp47 and Trp242 at 
the correct position for the initial binding. Helix B is then disrupted to assist in the active 
dimer forming at interface upon binding to the membrane [33]. However, more recent 
work combining high-resolution field-cycling 31P NMR relaxation experiments [34] with 
mutagenesis studies [30] showed that there was a discrete binding site for substrate and a 
separate one for a tightly bound PC (activator). The specific PC binding site was 
suggested to be rich in tyrosines that could form choline cation/Tyr π boxes or 
sandwiches. The tyrosine strip (Tyr246-247 and Tyr251 in Fig. 1-5B, left) near the 
membrane interface was proposed to have the PC recognition motif. However, all the 
evidence for the dimerization model and PC binding pocket were indirect requiring 
further experiments to validate one or both of these hypotheses. 
     The Bacillus PI-PLC enzymes are activated by strong binding to PC [10,34,38,39]. 
However, this is not a universal mechanism of interfacial activation for bacterial PI-
PLCs. The enzyme from Listeria monocytogenes is activated by many noncharged or 
zwitterionic amphiphiles in a somewhat nonspecific fashion. For that enzyme, the 
diluting amphiphile prevents cationic enzyme/anionic lipid aggregation and the resulting 
sequestration of the enzyme in a nonproductive state [39]. This nonspecific activation 
mechanism also likely reduces penetration of the highly cationic protein into a negatively 
charged bilayer [10,38,39]. Consistent with this mode of PC activation, L. monocytogenes 
PI-PLC has very low affinity for PC small unilamellar vesicles (SUVs) but very high 
affinity for anionic phospholipid interfaces. When I started there was limited knowledge 
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about the interfacial activation of PI-PLC from S. aureus. 
1.1.5 Lipid Recognition Specificity 
    Cells are dynamic systems where spatially and temporally localized signaling 
facilitates responses to the local environment. Variations in lipid composition between 
different organelles and between organelles and the plasma membrane [1] provide spatial 
localization of peripheral membrane proteins that recognize specific lipids. For example, 
a number of proteins specifically recognize rare, anionic phosphoinositides with 
stereospecific recognition of the phosphoinositide headgroups [45,46]. For pleckstrin 
homology, PROPPIN β propellers, and other domains, stereospecificity often depends on 
a network of hydrogen bonds between the phosphoinositide headgroup and conserved 
basic residues [45-47]. Similarly, proteins specific to the anionic phospholipid 
phosphatidylserine (PS) may coordinate Ca2+ ions for PS binding using conserved loop 
motifs as observed in annexin V [48] or directly bind PS via C2 domains as in 
coagulation factor V [49] and lactadherin [50] where polar side chains allow specific 
recognition of PS. The affinity of the proteins for the membrane may be further 
modulated by insertion of hydrophobic and aromatic amino acids into the bilayer 
[31,48,49], and/or multivalent interactions [46] via domain repeats [51] or specificity for 
more than one type of lipid [10,51]. 
    Although there are numerous examples of specific binding to anionic lipids, less is 
known about specificity for zwitterionic lipids such as phosphatidylethanolamine (PE) 
and phosphatidylcholine (PC). Specific binding via a trimethylammonium moiety, such 
as that found in PC headgroups, has been observed in proteins that bind proline betaine 
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and glycine betaine [52,53] or choline [54,55] as well as proteins that bind methylated 
lysine in histones [56-58] or methylated arginine [59]. In these structures, the 
methylammonium moiety is the center of a cation-π box with the faces of 2 to 4 aromatic 
residues located within 4–5 Å of the methylated amine allowing cation-π interactions 
with the aromatic residues. In search of the trimethylammonium binding motif in Protein 
Data Bank database, the only known structures containing PC with the choline held in a 
cation-π box are those for phosphatidylcholine transfer proteins. However, additional 
interactions with the acyl chains assist in PC binding by the transfer protein [60], and it 
was unclear whether the cation-π interaction by itself would provide sufficient binding 
energy to transiently bind a protein to the membrane. Further work was clearly needed to 
support the hypothesis that the cation-π box is an indeed motif for PC recognition. 
1.2 cis-Aconitate Decarboxylase (cADC) 
1.2.1 Metabolites and Macrophages 
    Small molecule metabolites can play important roles in cell growth and survival, 
amino acid and nucleotide biosynthesis, as well as energy production. In metabolism, the 
enzyme-catalyzed reactions, which change and transform small molecules in the cells, 
ensure the conversion of carbon and energy sources into usable metabolites. These 
endogenous molecules can also act as allosteric or competitive inhibitors in regulating 
expression and activity of related enzymes [61]. As the substrates and products of 
numerous metabolic reactions, the metabolites encompass a wide variety of chemical 
compounds, including organic acids, amino acids and amines, fatty acids and lipids, 
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sterols, vitamins, mono- and polysaccharides, as well as hormones [61]. The levels of a 
given metabolite vary depending on the availability and uptake of precursor molecules, 
enzyme activity, the number of pathways involved, and also fluctuated extracellular 
environment [62-64].  
    Macrophages are a type of differentiated monocyte that can be activated by diverse 
pathogen derived stimuli via numerous receptors. These processes will stimulate 
transcription of genes that regulate innate and adaptive immune responses. Such genes 
encode cytokines, chemokines, costimulatory molecules, and enzymes of cytokines and 
microbial products, leading the induction of an antimicrobial effector system [65,66]. 
These various endogenous and exogenous stimuli include cytokines secreted by immune 
cells. Such stimuli include interferon gamma (IFN-γ) and tumor necrosis factor (TNF), 
pathogen components like lipopolysaccharide (LPS), phagocytosed antigens, etc. [67-69] 
LPS usually stimulates the macrophage via binding to Toll-like receptors (TLRs), which 
is the most commonly used reagent in macrophage activation [65,70]. In the immune 
response, the activated macrophage can produce a large amount of reactive oxygen 
species or secret cytokines to kill invading microorganisms and maintain the proliferation 
and development of certain T cells [68,71,72]. The RAW264.7 tumor cell line is a widely 
used model for macrophages and has been used in studies of metabolism, macrophage 
activation and lipid synthesis [69,73,74]. This cell line was first isolated from a murine 
lymphocytic lymphoma induced by the Abelson leukemia virus [75]. It was found to be 
activated by LPS and produce nitric oxide (NOS) and tumor necrosis factor (TNF) 
[76,77].   
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1.2.2 Biosynthesis Pathway of Itaconic Acid (ITA) in Fungi 
    Itaconic acid (ITA) is a small-molecule effector of cells that has been overlooked in the 
biochemical community until recently. However, it has been very prominent in the field 
of polymers. ITA is an unsaturated dicarboxylic acid that is used for industrial synthesis 
of resins and bioactive compounds. By employing selective enzymatic transformations, 
ITA can also be used to create useful polyfunctional building blocks and was categorized 
as one of the “top 12” building block molecules from sugars [78]. ITA was originally 
discovered as a product of pyrolytic distillation of citric acid by Kinoshita (1932) in an 
osmophilic strain of green Aspergillus species [79]. After many attempts made to 
improve the economics of ITA manufacture, an optimized industrial process by using A. 
terreus was established. However, the economic and environmental circumstances 
around ITA production are still under investigation and development. Moreover, 
investigations into new properties of ITA have opened up possibilities for novel 
applications in the fields of polymer chemistry, pharmacy, and agriculture [80]. 
    In the industrial production processes to generate ITA, sugars such as glucose and 
sucrose are the generally used starting materials. For several decades, the metabolic 
pathway for ITA production was hotly debated and was not fully established. It was not 
clear whether ITA was produced as an offshoot of the tricarboxylic acid (TCA) cycle, 
from citramalate or from the condensation of acetyl-CoA [81-85]. Among the several 
postulated biosynthetic pathways leading to ITA accumulation, the one via aconitase and 
cis-aconitate decarboxylase (cADC) (Fig. 1-6A) is generally supported [81,82]. ITA 
biosynthesis starts with glycolysis in the cytosol where glucose is metabolized to 
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pyruvate mainly via the Embden-Meyerhof-Parnas pathway (EMP) pathway. Pyruvate is 
then either transported to the mitochondria and dehydrogenated into acetyl-CoA, or 
carboxylated to oxaloacetate in the cytosol. Oxaloacetate is first converted to malate, and 
then converted back to oxaloacetate after being transported into mitochondria. In 
mitochondria, citrate synthase converts acetyl-CoA and oxaloacetate to citric acid. 
Further on in the TCA cycle, citrate is converted into cis-aconitate and transported back 
into cytosol and then decarboxylated to itaconate [81]. The formation of ITA involves the 
shuttling of intermediate metabolites between different intracellular compartments and 
utilizes the different enzymatic capabilities of the respective compartments [86]. ITA 
biosynthesis was analyzed by fractionating cell extracts to distinguish the enzymatic 
activity of a mitochondrial from a cytosolic enzyme. 
1.2.3 cis-Aconitate Decarboxylase (cADC) 
    That ITA biosynthesis requires de novo protein synthesis in fungi confirmed the 
importance of enzymes such as aconitase and cADC. As an important step for the basic 
understanding of ITA biosynthesis, Dwiarti et al. purified a 55-kDa protein from the high 
ITA producing strain A. terreus TN484-M1 [87]. From partial sequencing of this protein, 
the responsible cADC gene was identified and this protein was shown to produce ITA 
from cis-aconitate [88]. Transcriptional approaches also supported this biosynthetic 
pathway [85]. cADC contains a conserved domain of the MmgE/PrpD family of proteins 
from bacteria and fungi, which includes several 2-methylcitrate dehydratases of bacteria 
that are involved in propionate catabolism.   
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Figure 1-6. Biosynthesis pathways of ITA. (A) Biosynthesis pathway of ITA in 
Aspergillus terreus. Metabolites are given in normal font and enzymes are given in italic. 
Dashed lines and arrows stand for the simplified steps [81,82,85]. (B) Biosynthesis 
pathway of ITA in murine macrophage. ITA labeling scheme from [13C5]glutamine (I) 
and [13C6]glucose (II and III) if the cADC pathway is active. PDH: pyruvate 
dehydrogenase; PC: pyruvate carboxylase. 
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    The MmgE/PrpD family is a diverse class of proteins from a wide range of organisms, 
including archaea, bacteria and most eukaryotes. Based on the phylogenetic analysis, it 
can be divided into two major branches, one that includes the PrpDs, most of which share 
>60% sequence identities and exhibit 2-methylcitrate dehydratase activity, and a second 
one that share <25% sequence identity to E. coli PrpD and are not associated with any 
known functions. The PrpD proteins are involved in the conversion of 2-methylcitrate to 
2-methylisocitrate; they work together with other enzymes in propionate metabolism 
pathway [89]. In the second group, the crystal structure of one protein, iminodisuccinate 
(IDS) epimerase; it exhibited a representative MmgE/PrpD fold [90]. It was suggested 
that this fold could serve as a scaffold for diverse functions, such as enzymatic 
dehydration and epimerization, as well as immune response and cell adhesion. This group 
also includes the mammalian immunoresponsive gene 1 (IRG1), which is highly 
expressed in macrophages activated by LPS [91] and in the uterus activated by 
progesterone and required for implantation in mouse [92]. 	  	  	  	  Regarding the localization of cADC, there have been some debates as to whether it is 
present in the mitochondria or in the cytoplasm since cis-aconitic acid (cis-aconitate) is 
produced in the TCA cycle while ITA is finally secreted into the culture broth [93]. 
Studies of the fungal cADC can provide a way to enhance ITA productivity by 
biotechnological methods, and more importantly, provide an understanding of the 
biological roles of ITA.  
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1.2.4 Mechanisms of Decarboxylases 
    Decarboxylation is a fundamentally important reaction in biological systems. This 
chemical transformation usually removes a carboxyl group from carboxylic acids and 
releases carbon dioxide (CO2). Enzymes that catalyze decarboxylation are called 
decarboxylases or carboxylyases (EC number 4.1.1). Decarboxylase enzymes play 
important roles in a wide variety of catabolic and anabolic pathways, including 
carbohydrate metabolism and synthesis as well as amino acid conversions [94]. 
Decarboxylases can be divided into two subfamilies, cofactor-dependent enzymes, which 
utilize different cofactors to catalyze the decarboxylation, and cofactor-independent 
enzymes. For the latter, orotidine 5’-monophosphate decarboxylase [95,96] and 
methylmalonyl CoA decarboxylase [97] are enzymes that do not need any cofactors. The 
cofactors involved in the enzymatic decarboxylation are either an organic cofactor such 
as biotin, flavin, NAD+, pyridoxal 5’-phosphate (PLP), a pyruvoyl group, and thiamin 
pyrophosphate (TPP), or an inorganic cofactor such as an iron, zinc, manganese and 
magnesium ions or complexes [98]. 
     The mechanisms for cofactor independent decarboxylases vary but the basic concept 
is similar. They all establish a well-defined substrate binding pocket, using amino acid 
residues of the enzymes to catalyze the decarboxylation of the organic acid. As an 
example, orotidine 5’-monophosphate decarboxylase (OMPDC) catalyzes the critical 
final step in the pyrimidine biosynthetic pathway. Based on the crystal structure solved 
with and without substrate [98], a hydrophobic pocket is the key factor. The proposed 
stepwise mechanism includes a conserved lysine, which protonates the carbon bound to 
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the pyrimidine’s leaving carboxylate, and an aspartate, which destabilizes the substrate 
for decarboxylation [96,99-101]. Unlike the OMPDC’s catalysis mechanism, the 
decarboxylation reaction of 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline 
decarboxylase (OHCUD) was postulated to occur directly by using C=N as an electron 
sink to stabilize the intermediate carbanion. A glutamate in active site destabilizes the 
ground state of the substrate to facilitate the carboxylate group release; a conserved 
histidine causes the subsequent deprotonation and protonation to generate a stereospecific 
product [102,103]. For methylmalonyl CoA decarboxylase (MMCD), catalysis involves a 
conserved tyrosine that forms a hydrogen bond with the leaving carboxyl group and 
orients the substrate. The hydrophobic environment around active site also facilitates 
decarboxylation and the loss of a neutral carbon dioxide molecule. The backbone amide 
groups can assist in stabilizing the proposed anionic intermediate and transition state by 
hydrogen bonding with the substrate [96]. A similar mechanism was observed in another 
enzyme, malonate semialdehyde decarboxylase (MSAD), which also catalyzes the 
decarboxylation of a β-keto acid [104,105]. Several other mechanisms exist such as that 
of arylmalonate decarboxylase (AMDase), which generate a thiol ester intermediate 
formed through a cysteine residue [106-108], and acetoacetate decarboxylase (AADase), 
which involves the perturbation of a lysine pKa by the highly hydrophobic environment 
and a second lysine [109]. The cofactor-independent decarboxylase mechanisms 
proposed are usually based on the crystal structure combined with other experimental 
observations. Most of these decarboxylation reactions are facilitated by substrate 
destabilization in the active site and subsequent carbon dioxide release. 
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1.2.5 Discovery of Itaconic Acid in Other Species 
    ITA has been found in other fungi, not just A. terreus, and these include Ustilago zeae 
[110], Ustilago maydis [111], Candida sp. [112], and Rhodotorula sp. [113]. More 
recently, ITA has been identified in the metabolomic analyses of mammalian tissue 
specimens [114-118]. However, there is little knowledge on how ITA is formed in 
mammalian cells. A previous study in our lab [114] elucidated the synthetic pathway for 
ITA in macrophage-derived cells. ITA production was attributed to the decarboxylation 
of cis-aconitate by a specific decarboxylase (Fig. 1-6B). This was verified by using 
isotope tracers method starting from [13C5]glutamine (Fig. 1-6B, Scheme I) or 
[13C6]glucose (Fig. 1-6B, Scheme II and III). However, up to the beginning of my project, 
there was no specific gene identified as encoding this enzymatic activity. At the 
beginning of this year, a group in Luxembourg identified immunoresponsive gene 1 
(IRG1) as the gene coding for an enzyme producing ITA through the decarboxylation of 
cis-aconitate [119].  
    The physiological role of ITA in mammalian cells is still unknown, as well as where 
the ITA was synthesized. Based on in vitro studies, ITA was shown to inhibit key 
enzymes of TCA cycle (isocitrate lyase [120] and fructose-6-phosphate 2-kinase [121]). 
Thus, ITA may act as an antibacterial agent and also may play an important role in 
central carbon metabolism. Despite an overall lack of information on ITA as a 
mammalian metabolite, there is evidence that ITA can be catabolized by both guinea pig 
and rat liver mitochondria [122,123]. In rats it was also shown that an itaconate diet leads 
to a reduced visceral fat accumulation, because of a suppressed glycolytic flux [121]. 
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1.2.6 Immunoresponsive Gene 1 (IRG1) 
    Lipopolysaccharide (LPS), which is a major glycolipid component of the outer 
membrane of Gram-negative bacteria, can dramatically enhance the inflammatory 
potential and performance of macrophages as a potent and pleiotropic stimulus [124,125]. 
Many genes are highly induced upon the activation of LPS, including TNF-A, IL-1A and 
B, Irg2, etc. [126-129]. These play crucial roles in the orchestration of various responses 
to protect the host against infection. The identification of LPS inducible genes has 
received a lot of interest in recent years and has been used to understand the complexity 
of macrophage responses. IRG1 cDNA was first identified by screening a cDNA library 
from an LPS-activated RAW264.7 cell line by Lee et al. in 1995 [91]. This novel cDNA 
is 2.3 kb having an open reading frame (ORF) of 1938 bases encoding a polypeptide of 
647 amino acid residues. IRG1 contains a glycosaminoglycan motif, many potential 
phosphorylation sites and was mapped to mouse chromosome 14. The IRG1 message 
appears 1.5 h after LPS stimulation and reaches its maximum at around 6 h. Message 
production was not dependent on new protein synthesis but was mediated by tyrosine 
kinase and protein kinase C (PKC) pathways. 
    Another novel IRG1 gene was [130] then identified that was regulated by the steroid 
hormone progesterone (P4) in the uterine epithelium. It was analyzed as the mammalian 
ortholog of the bacterial methylcitrate dehydratase. IRG1 was demonstrated to be a key 
marker of the implantation window in modulating steroid hormone responsiveness in the 
uterine luminal epithelium, which is induced through the PKC pathway. Moreover, IRG1 
was also identified as a novel target of progesterone receptors (PRs) in the pregnant 
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mouse uterus [92,131]. The identification of IRG1 showing a hormonally regulated 
pattern of expression in the uterus suggests novel functions of it during implantation 
[132]. 
    Microglial cells can secrete reactive species upon activation that can cause damage to 
neurons. Mahe and coworkers identified the presence of IRG1 in the microglial cells first 
(2001), and then showed its role as a marker of the IFN-γ-activated microglial-derived 
clone cells [133]. Microglia are the prime and major component of an intrinsic brain 
immune system in the central nervous system (CNS). However, the mechanism that 
determines its role is unclear. It was reported that IRG1 was selectively and functionally 
expressed in killer microglia in vivo and could be a potential therapeutic target for gene 
therapy of some neurodegenerative and neuroinflammatory diseases, such as Alzheimer’s 
disease and AIDS dementia [134]. 
    In macrophage systems, IFN-γ and TNF are essential cytokines for successful clearance 
of microbial infections. Microbes are often sensed via TLR signaling through the key 
adaptor molecule myeloid differentiation factor-88 (MyD88), which plays a critical role 
in inducing immunity against microorganism. Analysis of the pulmonary transcriptome 
upon infection with Chlamydia pneumonia, an intracellular bacterium that causes 
pneumonia in humans and mice, demonstrated a major impact of MyD88 on 
inflammatory responses but not on interferon-type responses. IRG1, as one of many 
MyD88-dependent genes, was involved in immune responses against C. pneumonia 
infection [135]. In contrast, infection by live, virulent Mycobacterium tuberculosis (Mtb) 
activated macrophages largely through TLR2 or TLR4 in a MyD88-independent 
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pathways which further clarified that IRG1 induction by Mtb was mediated via a pathway 
that does not require TLR2, TLR4, MyD88, etc. [136,137]. Different transcriptional and 
posttranscriptional regulation of IRG1 expression has been described for macrophages 
infected with mycobacteria or stimulated with LPS [138]. IRG1 was then found to be 
highly up-regulated in murine ANA-1 macrophages after stimulation by several 
proinflammatory cytokines and TLR agonists, as well as in spleen and lung of Listeria 
monocytogenes or Toxoplasma gondii infected mice [139]. The subcellular localization of 
IRG1 in murine macrophages, as a prototypic TNF- and IFN-γ-coregulated gene, was 
associated with mitochondria, which are known to play crucial roles in the regulation of 
cellular processes such as apoptosis and innate immune activation [140,141] 
    In summary, at the time I started working on the project to find the source of 
mammalian cADC, IRG1 has not been functionally characterized in macrophages and its 
up-regulation in stimulated macrophages was worthy of further investigation. 
1.3 Thesis directions 
    The first aim of my dissertation is to define membrane interactions of two bacterial 
phosphatidylinositol-specific phospholipase C (PI-PLC) enzymes: Bacillus thuringiensis 
(Bt) and Staphylococcus aureus (Sa) PI-PLCs. Understanding how the bacterial PI-PLCs 
interact with target membranes may provide specific ways to selectively inhibit them, and 
hence provide insights into novel methods to control bacterial infections. The two PI-
PLC enzymes studied in my work can also be used as models to explore the considerably 
more complicated enzymatic kinetics and membrane interaction of the mammalian PI-
PLC family.  
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    In order to investigate the importance of PI-PLC dynamics in membrane binding and 
enzymatic activity, we combined MD simulations, in silico and in vitro mutagenesis 
along with binding and activity assays, to study the role of loop motions and helix 
kinking in regulating the activity of BtPI-PLC. Two proline residues, Pro245 and Pro254, 
were associated with these correlated motions that appear in the simulations to limit the 
access of substrate. This observation in MD simulations led us to mutate these Pro 
residues both in silico and in vitro. The variations in both enzymatic activity and vesicle 
binding affinity between mutant protein and WT were measured to suggest how the 
correlated motions affect on the enzyme.  
    S. aureus PI-PLC shows 41.3% sequence similarity with BtPI-PLC but only has two of 
the four tyrosine residues in helix G which were initially predicted to contribute to 
binding to PC-containing membranes. Thus, I cloned the wild-type SaPI-PLC gene into a 
His-tagged overexpression system from the genomic DNA of S. aureus for further 
expression and purification. Serendipitously, one of my colleagues, Rebecca Goldstein, 
solved the structure of a homodimer of SaPI-PLC that suggested one could form transient 
dimers on the membrane surface. To that end I examined enzyme activity as a function of 
enzyme concentration, pH, and vesicle composition, measured binding of the protein to 
vesicles by fluorescence correlation spectroscopy (FCS), and tested our hypotheses with a 
series of mutations. The results show that SaPI-PLC has evolved a complex, apparently 
unique way to control its access to PI/GPI substrate.  
    There is little known about specific recognition motifs used by peripheral membrane 
proteins for binding to the PC headgroup. In cytosolic proteins, the cation-π box provides 
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a suitable receptor for choline recognition and binding through the trimethylammonium 
moiety. We proved this hypothesis by engineering the cation-π box into SaPI-PLC, which 
lacks specific PC recognition, with a double mutation protein, N254Y/H258Y. The 
interaction of this variant with PC-enriched vesicles was monitored by different 
techniques (FCS, 31P NMR, intrinsic fluorescence and also crystallization). Such simple 
PC recognition motifs could be engineered into a wide variety of secondary structures 
providing a generally applicable method for specific recognition of PC. 
    The second aim of this dissertation was to identify and characterize a mammalian cis-
aconitate decarboxylase (cADC). Itaconic acid (ITA) is a metabolite produced by primary 
macrophages and cell lines derived from macrophages that is dramatically increased upon 
stimulation [114]. It is synthesized by a cADC activity. Sequence searches with a known 
fungal cADC show little homology to ORFs in mammalian cells. I used the macrophage 
cell line RAW264.7, designed a series of assays, including cell fractionation, partial 
protein purification, MS proteomics study and siRNA transfections to show that cADC 
activity upon stimulation is from the protein encoded from immunoresponsive gene 1 
(IRG1). To identify the active site, a predicted homology model structure was built for 
fungal cADC. I cloned both IRG1 and fungal cADC into an E. coli expression system, 
purified and characterized the enzyme and compared their properties. The identification 
of this enzyme can help to clarify the unique decarboxylation mechanism and also open 
up future studies into the specific role of ITA in the mammalian immune system and 
cancers. 	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Chapter 2 
Materials and Methods 
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2.1 Chemicals 
2.1.1 Cloning and Mutagenesis Reagent 
   The QuikChange site-directed mutagenesis kit, all the competent cells used in cloning, 
mutagenesis (XL1-Blue or XL10-gold), and overexpression (BL21 Codonplus) were 
obtained from Agilent Technologies (Santa Clara, CA). The QIAprep spin miniprep kit 
and QIAquick PCR purification kit were purchased from Qiagen (Valencia, CA). 
Staphylococcus aureus genomic DNA from strain FPR3757 genomic DNA was 
purchased from ATCC (Manassas, VA). Mus musculus immunoresponsive gene 1 (Irg1) 
as transfection-ready DNA (NM_008392.1) was purchased from OriGene Technologies 
(Rockville, MD). pET-21a vector was supplied by Novagen (Darmstadt, Germany). 
Restriction enzymes (EcoRI, BamHI, XhoI, SapI and NheI-HF), Taq DNA polymerase, 
pMALTEV vector, IMPACT kit, quick ligation kit, calf intestinal alkaline phosphatase 
and Antarctic phosphatase were purchased from New England Biolabs (Ipswich, MA). 
All the PCR primers were purchased from Eurofins MWG Operon (Huntsville, AL).  
2.1.2 Resin for Purification 
   The Q Sepharose fast flow resin and phenyl sepharose resin were purchased from GE 
Healthcare (Piscataway, NJ). Micro bio-spin 6 columns were purchased from Bio-Rad 
Laboratories (Hercules, CA). Ni-NTA agarose resin was purchased from Qiagen 
(Valencia, CA). Chitin and amylose resin were purchased from New England Biolabs. 
2.1.3 Phospholipids 
    Most of the lipids used in this work were purchased from Avanti Polar Lipids Inc. 
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(Alabaster, AL), and used without further purification. These include the long chain 
lipids 1-palmitoyl-2-oleoyl-phosphatidylcholine (POPC), 1,2-dioleoyl-phosphatidylserine 
(DOPS), 1,2-dioleoyl-phosphatidylmethanol (DOPMe), 1,2-dioleoyl-phosphatidic acid 
(DOPA), 1,2-dioleoyl-phosphatidylglycerol (DOPG), L-α-phosphatidylinositol (PI) from 
bovine liver, dihexanoyl-phosphatidylcholine (diC6PC), diheptanoyl-phosphatidylcholine 
(diC7PC), dioctanoyl-phosphatidylethanolamine (diC8PE), dioctanoyl-phosphatidylseine 
(diC8PS)  and dioctanoyl-phosphatidyglycerol (diC8PG).  
2.1.4 Molecular Probes  
    The fluorescence labeling reagent Alexa Fluor 488 C5 maleimide (AF488-Cys) and 
Alexa Fluor 488 carboxylic acid, succinimidyl ester (AF488-N-term) were purchased 
from Invitrogen (Grand Island, NY). The spin labeling reagent 1-oxyl-2,2,5,5-
tetramethylpyrroline-3-methyl-methanethio-sulfonate (MTSL) was obtained from 
Toronto Research Chemicals Inc (Canada). 
2.1.5 Mammalian Cell Culture Reagent    
   The RAW264.7 cell line was purchased from the ATCC (Manassas, VA). The media 
for cell growth, Dulbecco's Modification of Eagles Medium (DMEM, with 4.5 g/L 
glucose and L-glutamine, without sodium pyruvate), was purchased from Cellgro 
(Manassas, VA). Heat inactivated fetal bovine serum (FBS) was purchased from Atlanta 
Biologicals (Lawrenceville, GA). MycoZap CL was purchased from Lonza Cologne AG 
(Germany). Mouse TLR 1-9 Agonist Kit was purchased from Invivogen (San Diego, CA). 
ON-TARGETplus SMARTpool, Mouse IRG1 and Control siRNA were purchased from 
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Dharmacon (San Jose, CA). GenMute siRNA Transfection Reagent for RAW264.7 Cell 
was purchased from SignaGen Laboratories (Rockville, MD).  
2.1.6 Other Chemicals 
    Most of the other chemicals, such as tris(hydroxymethyl)aminomethane (Tris), 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 2-(N-morpholino) ethane-
sulfonic acid (MES), bovine serum albumin (BSA), dithiothreitol (DTT), deuterium 
oxide (D2O), imidazole, sodium phosphate monobasic, sodium chloride, potassium 
chloride, magnesium chloride, manganese(II) chloride, calcium chloride, iron(II) chloride, 
glycine, ammonium persulfate (APS), N,N,N',N'-tetramethylethylenediamide (TEMED), 
5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB), pyridoxal 5’-phosphate (PLP), thiamine 
pyrophosphate (TPP), β-nicotinamide adenine dinucleotide hydrate (NAD+), chloroform, 
methanol, acetic acid, glycerol, Triton X-100 (TX-100), itaconic acid, cis-aconitic acid, 
L-glutamine, D-glucose, lysozyme, actinomycin D, phenylmethylsulfonyl fluoride 
(PMSF), protease inhibitor cocktail, lipopolysaccharides (LPS, 0111:B4) and 
iodoacetamide were obtained from Sigma-Aldrich (St. Louis, MO). LB broth and LB 
agar were obtained from Fisher Scientific (San Jose, CA). Kanamycin sulfate, 
chloramphenicol, ampicillin and isopropyl β-D-1-thiogalactopyranoside (IPTG) were 
purchased from American Bioanalytical, Inc. (Natick, MA). The detergent compatible 
(DC) BCA protein assay kit, molecular weight markers, agarose and 30% 
acrylamide/bisacrylamide solution were obtained from Bio-Rad Laboratories (Hercules, 
CA).  
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2.2 Cloning and Expression of B. thuringiensis PI-PLC and S. aureus PI-PLC 
   The original plasmid, B. thuringiensis PI-PLC (BtPI-PLC) gene (Fig. 2-1) cloned in the 
pHN1403 vector, was obtained from Dr. Ming-Daw Tsai (Ohio State University).  
    An affinity tagged overexpression system, formation of a His-tagged protein, was 
selected for S. aureus PI-PLC (SaPI-PLC) cloning since it results in relatively pure 
protein. The wide-type SaPI-PLC gene (Fig. 2-2) was obtained directly from S. aureus 
genomic DNA (strain FPR3757) by PCR. An EcoRI restriction site was used for cloning 
the 5’end of target gene, with a forward primer 5’-ggGAATTCtcagattcgttgagtaaaagtccag-
3’ (EcoRI site underlined). A XhoI restriction site was used for cloning the 3’end of 
target gene with the reverse primer 5’-ggCTCGAGtttattactatctataatttcacttacg-3’ (XhoI 
site underlined). Target genes flanked with EcoRI and XhoI sites were amplified under 
Taq DNA polymerase by PCR. 1% agarose gel was run to verify the PCR results. The 
PCR products were further purified by using the QIAquick PCR purification kit 
following the manufacturer’s instructions. The restriction enzymes EcoRI and XhoI were 
used to cut both the inserts and the empty pET21a vector. During this incubation time (37 
oC, 3-4 h), alkaline phosphatase was added at 2-2.5 h to avoid self-ligation. After another 
PCR purification, the quick ligation kit was used to perform the ligation of digested-insert 
and digested-vector. The ligation mixture was transformed into XL10-gold competent 
cells for plasmid propagation and preparations. Positive colonies could be identified by 
restriction digestion (ampicillin resistance). The QIAprep miniprep kit was used for 
purification of the plasmid DNA. The entire DNA sequence of the inserted target gene 
was sequenced with T7-promoter and T7-term by Genewiz (South Plainfield, NJ). 
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Figure 2-1. B. thuringiensis PI-PLC DNA and corresponding amino acid sequences. 
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GCTAGCTCTGTTAAT GAGCTTGAAAATTGG TCAAAATGGATGCAA CCTATACCTGATAAT 
 A  S  S  V  N   E  L  E  N  W   S  K  W  M  Q   P  I  P  D  N  
 
ATCCCGTTAGCACGA ATTTCAATTCCAGGA ACACACGATAGTGGG ACGTTCAAGTTGCAA 
 I  P  L  A  R   I  S  I  P  G   T  H  D  S  G   T  F  K  L  Q  
 
AATCCGATTAAGCAA GTGTGGGGAATGACG CAAGAATATGATTTT CGCTATCAAATGGAC 
 N  P  I  K  Q   V  W  G  M  T   Q  E  Y  D  F   R  Y  Q  M  D  
 
CATGGAGCTCGCATT TTTGATATAAGAGGA CGTTTAACAGATGAT AATACGATAGTTCTT 
 H  G  A  R  I   F  D  I  R  G   R  L  T  D  D   N  T  I  V  L  
 
CATCATGGGCCATTA TATCTTTACGTAACA CTGCATGAATTCATA AATGAAGCGAAACAA 
 H  H  G  P  L   Y  L  Y  V  T   L  H  E  F  I   N  E  A  K  Q  
 
TTTTTAAAAGATAAC CCGAGTGAAACAATT ATTATGTCTTTAAAA AAAGAGTATGAGGAT 
 F  L  K  D  N   P  S  E  T  I   I  M  S  L  K   K  E  Y  E  D  
 
ATGAAAGGGGCAGAA GGTTCATTTAGTAGT ACGTTTGAAAAAAAT TATTTTGTTGATCCT 
 M  K  G  A  E   G  S  F  S  S   T  F  E  K  N   Y  F  V  D  P  
 
ATCTTTTTAAAAACA GAAGGAAATATAAAA CTTGGAGATGCTCGT GGGAAAATTGTACTA 
 I  F  L  K  T   E  G  N  I  K   L  G  D  A  R   G  K  I  V  L  
 
CTAAAAAGATATAGT GGTAGTAATGAATCT GGAGGATATAATAAT TTTTATTGGCCAGAT 
 L  K  R  Y  S   G  S  N  E  S   G  G  Y  N  N   F  Y  W  P  D  
 
AATGAGACGTTTACC ACAACTGTAAACCAA AATGTAAATGTAACA GTACAAGATAAATAT 
 N  E  T  F  T   T  T  V  N  Q   N  V  N  V  T   V  Q  D  K  Y  
 
AAAGTGAATTATGAT GAGAAAGTAAAATCT ATTAAAGATACGATG GATGAAACGATGAAC 
 K  V  N  Y  D   E  K  V  K  S   I  K  D  T  M   D  E  T  M  N  
 
AATAGCGAGGATTTA AATCATCTATATATT AATTTTACAAGCTTG TCTTCTGGTGGTACA 
 N  S  E  D  L   N  H  L  Y  I   N  F  T  S  L   S  S  G  G  T  
 
GCATGGAATAGTCCA TATTACTACGCTTCT TATATAAATCCTGAA ATTGCAAACGATATA 
 A  W  N  S  P   Y  Y  Y  A  S   Y  I  N  P  E   I  A  N  D  I  
 
AAACAAAAGAATCCT ACAAGAGTAGGCTGG GTAATTCAAGACTAC ATAAATGAAAAGTGG 
 K  Q  K  N  P   T  R  V  G  W   V  I  Q  D  Y   I  N  E  K  W  
 
TCACCATTATTGTAT CAAGAAGTTATAAGA GCGAATAAGTCATTA ATAAAAGAATAA 
 S  P  L  L  Y   Q  E  V  I  R   A  N  K  S  L   I  K  E  *  
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Figure 2-2. S. aureus PI-PLC DNA and corresponding amino acid sequences.  
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TCAGATTCGTTGAGT AAAAGTCCAGAAAAT TGGATGAGTAAACTT GATGATGGAAAACAT 
 S  D  S  L  S   K  S  P  E  N   W  M  S  K  L   D  D  G  K  H  
 
TTAACTGAGATTAAT ATACCGGGTTCACAT GATAGTGGCTCATTC ACTTTAAAGGATCCA 
 L  T  E  I  N   I  P  G  S  H   D  S  G  S  F   T  L  K  D  P  
 
GTAAAATCAGTTTGG GCAAAGACTCAAGAT AAAGATTACCTTACC CAAATGAAGTCGGGA 
 V  K  S  V  W   A  K  T  Q  D   K  D  Y  L  T   Q  M  K  S  G  
 
GTCAGGTTTTTTGAT ATTAGAGGTAGAGCA AGTGCTGATAATATG ATTTCAGTTCATCAC 
 V  R  F  F  D   I  R  G  R  A   S  A  D  N  M   I  S  V  H  H  
 
GGCATGGTTTATTTG CATCATGAATTAGGA AAATTTCTCGATGAT GCTAAATATTACTTG 
 G  M  V  Y  L   H  H  E  L  G   K  F  L  D  D   A  K  Y  Y  L  
 
AGTGCTTATCCAAAC GAAACAATTGTGATG TCTATGAAAAAGGAC TACGATAGCGATTCT 
 S  A  Y  P  N   E  T  I  V  M   S  M  K  K  D   Y  D  S  D  S  
 
AAAGTTACGAAGACA TTTGAAGAAATTTTT AGAGAATATTATTAT AATAACCCGCAATAT 
 K  V  T  K  T   F  E  E  I  F   R  E  Y  Y  Y   N  N  P  Q  Y  
 
CAGAATCTTTTTTAC ACAGGAAGTAATGCG AATCCTACTTTAAAA GAAACGAAAGGTAAA 
 Q  N  L  F  Y   T  G  S  N  A   N  P  T  L  K   E  T  K  G  K  
 
ATTGTCCTATTCAAT AGAATGGGGGGTACG TACATAAAAAGTGGT TATGGTGCTGACACG 
 I  V  L  F  N   R  M  G  G  T   Y  I  K  S  G   Y  G  A  D  T  
 
TCAGGTATTCAATGG GCAGACAATGCGACA TTTGAAACGAAAATT AATAATGGTAGCTTA 
 S  G  I  Q  W   A  D  N  A  T   F  E  T  K  I   N  N  G  S  L  
 
AATTTAAAAGTACAA GATGAGTATAAAGAT TACTATGATAAAAAA GTTGAAGCTGTTAAA 
 N  L  K  V  Q   D  E  Y  K  D   Y  Y  D  K  K   V  E  A  V  K  
 
AATTTATTGGCTAAA GCTAAAACGGATAGT AACAAAGACAATGTA TATGTGAATTTCTTG 
 N  L  L  A  K   A  K  T  D  S   N  K  D  N  V   Y  V  N  F  L  
 
AGTGTAGCGTCTGGA GGCAGCGCATTTAAT AGTACTTATAACTAT GCATCACATATAAAT 
 S  V  A  S  G   G  S  A  F  N   S  T  Y  N  Y   A  S  H  I  N  
 
CCTGAAATTGCAAAA ACGATTAAAGCAAAT GGGAAAGCTAGAACG GGTTGGCTGATTGTT 
 P  E  I  A  K   T  I  K  A  N   G  K  A  R  T   G  W  L  I  V  
 
GACTATGCAGGATAT ACGTGGCCTGGATAT GATGATATCGTAAGT GAAATTATAGATAGT 
 D  Y  A  G  Y   T  W  P  G  Y   D  D  I  V  S   E  I  I  D  S  
 
AATAAATAA 
 N  K  *  
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2.3 Construction of Mutant Proteins  
     A series of BtPI-PLC mutants and SaPI-PLC mutants were constructed using 
QuikChange methodology [142] following the QuikChange Manual supplied by Agilent 
Technologies. Two complementary primers were designed with the mutated nucleotides 
near the center of the primer; the QuikChange primer design web-based program 
(http://www.genomics.agilent.com/primerDesignProgram.jsp) was used. All of the 
primers used are listed in Table 2-1. The mutated plasmid with staggered nicks was 
generated by PCR using PfuTurbo DNA polymerase for primer extension. The 
amplification product was digested with the Dpn I (a restriction enzyme used to digest the 
methylated parental DNA template), and then transformed into XL-Blue supercompetent 
cells for plasmid propagation. All mutant plasmids were confirmed by DNA sequencing. 
2.4 Protein Expression and Purification Protocols 
2.4.1 Expression of Recombinant PI-PLCs  
   The sequenced-ready plasmid was transformed into BL21-codonplus (DE3)-RIL 
competent cells using the heat-shock method. A single colony was inoculated into culture 
tubes with 5 mL LB media; the tubes were shaken overnight at 37 °C in the presence of 
appropriate antibiotics (34 µg/mL chloroamphenicol and 100 µg/mL ampicillin). The 
overnight culture was added to a large volume of fresh LB media (1 L or 2 L, with 
antibiotics added) in the ratio of 1:1000. This newly inoculated media was then incubated 
in a rotary shaker (200 rpm) at 37 °C. The over-expression of recombinant PI-PLCs was 
induced by adding IPTG at a final concentration of 0.8 mM (0.4 mM for cysteine mutant
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Table 2-1. Primers used in site-directed mutagenesis. The desired mutation codons are in 
capital and substitution bases are underlined (reverse primers are not listed). 	  
Mutant	   Primer	  
BtPI-­‐PLC	   	  
K38A	   5’-cgatagtgggacgttcGCGttgcaaaatccg-3’ 
K44A	   5’-gcaaaatccgattGCGcaagtgtggggaatg-3’ 
V46K	   5’-ccgattaagcaaAAGtggggaatgacgc-3’ 
R71A	   5’-gatataagaggaGCTttaacagatg-3’ 
K122A	   5’-gagtatgaggatatgGCAggggcagaaggttc-3’ 
N168C	   5’-gatatagtggtagtTGTgaatctggagg-3’ 
Q190_P_N191	  a	   5’-caactgtaaaccaaCCGaatgtaaatgtaacag-3’ 
V192C	   5’-ctgtaaaccaaaatTGCaatgtaacagtacaag-3’ 
K201A	   5’-cagtacaagataaatatGCAgtgaattatgatg-3’ 
N226C	   5’-gcgaggatttaTGTcatctatatattaattttac-3’ 
P245A	   5’-ggtacagcatggaatagtGCAtattactacgcttc-3’ 
P245G	   5’-ggtacagcatggaatagtGGAtattactacgcttc-3’ 
P245Y	   5’-ggtacagcatggaatagtTATtattactacgcttc-3’ 
P254A	   5’-cgcttcttatataaatGCTgaaattgcaaacg-3’ 
P254G	   5’-cgcttcttatataaatGGTgaaattgcaaacg-3’ 
P254Y	   5’-cgcttcttatataaatTATgaaattgcaaacg-3’ 
K279A	   5’-gactacataaatgaaGCGtggtcaccattattg-3’ 
SaPI-­‐PLC	    
V44C	   5’-ggatccagtaaaatcaTGTtgggcaaagactc-3’ 
V44W	   5’-ggatccagtaaaatcaTGGtgggcaaagactc-3’ 
H86E	   5’-cggcatggtttatttgGAGcatgaattaggaa-3’ 
H86Y	   5’-cggcatggtttatttgTATcatgaattagg-3’ 
Y211A	   5’-gatgagtataaagatGCCtatgataaaaaagttg-3’ 
D213C	   5’-gagtataaagattactatTGTaaaaaagttgaagc-3’ 
F249I	   5’-ggaggcagcgcaATTaatagtacttataac-3’ 
F249W	   5’-ggaggcagcgcaTGGaatagtacttataactatgc-3’ 
Y253K	   5’-gcgcatttaatagtactAAGaactatgcatcac-3’ 
Y253S	   5’-gcgcatttaatagtactAGTaactatgcatcac-3’ 
Y253W	   5’-gcgcatttaatagtactTGGaactatgcatcac-3’ 
N254Y	   5’-gcatttaatagtacttatTACtatgcatcaca-3’ 
H258Y	   5’-cttataactatgcatcaTATataaatcctga-3’ 
W287A	   5’-ctatgcaggatatacgGCGcctggatatgatg-3’ 
Y290A	   5’-ggatatacgtggcctggaGCTgatgatatcgtaag-3’ 
Y290S	   5’-ggatatacgtggcctggaAGTgatgatatcgtaag-3’ 
F249W/N254Y/H258Y	  b	   5’-ggaggcagcgcaTGGaatagtacttatTACtatgc-3’ 
Y253S/Y255S	   5’-gcgcatttaatagtactTCTaacTCTgcatcacatataaatcc-3’ 
N254Y/H258Y	   5’-gcatttaatagtacttatTACtatgcatcaTATataaatcctg-3’ 
Y253S/N254Y	  
Y255S/H258Y	  b	  
5’-gcgcatttaatagtactTCTTACTCTgcatcaTATataaatcc-3’ 
	  	  a	  Q190_P_N191	  stands	  for	  inserting	  a	  proline	  between	  Q190	  and	  N191.	  
	  	  b	  These	  two	  mutants	  were	  designed	  using	  N254Y/H258Y	  as	  the	  parent	  plasmid.	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proteins) when the optical density (O.D.) at 600 nm reached 0.7-0.9. The culture was 
incubated for another 20 h at 16 °C. The cells were then harvested by centrifugation at 
5000 rpm for 10 min (using a Beckman J2-MC centrifuge with JA-10 rotor) and frozen at 
-20 ºC for storage.  
2.4.2 Purification of BtPI-PLC 
    The cell pellets were suspended in 20 mM Tris-HCl, pH 8.9, and lysed by sonication 
on ice using a Branson Sonifier 250 Cell Disrupter (Branson Ultrasonic Corp., Danbury, 
CT). Cell debris was pelleted by centrifugation at 15,000 rpm (using a JA-17 rotor) for 35 
min. The supernatant with enzyme was ready for subsequent purification steps. Cell 
extract (dialyzed against 20 mM Tris-HCl, pH 8.9 overnight) was applied onto a Q-
sepharose fast flow (QFF) column (15 mm x 15 cm) equilibrated with 20 mM Tris-HCl, 
pH 8.9. The protein was eluted using an increasing NaCl gradient from 0 to 0.6 M in 20 
mM Tris-HCl, pH 8.0 at the flow rate of 2 mL/min. The fractions collected were analyzed 
by SDS-PAGE to identify those with BtPI-PLC. The protein was further purified using a 
phenyl-sepharose column (10 mm x 10 cm) equilibrated with 1 M NaCl in 20 mM Tris-
HCl, pH 8.0 then eluted with a decreasing NaCl gradient from 1.0 to 0 M at the flow rate 
of 1 mL/min. The fractions containing PI-PLC were collected and dialyzed against 20 
mM Tris-HCl, pH 8.0, and then concentrated by using Vivaspin 20 mL 10 kDa cut-off 
filters (Vivaproducts, Inc., Littleton, MA). Purity of PI-PLC variants was >90% as 
monitored by SDS-PAGE. Protein concentrations were measured by both Lowry assays 
and the absorption at 280 nm. Extinction coefficients at 280 nm, calculated using the 
ProtParam tool  (http://web.expasy.org/protparam [143]), were ε280 = 65.32 mM-1 cm-1 for 
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wild type (WT), the 190s loop variants, and most of the Pro variants, or ε280 = 66.81 mM-
1 cm-1 for the Pro to Tyr variants. Formation of the disulfide bond in the double Cys 
variant, Asn226Cys/Val192Cys (N226C/V192C), was confirmed using nonreducing 
SDS-PAGE. For fluorescence correlation spectroscopy (FCS) experiments, a single Cys 
residue, N168C, was introduced into the protein. For these cysteine-containing proteins, 
DTT was added during the purification process and in the storage.  
2.4.3 Purification of SaPI-PLC    
    The cell lysate with enzyme was prepared by suspending cell pellets in 20 mM Tris-
HCl, 10 mM imidazole, pH 8.5, followed by sonication and then centrifugation. The cell 
extract was incubated at room temperature with Ni-NTA agarose resin (1 L cells/5 mL 
resin) for around 1 h on a shaker. The solution containing the enzyme bound on the resin 
was loaded into a column and then washed using 200 mL buffer (20 mM Tris-HCl, 10 
mM imidazole, pH 8.5) at the flow rate of 2 mL/min. The UV signal was monitored 
during the washing and elution steps. The His-tagged protein was eluted using 0.01 to 
0.15 M imidazole gradient in the 20 mM Tris-HCl, pH 8.5. SDS-PAGE was used to 
identify the fractions to be collected for the second purification step using a QFF ion-
exchange resin. After overnight dialysis in 20 mM Tris-HCl, pH 8.3, the protein solution 
was applied to the QFF column and then eluted with a NaCl gradient increasing from 0 to 
around 0.1 M (this varied among the different mutant proteins). The concentration of the 
PI-PLC enzymes at greater than 95% purity (monitored by SDS-PAGE as shown in Fig. 
2-3) was measured by the absorption at 280 nm using the calculated extinction coefficient 
(ε280 = 60.28 mM-1 cm-1). The yield of purified protein was 60 mg/L cell culture.  
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Figure 2-3. Purification of SaPI-PLC monitored by SDS-PAGE. 	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2.5 CD Spectroscopy to Monitor Protein Stability (Tm) and Overall Folding 
   Secondary structure content and thermal stability of the PI-PLC variants were measured 
using far-UV circular dichroism (CD) on a model No. 202 CD spectrophotometer (AVIV 
Biomedical, Lakewood, NJ). All samples used for CD experiments were prepared by 
adding the desired amount of protein (0.05 mg/mL) to 10 mM borate, pH 8.0. In the 
wavelength scanning experiments at 25 oC, CD spectra were collected from 300 to 180 
nm with 1 nm wavelength steps. Secondary structure content was analyzed with the 
CDNN program [144] using the calculated molar ellipticity in the 190-260 nm range. 
Thermal stabilities for all proteins were measured by monitoring the ellipticity at 222 nm 
(primarily α-helix) while increasing the sample temperature 1.0 oC per min from 20 to 90 
oC, with 1 min equilibration time. 
2.6 Preparation of Phospholipid Aggregates 
    Enzyme kinetics experiments used PI/PC small unilamellar vesicles (SUVs) prepared 
by sonication; the composition of the SUVs is noted by XPC, the mole fraction of PC. 
Aliquots of phospholipids (PI, PG, and PC species) in chloroform were mixed, dried 
under N2, and then lyophilized overnight. The lipid film was rehydrated with the desired 
buffer. Small PI only, PI/PC and PG/PC vesicles were generated by sonicating the 
dispersed phospholipid solution on ice for 20 s and resting for 20 s, for a total time of 15-
20 min (the time needed is dependent on the total phospholipid concentration) using a 
Branson Sonifier 250. The average radius for PI and PI/PC (XPC = 0.5) vesicles 
characterized by DynaPro NanoStar Dynamic Light Scattering (DLS) instrument (Wyatt 
Technology Corp., Santa Barbara, CA) was 130 Å, with 20 and 46% polydispersity, 
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respectively. Similar sizes have also been documented for the PG/PC SUVs [145,146]. 
2.7 PI-PLC Activity Assays via 31P NMR Spectroscopy    
    Specific activities of the PI-PLC enzymes were measured by 31P NMR spectroscopy 
[10,31,38,43] using a VNMRS 600 (Varian, Cary, NC) spectrometer. For BtPI-PLC, the 
activity assay was usually carried in 50 mM HEPES, 1 mM EDTA, and 0.1 mg/mL 
bovine serum albumin (BSA is used to stabilize the protein at the very low concentrations 
used in these assays), pH 7.5, 28 oC. Most assays of SaPI-PLC were in 50 mM MES, pH 
6.5, with EDTA and BSA at 28 °C. However, for assays examining the pH dependence of 
activity, a mixed buffer system of MES and HEPES (total concentration of 50 mM) with 
the desired pH value was used. Specific activities in the presence of salt were determined 
using a NaCl (137 mM)/KCl (2.7 mM) mixture. The amount of enzyme added into 
different assay systems was adjusted so that <20% cyclic inositol phosphate product (and 
no inositol 1-phosphate) was generated in 30 min for the continuous assay and 15 min for 
the fixed time method. The amount of BtPI-PLC used was 0.1–0.25 µg/mL for mixed 
micelle assays, 0.2–2 µg/mL for PI cleavage when presented in vesicles, and 5–100 
µg/mL for cIP hydrolysis. SaPI-PLC concentrations used in assays ranged from 0.2 to 8 
µg/mL. Cleavage rates for PI solubilized in detergent micelles and hydrolysis of cIP were 
measured by continuously monitoring the relative integrated intensity of the cIP or I-1-P 
resonance (with 1H decoupling but no nuclear Overhauser effect), respectively, as a 
function of reaction time (Fig. 2-4, inset). The increase in cIP under these conditions is 
linear with time indicative of an initial rate being measured. Because we are dealing with 
a vesicle and some fusion of SUVs as diacylglycerol (DAG) is produced, this is not the 
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same as a steady-state rate with the substrate in solution, but it is operationally useful for 
comparing rates under different conditions (pH, concentration of enzyme, salt, etc.). 
Mixed micelles of PI with Triton X-100 (TX-100) or diC7PC were prepared by addition 
of the detergent solution to dry PI which will turned optically clear after mixing. Mixed 
micelles examined were either PI (8 mM)/TX-100 (16 mM) or PI (8 mM)/diC7PC (32 
mM) for BtPI-PLC and PI (4 mM)/TX-100 (8 mM) or PI (4 mM)/diC7PC (16 mM) for 
SaPI-PLC. The water-soluble substrate cIP (20 mM for BtPI-PLC and 5 mM for SaPI-
PLC) was used in the absence or presence of 8 mM diC7PC. For the specific activities of 
PI-PLCs toward PI in small unilamellar vesicles (SUVs), the enzyme and SUVs were 
incubated for a fixed length of time at 28 oC, and the reaction was quenched by the 
addition of a few drops of acetic acid (dropping the pH below 4) followed by TX-100 
addition to solubilize the remaining lipids in mixed micelles. The relative integrated 
intensity of the cIP resonance versus the total phospholipid concentration (initial [PI] or 
[PI] + [PC]) was used to calculate PI-PLC specific activity (as shown in Fig. 2-4). For the 
enzymatic assays of cysteine mutant variants, 5 mM DTT was added to avoid formation 
of any protein dimers. 
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Figure 2-4. Characterization of PI-PLC enzymatic reaction by 31P NMR. All the 
phosphorus species involved in the assay system are identified with arrows, including 
phosphatidylinositol (PI), phosphatidylcholine (PC), inositol 1,2-cyclic phosphate (cIP), 
and inositol-1-phosphate (I-1-P). No I-1-P was generated in PI cleavage by controlling 
the amount of enzyme added so that less than 20% product was generated. Inset: a series 
of 31P NMR spectra are shown monitoring the increase of cIP as a function of time in the 
continuous assay; the time increment between spectra was 1.7 min. 
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2.8 PI-PLC Site-Directed Spin Labeling 
    SaPI-PLC cysteine mutants D213C and N254Y/H258Y/D213C were specifically spin 
labeled on the cysteine by 1-oxyl-2,2,5,5-tetramethylpyrroline-3-methyl-methanethio-
sulfonate (MTSL) (Fig. 2-5, Scheme I). MTSL was prepared as a 10 mg/mL (37.8 mM) 
stock solution in methanol and stored at -20 oC. The SaPI-PLC stock protein was diluted 
into 50 mM HEPES buffer (50% D2O, 137 mM NaCl, 2.7 mM KCl, 1 mM EDTA, pH 
7.5) with 5 mM DTT as 5 mg/mL. Salt was added to avoid protein precipitations when 
the protein was mixed with SUVs. After incubation at room temperature for 30 min for 
full reduction of any intermolecular disulfide bonds, DTT was then removed by Micro 
Bio-Spin 6 columns. A 5-fold MTSL over total –SH was then added and the resulting 
solution incubated at room temperature for 2 h on a shaker. The excess spin label reagent 
was removed by three rounds of Micro Bio-Spin 6 columns. The labeling percentage was 
>95%, confirmed by DTNB assay, which is used to quantify the concentration of thiol 
groups in a sample [147]. This assay was done by mixing the DTNB reagent (2 mM 
stock) with 20% SDS, 1 M Tris-HCl, pH 8.0 buffer and either working buffer (as 
background) or protein solution, incubating for 15 min, then measuring the absorbance at 
412 nm. The similar values of spin-labeled protein and background indicated that almost 
all the free –SH was labeled. The prepared protein sample was then mixed with desired 
amount of SUVs solution for field cycling experiments. 
2.9 PI-PLC Labeling with Alexa Fluor 488    
    Fluorescent labeling of proteins was carried out according to the manufacturer’s 
protocol (Invitrogen); schemes for labeling chemistry are shown in Fig. 2-5 (Scheme II 
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and III). The dye was prepared as a 25 mM stock solution in anhydrous DMSO and 
stored at -20 °C. For BtPI-PLC, N168C mutant proteins were specifically labeled at 
Cys168 with the hydrophilic dye Alexa Fluor 488 C5 maleimide (AF488-Cys). Prior to 
labeling, the proteins were incubated with 5 mM DTT at room temperature for 30 min. 
The excess DTT was removed using Micro Bio-Spin 6 columns, which were pre-
equilibrated with buffer (20 mM Tris-HCl, pH 7.0). The dye was added immediately 
(mole ratio of dye:protein=3:1 to 5:1) and the solution incubated in the dark at room 
temperature for 2 h or longer. For different proteins, different amounts of dye were added 
and incubation time needed for optimal labeling efficiency was determined. Some 
proteins required incubation on ice. Since cysteine oxidation can interfere with the 
labeling, argon gas may be layered on top of the samples to remove oxygen prior to 
incubation. The tubes should then be sealed with parafilm. For labeling the N-terminus of 
SaPI-PLC with Alexa Fluor 488 carboxylic acid, succinimidyl ester (AF488-N-term), the 
dye was added into the protein sample at a slightly higher concentration (7 mg/mL, ~200 
µM, mole ratio of dye:protein = 5:1). The SaPI-PLC protein labeling reaction was carried 
out in phosphate buffer, pH 7.2, to maximize preferential labeling of the N terminus 
rather than lysine residues. After removal of unbound dye using three spin columns, the 
absorption at 280 nm for protein plus dye and at 495 nm for the dye were used to estimate 
the number of dye molecules incorporated. The equation used for calculating the labeling 
ratio was:  
[D]/[P]=(εp /εd)*A495/(A280 – 0.1A495) 
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where εp was the extinction coefficient of PI-PLC at 280 nm (refer to 2.4), εd was the 
extinction coefficient of AF488 at 495 nm (71,000 cm-1 M-1) and 0.1 A495 was the 
correction. All the BtPI-PLC variants had a labeling ratio of 100±10%, and the SaPI-
PLCs typically had 93–100% dye incorporation. The N-terminus labeling efficiency of 
SaPI-PLC was also measured by Mass Spectroscopy. Electrospray ionization mass 
spectral data of intact PI-PLC were obtained at the University of Massachusetts Amherst 
Mass Spectrometry Facility (Amherst, MA). For MS sample preparation, the 
concentrated protein solution (~0.3 mg total) was transferred into 5 mM ammonium 
acetate, pH 8.0, using Amicon concentrators and spinning at least eight times to get rid of 
salts. The sample was then lyophilized for MS. Labeling percentages ranged from 80 to 
99% with >70% of the protein containing a single Alexa Fluor 488 moiety and the 
remainder doubly labeled. At 99% labeling efficiency, 25–30% of the labeled protein has 
2 labels, whereas this percentage is lower (20–25%) at 80% labeling. The activity of 
labeled PI-PLC was tested and showed no significantly difference from that of unlabeled 
PI-PLC. 
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Figure 2-5. Labeling schemes for MTSL and Alexa Fluor 488. (I) Site-directed spin 
labeling of cysteine residues by MTSL; (II) Cysteine labeling with Alexa Fluor 488 C5 
maleimide; (III) N-terminus labeling with Alexa Fluor 488 carboxylic acid, succinimidyl 
ester. 
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2.10 Binding of PI-PLCs to Vesicles by Fluorescence Correlation Spectroscopy (FCS) 
    Fluorescence correlation spectroscopy (FCS) based binding assays were performed on 
a lab-built confocal setup based on an IX-70 inverted microscope (Olympus) as shown in 
Fig. 2-6 [145,146]. Alexa Fluor 488 (AF488) fluorescence was monitored at 22 oC with 
samples placed in chambered coverglass wells (Lab-Tek, Nunc), containing 10 nM 
labeled PI-PLCs (*WT, *Mutant where the * denotes AF488 labeling) plus 1 mg/mL 
BSA in 300 µl PBS, pH 7.4 for BtPI-PLC, and 50 mM MES, pH 6.5 for SaPI-PLC. To 
prevent protein adhesion to the wells, the chambers were incubated with 10 mg/mL BSA 
and rinsed with desired buffer prior to use. The anionic substrate analog DOPG was used 
for all FCS experiments because the PI cleavage product DAG leads to vesicle fusion 
[148]. SUVs containing DOPG and various mole fractions of POPC, XPC, were titrated 
into the labeled PI-PLC solutions to assess protein binding. For each XPC, FCS titrations 
were run in duplicate and repeated a second time with different vesicle and protein 
preparations in parallel with *WT binding assays for direct comparisons of apparent Kd 
values. Analysis of the data was based on previous work by Elson, Thompson and others 
[149-153]. The fitted diffusion coefficient for free, AF488-Cys labeled BtPI-PLC was 
54±2 µm2 s-1 and AF488-N-term labeled SaPI-PLC (Dfree) was 50±2 µm2 s-1; the vesicle 
diffusion coefficient, Dbound, determined from analysis of vesicles containing 
fluorescently labeled lipids, was in the range of 12–15 µm2 s-1 [145,146].  
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Figure 2-6. FCS experimental schematic. Individual laser lines from an air-cooled argon-
krypton, multi-line laser are separated using a quartz prism (P). For our experiments, the 
488 nm laser line is isolated and expanded 5 times by two lenses (L1 and L2), in order to 
be reflected into the sample using a 500drlp dichroic (D1). In the IX-70 inverted 
microscope, the 60X water objective (Obj) focuses the laser light into the sample and 
collects the emission. The emission passes through D1 and any remaining scattered laser 
light is blocked by an HQ505lp long pass filter (F1). The emission is focused onto a 30 
µm pinhole by the tube lens (L3) in the microscope to limit the detection volume and 
collimated by lens L4. To calculate the cross-correlation, the fluorescence signal is split 
by a 50-50 beam splitter (BS2) and passes through HQ535/50 bandpass filters (F2 and 
F3) to be focused on two avalanche photodiodes, APD1 and APD2, by lenses L5 and L6, 
respectively. The box shows a typical observation volume (1 µm3) with different species, 
free AF488 labeled protein and vesicle-bound AF488 labeled protein, diffusing in and out 
of the volume.  
 
 
 
      
  
P"
Ar%Kr"
Laser" L1""""""""""L2"
Obj"
"
F1"
L3"
"
L4"
"
F3"
L6"
BS2"
Donor"
APD1"
Acceptor"
APD2"
D1"
F2"
L5"
Pinhole"
AF488%Protein"
SUVs"
Diﬀusing"Fluorescent""
Molecules"
	  	  52 
    FCS experiments were performed using 488 nm excitation as described previously 
[145,146]. To account for the possibility that multiple proteins could bind to the same 
vesicle, autocorrelations (G(τ), obtained in crosscorrelation mode using a 50-50 
beamsplitter) for samples containing SUVs were fit to [152,153]:                                                
                                               G(τ) = Apgp(τ) + Avg v(τ)                                    (1) 
where p and v denote free protein and SUVs that are fluorescent due to PI-PLC binding, 
respectively and Aj is the amplitude of species j. The correlation function for species j, 
gj(τ) is given by [149,151]: 
 
where the values of ωo, the radius of the observation volume, and S, which depends on zo  
the extent of the observation volume, were determined from fits to the rhodamine 110 
calibration data using D=280 µm2 s-1 at 22 oC [150]. τD,j  is the diffusion time and Dj is 
the diffusion coefficient. The fraction of protein bound to the SUVs, f, may be 
determined from Ap and the time-averaged number of proteins in the observation volume 
in the absence of vesicles, <No> [152]: 
                                                  f = 1-Ap<No> =1-Ap/Ap,o                                            (5) 
where Ap,o=1/<No> is  the amplitude for free PI-PLC prior to titration determined from a 
single species fit. When calculating f, Ap,o is corrected for any volume changes from the 
titration. 
    The apparent dissociation constant, Kd, representing PI-PLC partitioning onto the 
vesicle surface, and a cooperativity coefficient, n, were determined using the empirical
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 equation: 
                                                   f = fmax [PL]n/(Kdn+[PL]n)                                        (6) 
where f, is the fraction bound for different total lipid concentrations, [PL], at fixed XPC, 
and fmax is the apparent maximum fraction bound. Representative correlation and binding 
curves are shown in Fig. 2-7A and B. As previously noted, SUVs are quite heterogeneous 
in size and this heterogeneity leads to fmax values of less than 100% (Table 2-2 [146]). In 
the BtPI-PLC system with pure POPC SUVs, the binding curves have hyperbolic shapes, 
so fits were performed with n fixed to 1. However, for POPC/DOPG mixtures with 
XPC<0.4 binding to BtPI-PLC or in the SaPI-PLC system, plots of f versus [PL] are 
noticeably sigmoidal and n was greater than 1. This apparent cooperativity in the case of 
BtPI-PLC likely results from the enzyme’s preference either for the subpopulation of 
vesicles with higher PC content or for PC-rich clusters/regions in the vesicles, both of 
which are scarce when XPC is low. For single vesicle concentrations at specific XPC 
compositions, FCS titrations were run in duplicate and were repeated at least one more 
time with different vesicle and protein preparations. 
    The fits to Equation 1 assume that the distribution of vesicle sizes is homogenous so 
that a single diffusion time (diffusion coefficient) can be used for vesicle bound proteins. 
In fact, the SUV size distributions are quite heterogeneous. Previous work in the lab 
showed that when FCS data are fit assuming that (i) only one protein binds per vesicle 
and (ii) there is only one diffusion time for vesicle bound protein, the SUV size 
heterogeneity has no significant effect on the determined value of the apparent Kd but it 
does result in underestimation of the fraction bound, f, and the maximum fraction bound, 
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fmax, plateaus at less than 100% binding [146]. The vesicle size distributions from 
dynamic light scattering (DLS) experiments for pure phosphatidylglycerol (PG) or 
phosphatidylcholine (PC) vesicles were used to generate simulated datasets in Matlab 
(Mathworks) [146]. For a given phospholipid concentration and Kd, the fraction bound, f, 
was calculated from Equation 6 with n=1. Datasets were generated using different values 
of α, the brightness of the vesicle relative to free protein according to: 
                                           
G τ( ) = Apgp τ( ) + Av P Dj( )gvj τ( )
j
∑                          (7) 
where P(Dj), derived from the DLS data, is the probability that an SUV has diffusion 
coefficient Dj. Ap and Av are the amplitudes for the free protein and vesicle bound protein, 
respectively, and the diffusion only correlation function for species i, gi(τ), is given by 
Equations 2-4. The amplitudes used in Equation 7 were calculated from the values of f 
and α: 
Ap = (1-f)Apo            (8)                Av = α(Apo – Ap)                (9) 
where Apo, the protein amplitude in the absence of vesicles, is set to 1. Equation 7 does 
not account for the more complicated situation where α is dependent on vesicle size, e.g. 
that larger vesicles are brighter because they bind more proteins or that PI-PLC prefers 
smaller vesicles making the small vesicles brighter.  
    The resulting simulated datasets were fit to Equation 1 using Origin (OriginLab). As a 
control, data were generated using a single diffusion coefficient for the vesicles, and fits 
to these data generated randomly distributed residuals and the input values for the 
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apparent Kd and f (data not shown). For the data simulated using a distribution of vesicle 
sizes and Equation 7, the fitting results were similar to those obtained when one protein 
was assumed to bind per vesicle [146]: (i) the residuals for the fits to the correlations 
were structured (ii) the values of f were underestimated (iii) the values obtained for the 
apparent Kd were not significantly different from the input values (Table 2-2). In addition, 
how much f is underestimated depends both on the vesicle size distribution used to 
simulate the data and on the value of α. As α increases, the values of f obtained from the 
fits decrease (Table 2-2). Therefore, the assumption that the SUV population is 
homogeneous when it is in fact heterogeneous results in accurate values for the apparent 
Kd and underestimated values for the fraction of protein bound to vesicles.  
    For *WT BtPI-PLC, f values determined using equations 1 and 5 (Fig. 2-7) were 
similar to those determined previously [145,146] where it was assumed that on average, 
one PI-PLC is bound per SUV. The average brightness of the SUVs relative to the protein 
[152], α = Av/(Ap,o-Ap), is shown in Fig. 2-8 as a function of phospholipid concentration 
for *WT BtPI-PLC. In low affinity conditions α ~ 1 indicating that on average one 
protein is bound per vesicle. For conditions where *WT BtPI-PLC has high affinity for 
vesicles, α is dependent on the vesicle concentrations with α ~ 1 at low and high vesicle 
concentrations and α = 2-3 for moderate vesicle concentrations indicating that more than 
one protein binds to each vesicle. For SaPI-PLC, the values of α are around 1 due to the 
weaker affinity of the enzyme for vesicles, indicating that for SaPI-PLC and these small 
PG/PC vesicles, on average one protein is bound per SUV during the diffusion time of 
~190 ms. 
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Table 2-2. Results from fitting the FCS data of *WT BtPI-PLC to Equation 1. The fitting 
is using Kd = 10 µM and size distributions from DLS for pure PC or pure PG SUVs. 	  
 
Vesicle	  
Distribution	  
Dv	  (μm2/s)	  
from	  fit	  	  
α	  	  in	  
simulation	  
α	  	  
from	  fit	  
Kd	  (μM)	  
from	  fit	  
fmax	  
from	  fit*	  
Distribution	  of	  
PC	  SUVs	   13.8	   1.0	   1.0	   10	   0.94	  
Distribution	  of	  
PG	  SUVs	   20.3	   1.0	   1.0	   10	   0.92	  
Distribution	  of	  
PC	  SUVs	   13.8	   0.80	   0.79	   10	   0.95	  
Distribution	  of	  
PG	  SUVs	   20.3	   0.80	   0.79	   10	   0.93	  
Distribution	  of	  
PC	  SUVs	   13.8	   1.5	   1.6	   10	   0.91	  
Distribution	  of	  
PG	  SUVs	   20.3	   1.5	   1.6	   10	   0.87	  
Distribution	  of	  
PC	  SUVs	   13.8	   2.0	   2.1	   10	   0.88	  
Distribution	  of	  
PG	  SUVs	   20.3	   2.0	   2.2	   10	   0.83	  
 
	  	  *Note	  the	  underestimation	  of	  fmax.	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Figure 2-7. Representative normalized correlations and binding curves for *WT BtPI-
PLC. (A) Normalized correlation curves for 10 nM *WT BtPI-PLC in solution (solid 
squares), in the presence of 15.5 µM PC SUVs (open circle), and 3335 µM PC SUVs 
(open triangel). The lines through these data are fits to Equation 1 with diffusion 
coefficient for the SUVs fixed at 15 µm2 s-1. The error bars are the S.D. calculated by 
subdividing the raw data into 50 sections. (B) Titration curves showing the fraction of 
*WT BtPI-PLC bound to pure POPC SUVs (solid squares), DOPG/POPC (XPC = 0.25) 
SUVs (open circles). Error bars represent the S.D. from 3 independent sets of titrations. 	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Figure 2-8. The dependence of α, the relative brightness of the vesicles, on total 
phospholipid concentration for WT BtPI-PLC (10 nM). α = Av/(Ap,o-Ap) where the vesicle 
and protein amplitudes, Av and Ap, respectively  were determined by fits to equation 1 in 
the main text, and Ap,o is the correlation amplitude in the absence of vesicles. The SUV 
lipid compositions are indicated in the legend. 
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2.11 Binding of SaPI-PLC to SUVs by Centrifugation-Filtration Assay 
     Estimation of apparent dissociation constants for SaPI-PLC proteins partitioning onto 
PG/PC SUVs was also carried out using a centrifugation/filtration assay described 
previously for this system [154]. Vesicle samples were incubated with 0.2 mg/mL protein 
in 0.5 mL of 50 mM MES (pH 6.5) or HEPEs (pH 7.5). After incubation for 15 min, the 
free proteins were separated from vesicle bound proteins by centrifugation through a 100 
kDa cut-off filter. Filtrates were analyzed by the DC BCA protein assay (according the 
instruction manual supplied by Bio-Rad) to calculate the free enzyme concentration, Ef, 
by comparing free protein concentrations from vesicle containing samples to the total 
enzyme, Et, for enzyme without vesicles centrifuged through the filter. The fraction 
bound to vesicles, fb, can then be calculated by  
fb= (Et-Ef)/Et 
For fixed vesicle concentrations, the values of fb can be used to compare the binding 
affinity of different mutant protein under certain conditions. 
2.12 PI-PLC Line Broadening of the diC7PC 31P Resonance 
    DiC7PC was titrated into a solution of 3 mg/mL (0.085 mM) PI-PLCs in the desired 
buffers containing 1 mM EDTA. Protein-induced line broadening at 242.76 MHz was 
measured on a Varian VNMRS 600 spectrometer. For the bacterial PI-PLCs with 
significant PC affinity, the lipid linewidth increases dramatically around the CMC (1.5 
mM [10]), as protein/lipid micelle complexes form, and then decreases as more diC7PC is 
added to reach a limiting linewidth. Proteins with weakened affinity for PC have very 
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little effect on the diC7PC 31P linewidth [30]. Linewidths at a given diC7PC concentration 
were measured for duplicate samples. 
2.13 Intrinsic Fluorescence of PI-PLC 
    Intrinsic fluorescence measurements of PI-PLCs (0.2 µM) were carried out on a Horiba 
Jobin Yvon FL3-22 Fluorolog Spectrometer (HORIBA Scientific, Edison, NJ). Samples 
were excited at 282 nm, and changes in the fluorescence intensity at the emission 
maximum, 337 nm, upon the addition of diC7PC were expressed as (I - I0)/I0, where I0 is 
the emission intensity of protein alone and I is the intensity in the presence of diC7PC. A 
small amount of background signal from buffer solution or buffer with different 
concentrations of diC7PC was subtracted from the control and sample intensities. The 
dependence of (I - I0)/I0 on diC7PC concentrations reflects protein binding affinity for 
that short chain lipid [31]. 
2.14 High Resolution 31P Field-Cycling NMR Spectroscopy 
   High resolution 31P field cycling NMR spin-lattice (R1) relaxation measurements, using 
a custom-built high resolution field cycling system on a Varian Unityplus 500 
spectrometer (Varian, Cary, NC) [155], were carried out with spin-labeled SaPI-PLC 
spin-labeled at D213C, placing the spin-label at a comparable position to its most 
effective position in BtPI-PLC, D205C [34]. The much larger dipole of the unpaired 
electron can relax 31P fast-exchanging into and out of a discrete binding site and back into 
the bilayer. The field dependence of the increase in R1 caused by the spin label for each 
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lipid (ΔR1) in a vesicle compared to the control (unlabeled protein) can be fit with the 
following expression:   
ΔR1 = RP-e(0)/(1 + ω2τP-e2)) + c 
Here RP-e(0) is the maximum relaxation enhancement for that fraction of ligand bound to 
the spin-labeled protein, and τP-e is the correlation time for the bound phospholipid/spin-
labeled PI-PLC interaction. A constant residual R1 at higher fields, c, is likely to reflect a 
limiting CSA contribution due to the paramagnetic interaction. 
    The parameters RP-e(0) and τP-e along with the total spin-labeled PI-PLC concentration, 
[PI-PLC-SL], and phospholipid concentration, Lo, are related to rP-e, the distance between 
the phospholipid 31P and the nitroxide when the ligand is bound. To a first approximation 
we assume that if there is a discrete site on the protein for an individual phosphorylated 
molecule, it is saturated with 3-5 mM of the ligand. We also assume that we are looking 
at a single PC or PMe binding in a given site for a time approaching 0.5 µs, long enough 
to suggest a specific complex as opposed to nonspecific lateral diffusion of the lipids 
around the protein, and that only phospholipid in the outer leaflet of the bilayer is in 
contact with the protein. For these small vesicles on average about 2/3 of the total of a 
specific phospholipid is in this monolayer. The average distance of the bound 
phospholipid on the protein at a specific site is calculated from the following expression: 
       rP-e6 = [PI-PLC-SL]/{(2/3)[ L]o} ×(S2 τP-e / RP-e(0)) (0.3 µ2(h/2π)2 γP2 γe2) 
S2, the order parameter of the electron spin-31P dipolar interaction, is approximated as 1 
because of the long rP-e compared to the size of local picosecond motions; µ, γP and γe are 
constants defined previously [145,146].  
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2.15 RAW264.7 Cell Culture and Activation with LPS 
    The RAW264.7 murine macrophage line (ATCC) was incubated at 37°C in a 5% CO2 
atmosphere at 95% humidity. Cells were maintained below 90% confluence, and the 
media was changed 2-3 times per week. Cells were sub-cultured at a ratio of 1:4. 
Adherent cells were passaged by incubating with 0.25% trypsin-EDTA for 2 min and 
scraping with a cell scraper. The RAW264.7 cell lines was cultured in DMEM 
supplemented with 25 mM glucose, 4 mM L-glutamine, 10% FBS, and 1 µL/mL 
Mycozap CL. LPS stimulation was carried by directly adding the desired amount LPS 
into the fresh changed medium and incubating for a period of time. The LPS stimulation 
time and concentration needed for optimal itaconic acid (ITA) production were 
determined by varying the incubation time (1 to 24 h) and LPS concentrations (0.5 ng/mL 
to 50 µg/mL).  
2.16 RAW264.7 Cell Stimulation with Toll-like Receptor (TLR) agonists 
    The murine Toll-like Receptor (TLR) agonists used to stimulate the RAW264.7 cells 
were included in the Invivogen Mouse TLR 1-9 Agonist Kit (Table 2-3). RAW264.7 
cells were grown to confluence in supplemented DMEM by using 60 mm cell culture 
plates and 3 mL fresh medium was added to each plate an hour prior to stimulation. The 
cells were stimulated with seven types of TLR agonists at concentrations (Table 2-3) 
sufficient to match or exceed the minimum working concentrations suggested by the 
Invivogen (http://www.invivogen.com/mouse-tlr1-9-agonist-kit). The cells unstimulated 
were used as controls. After 12 h of incubation, the cells were washed with PBS, 
harvested and stored at -80° C for later enzymatic analysis.   
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Table 2-3. The types of murine TLR agonists and concentrations used during cell 
stimulation. 
 
Agonist	   Target	   Specificity	   Concentration	  	  
Pam3CSK4	  
	  
	  
	  
TLR1/2	  
	  
	  
	  
A	  synthetic	  lipopeptide	  (LP)	  that	  simulates	  
the	  acylated	  amino	  terminus	  of	  bacterial	  
LP;	  a	  potent	  activator	  of	  the	  prion-­‐
flammatory	  transcription	  factor	  NF-­‐κB	  
10	  μg/mL	  
	  
	  
	  
HKLM	  
	  
TLR2	  
	  
A	  heat-­‐killed	  preparation	  of	  Listeria	  
monocytogenes	  
109	  cells/mL	  
	  
Poly(I:C)	  
	  
TLR3	  
	  
Polyinosinic-­‐polycytidylic	  acid:	  a	  synthetic	  
analog	  of	  double-­‐stranded	  RNA	  (dsRNA)	  
500	  μg/mL	  
	  
LPS-­‐EK	  
	  
TLR4	  
	  
Lipopolysaccharide	  (LPS)	  derived	  from	  E.	  
coli	  K12	  
100	  μg/mL	  
	  
FLA	  
	  
TLR5	  
	  
Flagellin	  isolated	  from	  Salmonella	  
typhimurium	  
10	  μg/mL	  
	  
FSL-­‐1	  
	  
	  
TLR6/2	  
	  
	  
A	  synthetic	  lipoprotein	  derived	  from	  
Mycoplasma	  salivarium	  similar	  to	  M.	  
fermentans	  derived	  LP	  
10	  μg/mL	  
	  
	  
ssRNA40	  
	  
	  
TLR7	  
	  
	  
A	  U-­‐rich	  20-­‐mer	  phosphorothioate	  
protected	  single-­‐stranded	  RNA	  derived	  
from	  the	  HIV-­‐1	  long	  terminal	  repeat	  
25	  μg/mL	  
	  
	  
  
	    
	  	  64 
2.17 Itaconic Acid (ITA) Analysis by 1H NMR 
    ITA is produced from cis-aconitate by a cis-aconitate decarboxylase (cADC). To assay 
the production of this metabolite by RAW264.7 cells, protein extracts were prepared and 
then assayed using 1H NMR. The assay is based on the observation that the chemical 
shifts of the –CH=CH2 protons of ITA are quite different from those in cis-aconitate (Fig. 
2-9). Confluent flasks of RAW264.7 cells were washed with PBS buffer and scraped into 
ice-cold hypotonic lysis buffer (20 mM HEPES, 3 mM MgCl2, 1 mM PMSF and 10 
µL/mL protease inhibitor cocktail, pH 7.5) and incubated on ice for 10 minutes in order 
to obtain a crude lysate. Cells were lysed by Ultrasonic Processor (Cole-Parmer, Vernon 
Hills, IL) until >90% were visible by Trypan Blue staining. To perform the crude lysate 
assays, an aliquot of a 200 mM cis-aconitic acid solution freshly prepared in lysis buffer 
and adjusted to neutral pH was added to a final concentration of 10 mM. Lysates were 
then incubated at 37°C with shaking at 100 rpm for 3 h. For metabolite extraction, a 4-
fold volume of ice cold methanol was added and samples were incubated on ice for 10 
min before centrifugation at 14,000 rpm, 4°C. The supernatant was dried under N2 gas, 
lyophilized, and dissolved in D2O for NMR analysis (Fig. 2-9, Scheme I). For partially 
purified fractions and enzyme assay, the reaction was quenched by NaOH; after 
lyophilization the samples were resuspended in D2O and 1H NMR spectra acquired at 600 
MHz (Fig. 2-9, Scheme II). Data were analyzed using VNMRJ software.  
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Figure 2-9. Characterization of cADC activity. (I) Characterization scheme for cell 
extract; (II) Characterization scheme for purified cADCs. The bottom box shows 
comparison of 1H NMR spectra of cis-aconitic acid (5.61 ppm), itaconic acid (5.82 and 
5.34 ppm) and enzymatic reaction with less than 20% product.  
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2.18 Actinomycin D Asssay 
    In cell biology, actinomycin D (ActD) is used to inhibit transcription. This compound 
can bind DNA at the transcription initiation complex and preventing elongation of RNA 
chain by RNA polymerase. However, ActD also shows toxicity to the mammalian cells. 
The RAW264.7 cells were monitored hour by hour (cell viability were checked under 
microscope) after applying different amount of ActD (from 10 ng/mL to 1 µg/mL) and 10 
ng/mL LPS. These cells were harvested to check cADC activity retaining.  
2.19 Partial Protein Purification of RAW264.7 Cell Extract 
    The crude lysate after sonication was further separated by regular centrifuge first 
(14,000 rpm, 30 min), both the supernatant and pellet was used to do cADC activity 
characterization. The high-level centrifugation, ultracentrifugation, was used to further 
separate the supernatant fractions (100,000×g, 90 min) on the TLA 120.2 rotor of an 
Optima TLX Ultracentrifuge (Beckman Coulter, Inc., Pasadena, CA).  
    Several protein purification methods were used to further separate the most active 
fractions for ITA production from the complex mixture of proteins in the cell lysate. 
Initially, an ion-exchange column was used to purify supernatant after ultracentrifugation. 
Upon application of a 0 to 0.6 M NaCl grandient (in 20 mM Tris-HCl, pH 8.0), the 
protein fractions were characterized for ITA production using the 1H NMR cADC 
activity assay. The protein fractions that generated ITA were collected for further 
purification steps, e.g., a hydrophobic column and gel-filtration. Superdex 75 and 200 
gel-filtration columns were used to separate the most active fractions and determine the 
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molecular weight range of the target enzyme by comparing with standard gel-filtration 
curve. 
2.20 Proteomics Study by Mass Spectrometry (MS) 
    Attempts to identify the cADC protein were carried out by Mass Spectrometry (MS) 
by comparing proteins in the same amount of unstimulated and stimulated RAW cells 
after the same steps of purification (sonication, centrifugation, ion-exchange purification). 
The protein fractions were collected for in-solution trypsin digestion and MS analysis of 
peptides. The two solutions were lyophilized first to concentrate the sample (and 
minimize the volume for MS), then resuspended in 30 µL of 8 M urea in PBS buffer, pH 
7.5. 100 mM ammonium bicarbonate was added to make a final volume of 100 µL, 
followed by heating the sample at 65 oC for 15 min with 150 mg/mL DTT. The samples 
then stayed at room temperature for 30 min with 92 mg/mL iodoacetamide. The samples 
were mixed by vortexing rapidly with adding 120 µL PBS buffer, after which trypsin was 
added at a ratio of 1:50 (enzyme: substrate) with 1 mM CaCl2 to digest the protein 
samples at 37 oC overnight. Trypsin cleavage was quenched with 5% of formic acid and 
the samples were centrifuged at 15,000 rpm for 20 min to pellet the undigested and 
precipitated protein. The supernatant was loaded on the column for MS analysis.	   The 
proteomics study of RAW264.7 cells by MS was done by Julianne Martell and Prof. 
Eranthie Weerapana (Department of Chemistry, Boston College, Chestnut Hill, MA). 
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2.21 Transfection of siRNA 
    In order to further confirm the cADC activity of IRG1 protein, the RAW264.7 cells 
were transfected with siRNA using ON-TARGETplus SMARTpool of Mouse IRG1 
genes. The cells were diluted to a density of 200, 000 cells/mL, and around 700,000 cells 
were plated in each of the 60 mm plates 24 h prior to transfections so that the monolayer 
cell density reached ~60% confluence at the time of transfection. The IRG siRNA 
transfection experiment followed the general protocol for transfecting siRNA in 
RAW264.7 cells provided by SignaGen Lab but with some changes. At 1 h before the 
transfections, fresh DMEM with FBS and antibiotics was added into each plate. The 
transfection complex was made by mixing 300 µL GenMute Transfection buffer, siRNA 
(either Mouse IRG1 siRNA or control siRNA) stock and 12 µL GenMute reagent to get a 
final concentration of 30 nM siRNA per well (this volume is for 60 mm plates). After 
incubation for ~15 min at room temperature, which allows the transfection complex to 
form, the solution was added to the cells dropwise while gently rocking the plate back 
and forth. The transfection medium was replaced by fresh DMEM ~5 h after transfections. 
After 16 h incubation, half of the plates were stimulated with 10 ng/mL LPS for 8 h. 
Changes in the cADC activity of untransfected cells, cells transfected with control siRNA 
and cells transfected with targeting siRNA of various concentrations were monitored. The 
DC BCA protein assay was used to quantify the total protein amount in each of the cell 
lysates to minimize the differences among each transfection cycles.  
2.22 Cloning and Overexpression of Immuneresponsive Gene 1 (IRG1) into pTXB1  
    The mouse IRG1 gene sequence shown in Fig. 2-10, was theoretically calculated to be 
	  	  69 
unstable by ProtParam (http://web.expasy.org/protparam/) with a computed instability 
index of 43.19.  
     A fusion protein tagged overexpression system was used for IRG1 cloning since 
fusion proteins facilitate protein purification and immobilization by using different kinds 
of molecular tags that can be used for affinity purification. After trying several 
overexpression systems, including His-tagged, GST-tagged, MBP-tagged, etc., only the 
IMPACT system was successful for IRG1 overexpression in E. coli. The pTXB1 system, 
as one vector of IMPACT system, allows the target gene to be cloned immediately 
adjacent to the intein cleavage site (without any extra amino acids by cloning into the 
NdeI and SapI sites). A C-terminus self-cleavable intein (~28 kDa) tagged fusion protein, 
which contains the chitin binding domain (CBD, 6 kDa), is generated and used for 
affinity purification of the fusion precursor on a chitin column. The native recombinant 
protein without modifications is then released by thiol induced self-cleavage activity of 
intein.  
    For the IRG1 gene, a NheI restriction site was used for cloning the 5’end of target gene, 
with the forward primer 5’-gcggGCTAGCatgatgctcaagtctgtcacagag-3’ (NheI site 
underlined). A SapI restriction site was used for cloning the 3’end of target gene with the 
reverse primer 5’-ggtggttGCTCTTCcgcaattggtaaacctgggcaacg-3’ (SapI site undelined). 
The C-terminal residue of the target protein has an effect on DTT-induced cleavage with 
pTXB1. The C-terminal amino acid of IRG1 protein, isoleucine only exhibits 60-85% 
cleavage after 16 h induction at 23 oC. Therefore, it was deleted to leave asparagine as the 
C-terminus (Asn exhibits 80-95% cleavage after 16 h induction at 23 oC). Target genes 
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flanked with NheI and SapI sites were amplified by PCR then inserted into the pTXB1 
vector. The entire DNA sequence of the inserted target gene was determined by Genewiz 
using the T7 promotor and Mxe Intein Reverse II Primer (5'-gattgccatgccggtcaagg-3’). 
    The plasmid pTXB1-IRG1 was transformed into E. coli host cells for overexpression. 
LB media containing 34 µg/mL chloroamphenicol and 100 µg/mL ampicillin was 
inoculated at 37°C with 5 mL freshly grown cultures and inoculated until O.D.600 nm 
reached 0.7-0.8. IPTG was added to the final concentration of 0.2 mM for induction of 
IRG1 protein expression. The cells continued to grow at 16°C overnight (16 h). Cell 
extract supernatants from disrupting cells by sonication and centrifuging 15,000 rpm for 
35 min exhibited cADC activity. However, only the cell debris showed an obvious 
overexpressed protein band corresponding to a MW of 82 kDa on SDS-PAGE gel (Fig. 
2-12A).   
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Figure 2-10. Immunoresponsive Gene 1 DNA and corresponding amino acid sequences. 
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ATGATGCTCAAGTCT GTCACAGAGAGCTTT GCTGGTATGATTCAC GGCTTGAAAGTGAAC 
 M  M  L  K  S   V  T  E  S  F   A  G  M  I  H   G  L  K  V  N  
CACCTGACAGATGGT ATCATTCGGAGGAGC AAGAGGATGATCCTG GATTCTCTGGGCGTT 
 H  L  T  D  G   I  I  R  R  S   K  R  M  I  L   D  S  L  G  V  
GGCTTCCTGGGGACA GGCACAGAAGTGTTC CATAAAGTCACCCAA TATAGTAAAATCTAC 
 G  F  L  G  T   G  T  E  V  F   H  K  V  T  Q   Y  S  K  I  Y  
AGTTCCAACACCTCC AGCACTGTTTGGGGT CGACCAGACTTCAGG CTCCCACCGACATAT 
 S  S  N  T  S   S  T  V  W  G   R  P  D  F  R   L  P  P  T  Y  
GCTGCTTTTGTTAAT GGTGTTGCTGTTCAC TCCATGGATTTTGAT GACACATGGCACCCT 
 A  A  F  V  N   G  V  A  V  H   S  M  D  F  D   D  T  W  H  P  
GCCACCCACCCTTCT GGGGCTGTCCTACCT GTCCTCACAGCTCTA TCGGAAGCCCTGCCT 
 A  T  H  P  S   G  A  V  L  P   V  L  T  A  L   S  E  A  L  P  
CAGACTCCCAAGTTT TCTGGCCTCGACCTG CTGCTGGCGTTCAAC GTTGGTATTGAAGTA 
 Q  T  P  K  F   S  G  L  D  L   L  L  A  F  N   V  G  I  E  V  
CAGGGACGATTAATG CACTTCTCCAAGGAA GCCAAAGACATACCA AAGAGATTCCACCCT 
 Q  G  R  L  M   H  F  S  K  E   A  K  D  I  P   K  R  F  H  P  
CCCTCTGTGGTGGGG ACTCTGGGAAGTGCT GCTGCTGCGTCCAAG TTTCTGGGGCTCAGC 
 P  S  V  V  G   T  L  G  S  A   A  A  A  S  K   F  L  G  L  S  
TTGACAAAGTGCCGC GAGGCATTGGCTATT GCTGTTTCCCACGCA GGGGCACCCATAGCG 
 L  T  K  C  R   E  A  L  A  I   A  V  S  H  A   G  A  P  I  A  
AACGCTGCCACTCAG ACTAAGCCCCTTCAT ATTGGCAATGCAGCC AAGCATGGGATGGAA 
 N  A  A  T  Q   T  K  P  L  H   I  G  N  A  A   K  H  G  M  E  
GCCACGTTTCTGGCA ATGCTGGGCCTCCAA GGAAACAAACAGATC TTGGACCTGGGGTCA 
 A  T  F  L  A   M  L  G  L  Q   G  N  K  Q  I   L  D  L  G  S  
GGGTTCGGTGCCTTC TATGCCAACTACTCC CCCGAAGACCTTCCA AGCCTGGATTCTCAC 
 G  F  G  A  F   Y  A  N  Y  S   P  E  D  L  P   S  L  D  S  H  
ATCTGGCTGTTGGAC CAGCAGGATGTGGCC TTTAAGAGCTTCCCG GCACATCTGGCTACC 
 I  W  L  L  D   Q  Q  D  V  A   F  K  S  F  P   A  H  L  A  T  
CACTGGGTGGCAGAT GCAGCTGCAGCCGTG AGAAAGCACCTTGTG ACACCAGAAAGAGCC 
 H  W  V  A  D   A  A  A  A  V   R  K  H  L  V   T  P  E  R  A  
CTGTTCCCTGCTGAC CACATCGAGAGAATC GTGCTCAGGATCCCT GACGTCCAGTACGTA 
 L  F  P  A  D   H  I  E  R  I   V  L  R  I  P   D  V  Q  Y  V  
AACAGGCCCTTCCCG GACTCAGAGCATGAA GCCCGTCATTCTTTC CAGTATGTGGCCTGT 
 N  R  P  F  P   D  S  E  H  E   A  R  H  S  F   Q  Y  V  A  C  
GCCTCGCTGCTCGAC GGTAGCATCACTGTC CCATCCTTCCACAGC CAGCAGGTCAATAGG 
 A  S  L  L  D   G  S  I  T  V   P  S  F  H  S   Q  Q  V  N  R  
CCTCAGGTGAGAGAG TTGCTCAAGAAGGTG AAGCTGGAGCATCCT CCTGACAACCCGCCA 
 P  Q  V  R  E   L  L  K  K  V   K  L  E  H  P   P  D  N  P  P  
AGCTTCGACACGCTA TACTGTGAAATAAGC ATCACTCTAAAGGAC GGGACCACTTTCACC 
 S  F  D  T  L   Y  C  E  I  S   I  T  L  K  D   G  T  T  F  T  
GAGCGCTCTGACACC TTCTATGGTCACTGG AGGAAACCACTGAGC CAGGAAGATCTGCGC 
 E  R  S  D  T   F  Y  G  H  W   R  K  P  L  S   Q  E  D  L  R  
AACAAGTTCCGAGCC AATGCCTCAAAGATG CTATGCAGGGACACG GTGGAAAGCCTTATA 
 N  K  F  R  A   N  A  S  K  M   L  C  R  D  T   V  E  S  L  I  
ACGGTAGTAGAAAAG CTAGAAGACCTAGAA GACTGCTCTGTGCTA ACCAGACTTCTGAAA 
 T  V  V  E  K   L  E  D  L  E   D  C  S  V  L   T  R  L  L  K  
GGACCCTCTGTCCAA GATGAAGCTTCAAAA CTATCCAGCATGTCC TCATTCGATCACACA 
 G  P  S  V  Q   D  E  A  S  K   L  S  S  M  S   S  F  D  H  T  
ACGTTGCCCAGGTTT ACCAATATCTAA 
 T  L  P  R  F   T  N  I  *  
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    The first step of purification was elution form a chitin column. After loading 
supernatant (0.5 mL/min), the chitin column was washed with ~500 mL high-salt column 
buffer (20 mM Tris-HCl, 1.0 M NaCl, pH 8.5), then ~500 mL medium-salt column buffer 
(20 mM Tris-HCl, 0.5 M NaCl, pH 8.5) at flow rate of 2 mL/min and finally quickly 
washed with 3 column volumes of DTT containing cleavage buffer (20 mM Tris-HCl, 0.5 
M NaCl, pH 8.5, 50 mM DTT). The on-column cleavage of the fusion protein was 
carried at 4 oC for 16-20 hours with 2 column volumes of DTT containing buffer to 
ensure a sufficient yield of IRG1 protein (room temperature was avoided because of the 
predicted low stability of the target protein). The target protein with the intein-tag cleaved 
was eluted from the chitin column and dialyzed at 4 oC. That solution was then applied to 
a QFF column. Proteins were eluted with a 0 to 0.5 M NaCl gradient (in 20 mM Tris-HCl, 
1 mM DTT, pH 8.0). Fractions from 0.09 to 0.2 M NaCl gradient had the purest protein. 
Elution at that salt concentration is consistent with where cADC activity eluted in the 
partial purification from the RAW 264.7 cell extract. Recombinant IRG1 protein was 
collected and concentrated for storage.  The best yield of IRG1 was 2.5 mg/L. 
2.23 Cloning and Overexpression of Fungal cis-Aconitate Decarboxylase (cADC)  
    The cis-aconitate decarboxylase (cADC) gene from Aspergillus terreus was a generous 
gift from Dr. A. Li, TNO Microbiology and Systems Biology, The Netherlands. The gene 
and amino acid sequence are shown in Fig. 2-11. The cADC enzyme was theoretically 
calculated to be unstable by ProtParam with a computed instability index of 43.89.  
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Figure 2-11. A. terreus cis-aconitate decarboxylase DNA and corresponding amino acid 
sequences. 
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ATGACCAAGCAATCT GCGGACAGCAACGCA AAGTCAGGAGTTACG GCCGAAATATGCCAT 
 M  T  K  Q  S   A  D  S  N  A   K  S  G  V  T   A  E  I  C  H  
TGGGCATCCAACCTG GCCACTGACGACATC CCTTCGGACGTATTA GAAAGAGCGAAATAC 
 W  A  S  N  L   A  T  D  D  I   P  S  D  V  L   E  R  A  K  Y  
CTGATTCTCGATGGT ATTGCATGTGCCTGG GTTGGTGCAAGAGTG CCTTGGTCAGAGAAG 
 L  I  L  D  G   I  A  C  A  W   V  G  A  R  V   P  W  S  E  K  
TATGTGCAGGCAACA ATGAGCTTTGAGCCG CCAGGAGCCTGCAGG GTGATTGGATATGGG 
 Y  V  Q  A  T   M  S  F  E  P   P  G  A  C  R   V  I  G  Y  G  
CAGAAACTGGGGCCT GTTGCAGCAGCCATG ACCAATTCCGCTTTC ATACAGGCCACAGAG 
 Q  K  L  G  P   V  A  A  A  M   T  N  S  A  F   I  Q  A  T  E  
CTTGACGACTACCAC AGCGAAGCCCCCCTA CACTCTGCAAGCATC GTCCTCCCTGCGGTC 
 L  D  D  Y  H   S  E  A  P  L   H  S  A  S  I   V  L  P  A  V  
TTTGCAGCAAGTGAG GTCTTAGCCGAGCAA GGCAAAACAATTTCT GGTATAGATGTCATT 
 F  A  A  S  E   V  L  A  E  Q   G  K  T  I  S   G  I  D  V  I  
CTAGCCGCCATTGTG GGGTTTGAATCTGGC CCGCGGATCGGCAAA GCAATTTACGGATCG 
 L  A  A  I  V   G  F  E  S  G   P  R  I  G  K   A  I  Y  G  S  
GACCTCTTGAACAAC GGCTGGCATTGTGGA GCCGTGTATGGTGCT CCAGCTGGTGCGCTG 
 D  L  L  N  N   G  W  H  C  G   A  V  Y  G  A   P  A  G  A  L  
GCCACAGGAAAGCTC CTCGGTCTAACTCCA GACTCCATGGAAGAT GCTCTCGGAATCGCG 
 A  T  G  K  L   L  G  L  T  P   D  S  M  E  D   A  L  G  I  A  
TGCACGCAAGCCTGT GGTTTAATGTCGGCG CAATACGGAGGCATG GTCAAGCGCGTGCAA 
 C  T  Q  A  C   G  L  M  S  A   Q  Y  G  G  M   V  K  R  V  Q  
CATGGATTCGCAGCG CGTAATGGTCTTCTT GGGGGACTGTTGGCC TATGGTGGGTACGAG 
 H  G  F  A  A   R  N  G  L  L   G  G  L  L  A   Y  G  G  Y  E  
GCCATGAAGGGTGTC CTGGAGAGATCTTAT GGCGGTTTCCTCAAA ATGTTCACCAAGGGC 
 A  M  K  G  V   L  E  R  S  Y   G  G  F  L  K   M  F  T  K  G  
AATGGCAGAGAGCCT CCCTACAAAGAGGAG GAAGTGGTGGCCGGT CTCGGTTCATTCTGG 
 N  G  R  E  P   P  Y  K  E  E   E  V  V  A  G   L  G  S  F  W  
CATACCTTTACTATT CGCATCAAGCTCTAT GCCTGCTGCGGACTT GTCCATGGTCCAGTC 
 H  T  F  T  I   R  I  K  L  Y   A  C  C  G  L   V  H  G  P  V  
GAAGCTATCGAAAAG CTTCAGAGGAGATAC CCCGAGCTCTTGAAT AGAGCCAACCTCAGC 
 E  A  I  E  K   L  Q  R  R  Y   P  E  L  L  N   R  A  N  L  S  
AACATTCGCCATGTT TATGTACAGCTTTCA ACAGCCTCGAACAGT CACTGTGGATGGATA 
 N  I  R  H  V   Y  V  Q  L  S   T  A  S  N  S   H  C  G  W  I  
CCAGAGGAGAGGCCC ATCAGTTCAATCGCA GGGCAGATGAGTGTC GCATACATCCTCGCC 
 P  E  E  R  P   I  S  S  I  A   G  Q  M  S  V   A  Y  I  L  A  
GTCCAGCTGGTCGAC CAGCAATGTCTTCTG GCTCAGTTTTCTGAG TTTGATGACAACTTG 
 V  Q  L  V  D   Q  Q  C  L  L   A  Q  F  S  E   F  D  D  N  L  
GAGAGACCAGAAGTG TGGGATCTGGCCAGG AAGGTTACTCCATCT CATAGCGAAGAGTTT 
 E  R  P  E  V   W  D  L  A  R   K  V  T  P  S   H  S  E  E  F  
GATCAAGACGGCAAC TGTCTCAGTGCGGGT CGCGTGAGGATTGAG TTCAACGATGGCTCT 
 D  Q  D  G  N   C  L  S  A  G   R  V  R  I  E   F  N  D  G  S  
TCTGTTACGGAAACT GTCGAGAAGCCTCTT GGAGTCAAAGAGCCC ATGCCAAACGAACGG 
 S  V  T  E  T   V  E  K  P  L   G  V  K  E  P   M  P  N  E  R  
ATTCTCCACAAATAC CGAACCCTTGCGGGT AGCGTGACGGACGAA TCCCGGGTGAAAGAG 
 I  L  H  K  Y   R  T  L  A  G   S  V  T  D  E   S  R  V  K  E  
ATTGAGGATCTTGTC CTCAGCCTGGACAGG CTCACCGACATTACC CCATTGCTGGAGCTG 
 I  E  D  L  V   L  S  L  D  R   L  T  D  I  T   P  L  L  E  L  
CTTAATTGTCCCGTG AAATCGCCACTGGTA TAA 
 L  N  C  P  V   K  S  P  L  V   *  
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Figure 2-12. Purification of (A) IRG1 and (B) A. terreus cADC monitored by SDS-
PAGE. 
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     A maltose-binding protein (MBP) fusion was used for the fungal cADC cloning. The 
pMALTEV system allows the target gene to be cloned adjacent to the MBP tag with a 
TEV cleavage site. The N-terminal MBP fused protein is generated and purified on 
amylose resin based on the affinity of MBP for the resin matrix. The native recombinant 
protein without modifications is released by TEV enzyme induced cleavage of the MBP 
tag at 4 oC. Further chromatographic steps can lead to very pure protein. 
    A BamHI restriction site was used for cloning the 5’end of the cADC gene, with the 
forward primer 5’-ggcgGGATCCatgaccaaacaaagtgctgattctaacg-3’ (BamHI site 
underlined). A XhoI restriction site was used for cloning the 3’end of target gene with the 
reverse primer 5’-gcggCTCGAGttacaccagcggggatttaaccggac-3’ (XhoI site undelined). 
The target gene flanked with BamHI and XhoI sites was amplified by PCR and then 
inserted into the pMALTEV vector. The entire DNA sequence of the inserted target gene 
was sequenced by Genewiz using the MalE Primer (5'-ggtcgtcagactgtcgatgaagcc-3’) and 
T7-term primer.  
   Cell growth was the same as for IRG1 expression. Cell extract supernatants after cell 
lysis by sonication and centrifugation at 15,000 rpm for 35 min showed an obviously 
overexpressed MBP-fused protein band corresponding to a MW of 97 kDa on SDS-
PAGE gel (Fig. 2-12B). The lysis buffer used was 20 mM phosphate, pH 6.5, with 1 mM 
DTT, 1 mM PMSF, 5 µL/mL protease inhibitor cocktail and 0.3 M NaCl. The protein 
was immobilized on the amylose beads by mixing crude extract supernatant gently with 
the resin, equilibrated in the same buffer, at 4 oC for around 3 h. The column formed from 
the treated resin was washed first with ~500 mL high-salt buffer (20 mM phosphate, 1 
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mM DTT, 0.5 M NaCl, pH 6.5) then with another ~500 mL of salt-gradient buffer (from 
0.5 to 0.1 M NaCl). The MBP-fused protein was eluted with 3-4 mL (for 1 L cells) of the 
final column buffer (20 mM phosphate, 1 mM DTT, 0.1 M NaCl, pH 6.5) mixed with 10 
mM maltose.  
2.24 Kinetic Measurements of cADC Activity  
     For the kinetic assays of purified enzymes, the cis-aconitate reactions were quenched 
by NaOH as shown in Scheme II in Fig. 2-9. To obtain the pH optimum of IRG1 and 
fungal cADC, buffer at a particular pH was prepared with a MES-HEPES mixed buffer 
system. The pH range tested for IRG1 was 6.5-8.5, and that for fungal cADC was 5.0-8.0. 
The amount of enzyme used was adjusted so that <20% ITA production was observed. 
For determining the Km, the enzymatic activities were monitored by increasing the 
concentration of substrate (cis-aconitic acid) from 0.1 to 20 mM for IRG1 and 1.0 to 20 
mM for fungal cADC. For cofactor and inhibitor screening, the particular additive was 
mixed directly with the substrate solution in assay buffer at the optimal pH. The amount 
of cofactor added was based on reported values for those molecules for other 
decarboxylase. The ratio of potential inhibitor to substrate started 2:1 then decreased to 
1:1 if any inhibition was observed. 
2.25 Mutagenesis Studies of IRG1 and Fungal cADC 
    The construction of mutant proteins followed protocols used for the PI-PLC enzymes. 
All the primers used are shown in Table 2-4.  
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Table 2-4. Primers used in site-directed mutagenesis with desired mutation codons in 
capital and substitution bases underlined (reverse primers are not listed). 
 
Mutant	   Primer	  
Fungal	  cADC	    
E100A	   5’-cttttatccaagccacaGCActggacgattatcac-3’ 
Y104A	   5’-ccacagaactggacgatGCTcacagtgaggcg-3’ 
H111A	   5’-gtgaggcgccgctgGCCtcagcgtccattg-3’ 
H168A	   5’-gctgaacaacggctggGCTtgtggtgcagtatacg-3’ 
K217A	   5’-tacggcggtatggtgGCGcgtgtccaacacgg-3’ 
K288A	   5’-cttttactattcgtatcGCGctgtacgcatgctg-3’ 
H396A	   5’-cgtaaagtcacaccgagtGCCagcgaggagttcg-3’ 
K428A	   5’-caccgagactgtcgaaGCGccgctgggtgtg-3’ 
IRG1	    
D93A	   5’-gctgttcactccatgGCTtttgatgacacatgg-3’ 
H103A	   5’-ggcaccctgccaccGCCccttctggggctg-3’ 
H159A	   5’-gacataccaaagagattcGCCcctccctctgtg-3’ 
K207A	   5’-cgctgccactcagactGCGccccttcatattgg-3’ 
K272A	   5’-gcaggatgtggcctttGCGagcttcccggcac-3’ 
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Chapter 3 
Role of Pro245 and Pro254 in Membrane Binding and 
Enzymatic Activity of Bacillus Phosphatidylinositol-specific 
Phospholipase C 
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3.1 Introduction 	  	  	  	  Peripheral membrane proteins interact transiently with bilayers. Often the interactions 
occur via loops whose conformations can change prior to or during membrane binding. 
B. thuringiensis PI-PLC (BtPI-PLC) fits into this category with loops above the active 
site (in the center of the αβ-barrel) that might be important for membrane binding. Initial 
NAMD simulations of BtPI-PLC in solution, carried out by Prof. Patrick Wintrode of the 
Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, 
were used to investigate the importance of PI-PLC dynamics, focusing on the loops, in 
membrane binding and enzymatic activity. He started with the X-ray crystal structure of 
free Bacillus cereus PI-PLC [28]. The MD simulations for this Bacillus PI-PLC alone (no 
membranes present) showed anti-correlated motions between the first two-thirds and last 
one-third of the PI-PLC structure, essentially the 2 halves of the β barrel (Fig. 3-1). Such 
anti-correlated barrel motions were not observed in MD simulations for the intracellular 
bacterial pathogen L. monocytogenes PI-PLC (data not shown). In addition, Bacillus PI-
PLC showed coordinated motion closing of loops over the active site. Multiple sequence 
alignments (MSA) revealed that a number of residues in these loops are conserved in 
Bacillus, Staphylococcus and other extracellular bacterial pathogens, but not in Listeria 
(this analysis was done by Prof. Anne Gershenson, Department of Biochemistry & 
Molecular Biology, University of Massachusetts, Amherst, Massachusetts). Both the MD 
simulations and conservation results suggested that proline residues 245 (cap) and 254 
(kink) in helix G of Bacillus PI-PLC might be important for the correlated motions. 
Considering this, we constructed a series of mutants for Pro245 and Pro254 in B. 
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thuringiensis PI-PLC. Both in silico and in vitro mutagenesis studies were applied to 
identify the roles of these two proline residues in membrane binding and enzymatic 
activity. Further tests of the role of dynamics in PI-PLC activity were performed by 
altering the flexibility of the 190s loop. This loop is far from the active site and 
membrane binding regions of PI-PLC, but the simulations suggest that it plays a role in 
PI-PLC clamshell motions. Mutations in the 190s loop aimed at altering loop flexibility 
were designed to study the influence of loop motions on enzyme activity and membrane 
association.  
3.2 MD Simulations and Correlated Motions 
    The MD simulations, calculation of the root mean square fluctuations (RMSF) and 
principal component analyses (PCA) were done by Prof. Wintrode. He was trying to 
determine whether any of the dynamic motions could be correlated with activity and/or 
binding to membranes [156]. Larger scale motions observed in the simulations of WT 
included a clamshell-like opening and closing behavior that involved many components 
(highlighted in red in Fig. 3-1A), including the 190s loop (residues 188-192), the helix B 
region (residues 39-47), as well as the loops N-terminal to helix F (residues 201-203) and 
helix G (residues 238-245). This collective motion in which the loops and helix B open 
and close over the active site is associated with the kinking of helix G about Pro254. 
Previous work also identified the helices B and G as important for PI-PLC membrane 
binding [30,34,146]. In the triosephosphate iosomerase (TIM) barrel superfamily, the 
loop between strand 7 and helix G is often part of a phosphate-binding motif [157]. 
Dynamics of this loop are also important in the activity of other TIM barrels. In 
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triosephosphate iosomerase, the corresponding loop is the active site lid [158] while 
motions of this same loop, containing the catalytic Cys319, is important for activity and 
allostery in inosine monophosphate dehydrogenase (IMPDH) [159].     
    If helix B, F and G regions that close over the active site are important for enzyme 
activity, there might be significant sequence conservation in these regions. Analysis of 
the PI-PLC MSA showed that this region is quite divergent in the PI-PLC family, 
consistent with the diversity of lipid binding specificities. However, clustering the MSA 
using just the helix G region revealed that the phosphate-binding loop is relatively 
conserved in secreted PI-PLCs from extracellular bacterial pathogens and soil bacteria 
(Fig. 3-1D). In these species, the proline residue in helix G associated with kinking, 
Pro254, is 100% conserved while the proline that caps helix G, Pro245, is less conserved. 
The conservation in this region as well as its association with membrane binding led us to 
mutate these proline residues both in silico and in vitro. We used 3 types of mutations: (i) 
Pro to Gly which may increase flexibility and thus dynamics, (ii) Pro to Ala aimed at 
either uncapping or unkinking helix G and (iii) Pro to Tyr mutants designed to alter 
phospholipid binding. An additional Tyr residue near or in helix G, which is already rich 
in Tyr residues associated with membrane binding [146], should increase the probability 
of cation-π interactions with choline moieties in the membrane [34,160,161]. 
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Figure 3-1. Structure, dynamics and conservation of Bacillus PI-PLC. (A) The ribbon 
diagram of crystal structure of B. cereus PI-PLC (PDB 1PTG) made using UCSF 
Chimera [162] shows the N-terminal and C-terminal halves of the β barrel in light blue 
and dark blue, respectively, helices F and G in turquoise. Regions that show large 
fluctuations in the WT MD simulations are in dark red and the active site is indicated by 
histidine residues 32 and 82 (blue) and myo-inositol (green). The two Pro residues of 
interest are shown in pink. RMSFs from the MD simulations in solution for (B) P(cap) 
variants and (C) P(kink) variants with WT (black), Pro to Ala variants (cyan) and Pro to 
Tyr variants (red). Regions with the largest fluctuations are highlighted in gray. (D) A 
selection from the multiple sequence alignment clustered using the helix G region from 
Jalview [163] with Blosum62-based coloring. Higher conservation is reflected as darker 
shading. The abbreviations are: Bt, Bacillus thuringiensis; Ba, Bacillus anthracis; Sa, 
Staphylococcus aureus; Ea, Erwinia amylovora (fireblight); Ssp, Streptomyces species; 
Lm, Listeria monocytogenes. 
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    In the simulations, all of the Pro variants show reduced RMSFs relative to wildtype 
particularly for the 190s loop (Fig. 3-1B and C). For the P(cap) mutants, the anti-
correlation between movements of the N-terminal two-thirds of the protein and C-
terminal one-third is lost. In a similar vein, the clamshell-like motion is damped in 
P(kink)Y and essentially disappears in P(kink)A and the loop motions over the active site 
appear much less coordinated in both kink variants, particularly in P(kink)Y. These 
significant changes in the MD simulations suggested that mutating either of these Pro 
residues would alter Bacillus PI-PLC activity and/or lipid binding. Similar clamshell 
motions in the PCA and chained correlations, are observed in MD simulations of PI-PLC 
bound to DMPC membranes (data not shown), suggesting that the clamshell motion and 
associated correlations may be important both in solution and on the membrane.  
3.3 Purification, Secondary Structure and Thermostability  
    The mutant PI-PLCs were designed and purified as described in sections 2.3 and 2.4. 
Formation of the disulfide bond in the double-cysteine variant, Asn226Cys/Val192Cys 
(N226C/V192C) was confirmed using non-reducing SDS-PAGE that will show a gel 
shift when the intermolecular disulfide bond forms (data not shown). Secondary structure 
content and thermal stability of the PI-PLC variants were measured and all of the PI-PLC 
variants showed similar CD spectra and the secondary structure content (Fig. 3-2). 
Thermal stabilities for all PI-PLC variants were similar to WT with melting temperatures 
(Tm) within 1.5 °C of the Tm for WT (54±1 °C), except for P254G, which is slightly less 
stable (Tm = 51 °C). Thus, any differences in activity or binding are not due to significant 
alterations in protein structure. 
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Figure 3-2. Comparison of CD spectra for WT (¢) and P(kink)A (). Similar agreement 
with the WT far UV CD data is observed for all of the PI-PLC mutants. 
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3.4 Phosphotransferase Activity in Micelles 
   PI dispersed in diC7PC micelles is a better PI-PLC phosphotransferase substrate than PI 
presented in TX-100 micelles [10,43], and the same trend is observed for the Pro 
variants. The P(cap) variants all show decreased activity toward PI/TX-100 mixed 
micelles, with P(cap)A retaining the most activity (Fig. 3-3A). When PI is solubilized in 
diC7PC micelles, enzymatic activity is enhanced, but the cap variants still exhibit lower 
activity than WT. The kink variants exhibit a very different profile with the mixed 
micelles. For PI/TX-100, P(kink)A was significantly more active than WT (990±170 
versus 620±150 µmol min-1 mg-1) while P(kink)G and P(kink)Y have lower activity than 
WT. For PI in diC7PC micelles, activities of the kink variants are equivalent to WT. 
Combining the two Ala mutations, P(cap)A/P(kink)A, results in a variant with ~50% of 
the P(cap)A activity towards PI in both TX-100 and diC7PC micelles despite the benign 
effects of the P(kink)A mutation. 
3.5 Phosphodiesterase Activity in the Absence and Presence of Micelles 
    The second step in the PI-PLC reaction, cIP hydrolysis to I-1-P, can be mimicked by 
incubating soluble cIP with PI-PLC. Although the enzyme, substrate and product in this 
reaction are all soluble, addition of PC micelles greatly enhances activity (Fig. 3-3B) 
[43]. For the cap variants, changes in cIP cleavage rates are complex. In the absence of 
diC7PC, P(cap)A and P(cap)G displayed ~50% and ~10% the specific activity of WT, 
respectively. In contrast, the specific activity of P(cap)Y was ~2-fold higher than WT. 
This higher activity may reflect improved cIP binding, which is quite weak for WT [34]. 
In many proteins that bind a myo-inositol moiety, including PI-PLC, a tyrosine is seen to 
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stack with the inositol ring and its removal destabilizes binding [28,29]. Placing a Tyr in 
the cap position may aid in positioning cIP in the active site. Addition of diC7PC 
increased the activity for all of the cap variants, but the activities were still far below WT. 
For the kink variants, specific activities were at least 50% of WT and the cIP hydrolysis 
rate with micellar diC7PC present increased 24±2 times, similar to that observed for WT 
PI-PLC. The double Pro variant, P(cap)A/P(kink)A, behaved similarly to P(cap)A 
suggesting that the cap mutation overrides the increase in activity towards cIP observed 
for the P(kink)A variant. 
    For both types of micelle-based assays, the cap variants show greater reductions in 
activity than the kink variants. The cIP hydrolysis results for the P(cap)A/P(kink)A 
suggest that the cap is key for activity towards the soluble substrate. Cap mutations also 
significantly reduce the activity enhancement observed in the presence of PC, suggesting 
that the cap plays an important role in enhancement of PI-PLC enzymatic activity by PC, 
perhaps related to the barrel breathing motions observed in the WT simulation that 
disappear in the simulations for the cap variants. 
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Figure 3-3. Specific activities of PI-PLC variants towards PI solubilized in micelles and 
the soluble substrate cIP. (A) Specific activity for PI cleavage in mixed micelles 
containing 8 mM PI in 16 mM TX-100 (■) or in 32 mM diC7PC (▨); (B) Specific 
activity for cleavage of 20 mM cIP in the absence (■) and presence (▨) of 8 mM 
diC7PC. The error bars are the S.D. of the specific activities. 
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3.6 Binding and Phosphotransferase Activity for Vesicles 
    PI-PLC partitioning to vesicles is inextricably linked to activity, and PC content 
significantly enhances binding. PI-PLC prefers SUVs over the less curved large 
unilamellar vesicles [145], and WT PI-PLC has an apparent Kd of 4-6 mM for pure PG 
SUVs in PBS buffer. Addition of PC leads to substantial drops in Kd for XPC=0.1-0.5 and 
increases in enzymatic activity. The extent of the activity increase is dependent on the PI 
concentration with respect to Kd. For 8-10 mM PI, concentrations considerably above the 
apparent Kd, there is a 2-3-fold increase in specific activity with the addition of PC 
suggesting this non-substrate phospholipid activates the enzyme by more than just 
anchoring the protein to the vesicle [145,146]. However, while the apparent Kd continues 
to drop, reaching a minimum of ~1 mM at XPC=0.8, activity is greatly reduced for 
XPC>0.5.  Very tight binding sequesters the enzyme on the vesicle surface, apparently in 
PC rich regions, leading to reduced activity [145]. How are SUV activity and binding 
related for the Pro variants?  
    Despite its reduced activity in the micelle assays, the apparent Kd of P(cap)A for SUVs 
is virtually identical to that of WT for pure PG SUVs and only 2-3 times higher than WT 
in the presence of PC (Fig. 3-4A). Specific activities of P(cap)A towards PI/PC SUVs 
were almost the same as WT across the XPC range examined (Fig. 3-4B). In contrast to 
the Ala variant, the P(cap)Y variant binds much less tightly to SUVs, with apparent Kd 
values between 0.5 and 0.9 XPC that are more than an order of magnitude higher than WT 
(Fig. 3-4A). This loss of binding affinity is associated with reduced activity of P(cap)Y 
for PI in SUVs, although the concentration of substrate in SUVs was well above the 
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apparent Kd values. However, what is striking for P(cap)Y is that the specific activity 
does not drop at XPC=0.8 where WT activity drops ~50%, in part because of sequestration 
of the enzyme in PC-rich regions [145]. Rather the specific activity of P(cap)Y is 
constant in the range of XPC=0.2 to 0.8. Lower affinity for SUVs may be an advantage at 
high XPC allowing the enzyme to access the next substrate lipid [146].   
    The kink variants behave quite differently (Fig. 3-4). P(kink)A is relatively non-
perturbing with binding affinities and activities that are similar to WT. P(kink)Y binding 
affinities are similar to WT except for XPC=0.5-0.6 where the apparent Kds are 2-3 times 
higher. These differences in Kd would not be noteworthy, except for the anomalous 
activity of P(kink)Y towards both pure PI SUVs, where its activity is only 60% that of 
WT despite nearly identical apparent Kds, and its activity towards SUVs with XPC=0.5 
(1:1 PI/PC) where it, reproducibly, has 1.9 times WT specific activity. This increase in 
activity is not readily explained by its slightly lower affinity for SUVs. The lower 
specific activity of P(kink)Y in the absence of PC for both pure PI SUVs and cIP, as well 
as the generally reduced activity of P(kink)Y despite lipid binding affinities that are 
similar to WT suggest that freezing PI-PLC motions are particularly detrimental for 
activity.  
    For these FCS binding experiments, a single Cys residue, N168C, was introduced into 
the proteins. Residue 168 is far from both the PI-PLC membrane binding region and 
active site, and fluorescent labeling has only minor effects on binding and activity (Table 
3-1).  
  
	  	  90 
Figure 3-4. Membrane binding and activity towards SUVs. (A) Binding of PI-PLC 
variants to DOPG/POPC SUVs as a function of the mole fraction PC, XPC. (B) Variation 
of the specific activity of PI-PLC Pro variants towards PI/POPC SUVs with 8 mM PI and 
varying XPC: WT (), P(cap)A (¢), P(cap)Y (£), P(kink)A (▲), and P(kink)Y (r).The 
error bars are the S.D. determined from two independent protein and SUV preparations. 
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Table 3-1. PI-PLC specific activities towards SUVs. The lipid compositions are PI (8 
mM) and PI/PC (8 mM/2 mM). 	  
  
PI-­‐PLC	  Variantsa	  
Specific	  Activity	  
(μmol	  min-­‐1	  mg-­‐1)	   PC	  activationd	  
PIb,c	   PI/PC	  (4:1)	  
WT	  	   40±12	   460±40	   12	  
N168C	  	   23±7	   430±60	   19	  
P(cap)A	  	   30±9	   410±20	   14	  
N168C/P(cap)A	  	   45±14	   500±40	   11	  
P(cap)G	  	   5±1	   130±30	   29	  
P(cap)Y	  	   6±2	   160±20	   28	  
N168C/P(cap)Y	  	   9±3	   210±20	   23	  
P(kink)A	  	   48±14	   480±50	   10	  
N168C/P(kink)A	  	   31±9	   470±30	   15	  
P(kink)G	  	   36±11	   500±10	   15	  
P(kink)Y	  	   24±7	   440±20	   18	  
N168C/P(kink)Y	  	   26±8	   470±20	   18	  
 
a	  P(cap)	  =	  Pro245	  and	  P(kink)	  =	  Pro254.	  
	  
b	  The	  low	  activities	  for	  these	  PI-­‐PLCs	  towards	  pure	  PI	  SUVs	  have	  much	  larger	  errors,	  typically	  30%	  
if	  different	  batches	  of	  SUVs	  are	  used,	  so	  the	  uncertainties	  represent	  30%	  of	  the	  average	  value	  
for	  each	  mutant	  (obtained	  in	  many	  cases	  on	  different	  SUV	  preparations).	  	  
	  
c	  For	  a	  given	  variant,	  the	  activity	  with	  or	  without	  the	  N168C	  mutation	  is	  within	  the	  uncertainty.	  	  
	  
d	  PC	   activation	   is	   the	   ratio	   of	   the	   specific	   activity	   towards	   PI/PC	   SUVs	   divided	   by	   the	   specific	  
activity	  towards	  pure	  PI	  SUVs.	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3.7 Restricting Dynamics of the 190s Loop 
    While the simulations suggest that mutating the Pro residues in helix G alters 
dynamics, thus affecting enzymatic activity and membrane binding as discussed above, 
crosslinking the loops involved in the clamshell-like motions would provide a more direct 
test of the relationship between dynamics and activity. Unfortunately, many of the 
structural elements that contribute to motions are known to be crucial for binding and 
activity, e.g., helix B and the phosphate-binding loop. We therefore chose to alter the 
dynamics of the 190s loop on the other side of PI-PLC, a region of the protein not 
previously associated with enzymatic activity or membrane binding because it is far from 
both the active site and the lipid binding regions containing helices B, F and G and 
associated loops (Fig. 3-1A). Nonetheless, obvious, pendulum-like motions of this loop 
are correlated with the motions in the helix B, F and G regions, and constraining this loop 
should alter PI-PLC dynamics. Two sets of mutations were designed to alter 190s loop 
motions: (i) the loop was constrained in the V192C/N226C construct by introducing a 
disulfide bond between the 190s loop and an adjacent loop, and (ii) the flexibility of the 
190s loop was altered by introducing a Pro residue between Gln190 and Asn191 
(Q190_P_N191). The changes of enzyme structure caused by these mutations would not 
have large effect on the enzymatic activity since the 190s loop is fay away from the 
active site. Despite the distance of this loop from the PI-PLC active site and membrane 
binding regions, both variants display less than 40% of the wild-type activity towards 
pure PI SUVs (Fig. 3-5), lower activity than all of the helix G Pro variants except for 
P(cap)Y which has only 15% of the WT activity. The activity deficits of the 190s loop 
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Figure 3-5. Constraining the 190s loop lowers activity towards pure PI SUVs. Specific 
activities of the 190s loop variants towards SUVs with increasing PC content: WT 
(black), V192C/N226C (white), and Q190_P_N191(gray). 
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variants are rescued at 0.2 XPC, while at 0.8 XPC the disulfide-bonded variant has slightly 
more activity than WT and Q190_P_N191 displays 70% of the WT activity. The activity 
trend for the 190s loop variants resemble those of the P(kink) variants suggesting that 
these two very different sets of mutations may have similar effects on PI-PLC dynamics 
and activity. 
3.8 Discussion 
   Experimentally measuring changes in dynamics is particularly difficult for peripheral 
membrane proteins such as PI-PLCs that dynamically associate and dissociate from the 
interface. For these enzymes, catalysis requires two discrete steps, the initial partitioning 
of the protein to the bilayer surface followed by docking of a substrate into the active site 
in the optimal orientation. MD simulations provide a way to predict how mutations may 
alter the dynamics of the free protein conformation that first interacts with the membrane 
and the effects of interesting mutations on protein partitioning and/or activity can then be 
determined experimentally. Naively, one might expect that alterations in the free protein 
dynamics would compromise binding but have little effect on the activity of the 
membrane bound enzyme. However, for PI-PLC variants that are predicted to have 
altered dynamics, activity is more likely to be perturbed than binding. While partitioning 
to the membrane likely alters the conformation and/or dynamics of the mobile loops and 
helices that contact the interface, much of the protein is not in contact with the surface 
and some of the lowest energy modes may still be accessible, as observed for the MD 
simulations performed in the presence of a membrane. Constraints on the conformation 
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and dynamics of the bound protein may also be different between SUVs and the even 
more highly curved micelles.  
     The relative conservation of the putative PC binding regions in extracellular bacterial 
pathogens, the likely importance of this region in membrane binding and the correlated 
loop motions observed in the MD simulations focused our attention on the helix B and G 
regions. Helix G is a long helix containing several Tyr residues known to be important 
for interfacial binding [30,34]. Pro mutations in this helix do disrupt the correlated 
motions observed in the simulations. P(cap) (Pro245), the Pro cap for helix G, is >9 Å 
from the active site and could directly interact with substrate as it enters the active site in 
addition to directly affecting membrane binding as well as protein conformation and 
dynamics. In contrast, P(kink) (Pro254), the Pro in the middle of helix G around which 
the helix kinks in the MD simulations, is  >15 Å distance from the active site, and both 
this distance and its location in the helix preclude direct interactions with substrates. 
Since no significant effects on binding are observed for the P(kink) variants, changes in 
activity are likely due to altered protein conformations or dynamics. 
    Despite similarities in how the Pro mutations reduce the RMSF of loops in the MD 
simulations (Fig. 3-1B and C), the P(cap) variants generally have larger effects on PI-
PLC activity and binding than do the P(kink) variants. The Pro cap is N terminal to Tyr 
residues 246-248 that are important for binding to membranes containing PC [34,146]. 
Mutagenesis of all three of these Tyr residues to Ser results in low binding affinity for 
and activity towards SUVs containing PC [146]. Interestingly, of the cap variants, 
P(cap)Y, which might have been expected to aid in π-choline cation interactions with PC, 
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exhibits the lowest affinity for PC-rich SUVs. The loss in activity of the P(cap) variants is 
also observed for micelle based assays and activity towards the soluble substrate cIP. 
Removing Pro245 likely alters the accessible conformations near the N terminus of helix 
G, reducing the probability that the Tyr residues bind to the membrane. Alternatively, the 
alterations in dynamics observed in this P(cap) variant MD simulations could also reduce 
the active site binding affinity for substrate. 
    While in silico mutagenesis of P(kink) (Pro254), the Pro about which helix G flexes, 
has large effects on the MD simulations, damping fluctuations throughout the protein, the 
P(kink) variants show much smaller deficits in activity and binding. In the P(kink)A MD 
simulations, the extended rather than kinked helix G freezes motions in a manner that 
leaves the active site open. This dynamical change would favor substrate access to the 
active site resulting in little change in activity or overall vesicle binding, as observed 
experimentally. In WT, helix B as well as the helix F and G loops close and open over the 
active site in a coordinated manner; however, loop motion is uncoordinated in P(kink)Y, 
and in the first principal component occlusion of the active site appears more likely. This 
would translate to the observed lower specific activity of P(kink)Y in the absence of PC 
(where only active site binding occurs). In the presence of PC, the helix G region, which 
has been implicated in binding PC, would be more constrained, presumably favoring an 
open active site. This analysis argues that enhancement of activity by PC results because 
PC binding constrains both the helix G and the helix B regions, which would otherwise 
intermittently limit access to the active site. This picture is supported by mutations in the 
190s loop designed to restrict dynamics. Decreases in activity are largest in the absence 
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of PC, and rescued by low mole percent PC again suggesting that one of the roles of PC 
is to subtly alter PI-PLC dynamics. 
    For both the P(kink) and P(cap) variants, changes in activity are not consistently 
correlated with changes in binding. The P(kink) variants bind to vesicles with apparent 
Kds that are similar to wild-type protein despite changes in activity, while defects in 
P(cap)Y activity appear to be larger than would be predicted from the Kd increase. 
However, in all cases, changes in activity appear to be correlated with the changes in 
enzyme dynamics observed in the free protein simulations. Some studies of protein 
models suggested that the dynamic motions were often intrinsic to the protein structure, 
independent of the membrane environment [164]. This finding is supported by results 
from the protein plus membrane simulations (data not shown). Thus, despite the 
constraints imposed by interfacial binding, the dynamics and protein modes of free PI-
PLC in solution are likely still relevant for the membrane bound protein.  
3.9 Conclusions 
    The combination of MD simulations, in silico and in vitro mutagenesis along with 
binding and activity assays provides a role for loop and helix motions in regulating the 
activity of Bacillus PI-PLC. In this model, the coordinated closing of the helix B region 
and helix G region in the free enzyme limits access to the active site, while PC binding in 
the region of helix G leads to an open active site. Structural alignments of the Bacillus PI-
PLC [28] with the well-studied yeast TIM [165,166] as well as parasite IMPDHs 
[167,168] show that the phosphate-binding loop N-terminal to helix G in PI-PLC aligns 
with the active site lid in yeast TIM and the dynamic loop containing catalytic Cys319 in 
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IMPDH from two parasites, Tritrichomonas foetus and Cryptosporidium parvum. 
Interestingly, while the helix C terminal to these loops is capped by a Pro residue in yeast 
TIM, Pro in this position is only slightly conserved in TIM [169,170]. The corresponding 
helix is capped by Pro in C. parvum IMPDH but not T. foetus IMPDH. This is 
reminiscent of extracellular bacterial PI-PLCs where helix G is capped by Pro245 in 
Bacillus PI-PLC but not in PI-PLC from Staphylococcus aureus (Fig. 3-1D). Thus, there 
are many ways to control the motions of this loop and associated allostery in TIM barrels, 
including a balance of loop rigidity and flexibility in TIM [171], ion binding in parasite 
IMPDH [159] and the cation-π latch in S. aureus PI-PLC (refer to Chapter 4). The Pro 
cap on helix G may be one more non-conserved way to modulate loop motions and 
allostery in TIM barrels. 
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Chapter 4 
Cloning, Expression and Characterization of  
Staphylococcus aureus PI-PLC 
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4.1 Introduction 
    Secreted bacterial phosphatidylinositol-specific phospholipase C (PI-PLC) enzymes 
contribute to virulence in pathogenic bacteria. Several of the PI-PLCs are usually 
activated by the zwitterionic phospholipid phosphatidylcholine (PC) [10,38,39]. 
Intriguingly, the activation mechanism varies among the PI-PLCs. Bacillus PI-PLC 
enzymes exhibit high affinity for PC interfaces but Listeria PI-PLC is activated due to 
lipid dilution effect and shows very low affinity for PC [34, 39]. Staphylococcus aureus 
PI-PLC (SaPI-PLC), a likely virulence factor whose production was shown to be 
upregulated in a study of methicillin-resistance S. aureus [23], shows 41.3% sequence 
similarity with B. thuringiensis PI-PLC but presents yet another wrinkle in the properties 
of these exoproteins.  
    In this study, the wild-type SaPI-PLC gene was cloned into a His-tagged 
overexpression system from genomic DNA of S. aureus (strain FPR3757) for further 
expression and purification. The enzymatic activities and membrane association of SaPI-
PLC as a function of enzyme concentration, pH, and vesicle composition were examined 
in comparison with BtPI-PLC. Meanwhile, the structure of SaPI-PLC solved by Rebecca 
Goldstein, one of my colleagues, suggested the enzyme could form transient dimers on 
the membrane surface. To that end, a series of mutations was designed to test the 
hypotheses about dimerization of SaPI-PLC. The results showed that SaPI-PLC has 
evolved a complex, apparently unique way to control its access to PI/GPI substrate.  
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4.2 Purification, Secondary Structure and Thermostability 
     The overexpression and purification of recombinant SaPI-PLC are described in detail 
in sections 2.3 and 2.4 of this thesis. Secondary structure and thermal stability of SaPI-
PLC variants were determined using far-UV CD. Compared with recombinant wild type 
SaPI-PLC (WT), there are no significant changes in structure and thermal stability for the 
single mutation enzymes (Table 4-1, Fig. 4-1). Although Y253S/Y255S has the same 
secondary structure content, its thermal denaturation temperature is 5 °C lower than WT.  
4.3 Testing the Role of a Cation-π Latched Loop in SaPI-PLC 
4.3.1 Two SaPI-PLC Structures at Acidic and Basic pH 	  	  	  	  Rebecca Goldstein determined two discrete crystal structures of this enzyme at pH 4.6 
and pH 7.5 (as shown in Fig. 4-2A), and found that under acidic conditions, a large 
section of mobile loop at the αβ-barrel rim in the vicinity of the active site shows ∼10 Å 
shift. This is due to a titratable intramolecular cation-π interaction between His258 and 
Phe249 since the loop shift does not exist in the mutant protein H258Y. To explore how 
the two conformations are related to enzymatic activity, we measured PI-PLC activity 
toward SUVs composed of either pure PI or PI/PC (4:1) at pH 5.5, 6.5, and 7.5 (as shown 
in Fig. 4-3). Considering the enzyme mechanism also involves histidine residues, we 
examined the activity of H258Y, which cannot form the cation-π latch as a control.  
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Table 4-1. Comparison of secondary structure content of WT and selected mutant SaPI-
PLC enzymes. 
 
Protein	  
Secondary	  Structure	  
Tm	  (oC)	  
α-­‐Helix	   β-­‐Sheet	   β-­‐Turn	   Random	  Coil	  
	   %	   	  
WT	  	   19.4	   32.2	   16.8	   31.7	   62.8	  
F249W	   19.8	   31.8	   16.9	   31.6	   61.8	  
Y253S/Y255S	   19.4	   32.1	   16.8	   31.6	   57.7	  
N254Y/H258Y	   19.0	   32.4	   16.8	   31.7	   62.4	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Figure 4-1. Comparison of CD spectra for WT and selected mutant SaPI-PLC enzymes: 
WT(¢), F249W(£), Y253S/Y255S() and N254Y/H258Y(r). Similar agreement with 
the WT far UV CD data is observed for all of the PI-PLC mutants. 
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4.3.2 Influence of Cation-π Interaction on PI Cleavage 
    A comparison of activities toward PI vesicles at pH 5.5, 6.5, and 7.5 shows that the 
recombinant enzyme has higher activity at pH 5.5 than H258Y (Fig. 4-3A), which 
indicated that this inward-folded rim loop position at acidic pH was associated with 
higher enzymatic activity. Specific activities are similar and lower for both enzymes as 
the pH increases (and presumably the His−cation-π interaction is broken because of the 
histidine deprotonation). In the structure, this cation-π latch can enable water-soluble 
product cIP diffuse from the active site and could allow for processive catalysis for the 
enzyme bound to membranes under acidic conditions. 
4.3.3 Effect of Other Phospholipids on PI Cleavage 
    When 20 mol% PC is present in the vesicles, the activities are low at pH 5.5 but 
increase as the pH is raised (Fig. 4-3B). This indicated that other more subtle 
conformational changes in the protein occur with PC added and the pKa values for the 
active site histidines may be shifted. The higher activity of WT SaPI-PLC at pH 6.5 
suggests that the presence of that zwitterionic phospholipid PC provides cationic choline 
moieties to compete with cationic His258 for interactions with the Phe249 π-system. This 
could extend the loop structure allowing better partitioning of the Phe side chain into 
membranes which in turn could lead to more efficient PI cleavage and product release. 
    Consistent with the idea that the choline cation competes with His258, we have 
examined the effect of different short chain phospholipids on cleavage of PI dispersed in 
Triton X-100 micelles. The use of the Triton micelle matrix and micelle forming 
additives should avoid changes in bilayer behavior that may occur with the different 
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long-chain phospholipids (PE in particular). In this qualitative turbidity assay it is clear 
that both diC7PC and diC8PE activate the enzyme above what is observed with the PI 
dispersed in TX-100, while diC8PG and diC8PS are inhibitory (roughly 10-fold less 
active than with the short-chain PC added), presumably by binding to the active site. The 
amino group of PE, like the trimethylammonium group of PC, could interact with Phe249 
and similarly alter pKa values or lead to a more productive conformation involving that 
rim loop. 
4.4 Influence of Functional Oligomerization on SaPI-PLC Enzymatic Activity  
4.4.1 SaPI-PLC Dimer Structure 
     Rebecca Goldstein serendipitously found that SaPI-PLC crystallized as a complete 
homodimer in the presence of diC4PC and Mg(NO3)2 at acidic pH. The dimer interface is 
a hydrophobic box formed by the direct interaction of the side chains belonging to helix 
B of each monomer  (Val41 and Val44, in Fig. 4-4A and B). Besides this valine box, 
there are several other interactions that aid in the dimerization, for example the ionic 
bonding between Lys38 and Asp50 and hydrogen bonding between Thr36 and Tyr285. 
On the other hand, in the monomeric structure, there is an anion-binding pocket adjacent 
to helix B made up of Asp38, Lys39, His86 and Lys42 (Fig. 4-4C). However, in the 
dimer, helix B of one monomer occludes the pocket of the other, limiting water-soluble 
or membrane-bound anion binding. Thus, in the dimer, this unoccupied positively 
charged region could contribute to electrostatic steering to anionic phospholipids, but the 
discrete binding pocket is no longer accessible. 
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Figure 4-2. Overlay of the acidic pH (green, PDB 3V16) and basic pH (blue, PDB 3V18) 
structures of SaPI-PLC. The red circle highlights the mobile rim loop and the large 
conformational change in it with pH. Key residues forming the cation-π interaction are 
labeled. myo-Inositol is depicted in red space-filling representation and the chloride ion 
as a green sphere. The C-terminus, N-terminus and helix B are labeled. A gray bar 
represents the membrane interface. 
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Figure 4-3. The effect of conformational changes between acidic and basic structures on 
enzymatic activity. The pH dependence of the specific activity of SaPI-PLC (■) and the 
H258Y (□) mutant toward (A) 4 mM PI and (B) PI/PC (4 mM:1 mM) small unilamellar 
vesicles in 50 mM MES/HEPES, 1 mM EDTA with 0.1 mg/mL BSA adjusted to the 
indicated pH.  
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4.4.2 SaPI-PLC Enzymatic Activity: Testing for a Functional Oligomer 
    The pH optimum for SaPI-PLC enzymatic activity depends on the SUV composition 
(Fig. 4-5A). Toward pure PI SUVs, the pH optimum is pH 5.5–6, whereas for vesicles 
with 0.5 XPC, the optimum is shifted to pH 6.5–7. Thus, most assays were carried out at 
pH 6.5. Specific activity increases dramatically when PC is present in the bilayer. Similar 
PC enhanced activity and a shift in the pH profile were observed with PI dispersed in 
micelles of diC7PC versus Triton X-100 (Fig. 4-5C). Unlike BtPI-PLC, where specific 
activity decreases when XPC=0.5 [146], no surface dilution inhibition is observed for 
SaPI-PLC with increasing PC content up to 0.8 XPC, either for fixed total phospholipid 
(Fig. 4-5B) or fixed PI with increasing amounts of PC. Because the dimer structure with 
its occluded anion-binding site was obtained in the presence of PC, SaPI-PLC salt 
sensitivity might be ameliorated by PC. Indeed, the presence of PC rescues the loss of 
activity observed at moderate salt concentrations (Fig. 4-5B), and higher XPC results in 
lower salt sensitivity. This is consistent with a transient dimer that has lost the ability to 
bind soluble anions in the anion-binding pocket. That this is an interfacial phenomenon is 
shown by cIP kinetics (Fig. 4-5D), which exhibits both only a small activation by diC7PC 
micelles and only about a 2-fold drop in specific activity with added salt.  
     A more direct indication of a functional dimer is the observation that, in the absence 
of salt, SaPI-PLC specific activity is dependent on enzyme concentration, particularly 
when the substrate is pure PI SUVs (Fig. 4-6A). For comparison, the specific activity of 
BtPI-PLC, which is unlikely to form the same dimer through helix B, does not depend on 
enzyme concentration and is only weakly salt dependent (Fig. 4-6B). If PC is present in 
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the bilayer, there is still an increase in SaPI-PLC-specific activity with increasing enzyme 
concentration, but this reaches an optimal value at a much lower enzyme concentration 
(Fig. 4-6C). This dependence of PI-PLC specific activity on protein concentration 
strongly suggests that the optimally active form of the enzyme is a dimer. The presence 
of PC in the membrane must shift the equilibrium between protein monomer and 
oligomer to lower protein concentrations. 
     As a further test of this hypothesis, I mutated Val44, one of the key components of the 
dimer interface in the crystal structure. This valine was replaced with: (i) a cysteine, a 
small hydrophobic amino acid but is capable to form hydrogen bonding to destabilize the 
dimer interface (a large excess of DTT was present to prevent any disulfide formation) or 
(ii) a tryptophan, a large side chain with a propensity to partition into membranes that 
might be expected to strengthen the transient dimer interaction. For PI SUVs, the specific 
activity of V44C was lower than that of the WT enzyme and increased at most 2-fold 
(compared with 5-fold for WT) over the protein concentration range examined (Fig. 4-
6D). In contrast, the specific activity of V44W was higher than wild type and appeared to 
reach a maximum value at lower enzyme concentrations. These data strongly suggests 
that SaPI-PLC functions optimally as a transient dimer on the SUVs. They strongly 
suggest that enhanced protein dimerization on the surface is part of the PC activation 
mechanism for SaPI-PLC. 	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Figure 4-4. S. aureus PI-PLC can form a homodimer. (A) S. aureus PI-PLC dimer 
structure (PDB 4F2B); (B) a close-up of the dimer interface; (C) close up view of the 
anion binding site with key residues labeled. (D, E) View of the anion binding pocket as 
seen looking down from the membrane interface in the homodimer (D), where it is 
unoccupied, and the in silico Y253S (monomer Y253S: PDB 4F2T) dimer (E), generated 
from the monomer with a sulfate ion bound in the anion site.  
 
	  
                     (D)                                               (E) 
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Figure 4-5. PC modulates the pH and salt dependence of SaPI-PLC activity as measured 
by production of cIP from PI using 31P NMR. (A) The pH dependence for SaPI-PLC 
cleavage of PI in pure PI SUVs (4 mM) () and PI/PC (4 mM/4 mM) () SUVs. (B) 
The specific activity at pH 6.5 increases with increasing XPC ( ) and is not as sensitive to 
the addition of 140 mM salt (▨). The total phospholipid concentration was held constant 
at 4 mM for the indicated XPC. The enzyme concentration was 4 µg/mL for pure PI SUVs 
and 0.3 µg/mL for PI/PC SUVs. (C) The specific activity for cleavage of 4 mM PI in 8 
mM Triton X-100 () or 16 mM diC7PC () micelles. (D) The specific activity toward 5 
mM cIP alone or with 5 mM diC7PC and in the absence ( ) or presence of 140 mM salt 
(▨). Error bars in each plot represent S.D. from multiple assays. 	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Figure 4-6. SaPI-PLC relative specific activity (R.S.A.), as measured by production of 
cIP from PI using 31P NMR, increases with enzyme concentration suggesting 
oligomerization of this protein (but not BtPI-PLC) on interfaces. For SaPI-PLC, specific 
activities are normalized to the highest specific activity obtained for WT enzyme acting 
on 4 mM PI SUVs in the absence of added salt (9.8 µmol min-1 mg-1 at pH 6.5). For BtPI-
PLC activities are normalized to 164 µmol min-1 mg-1 at pH7.5, the optimal activity 
toward 8 mM PI SUVs in the absence of salt. R.S.A. as a function of protein 
concentration is shown for: (A) SaPI-PLC toward PI (4 mM) SUVs in the absence () 
and presence () of 140 mM salt; (B) BtPI-PLC toward 8 mM PI SUVs in the absence 
(¢) and presence (☐) of 140 mM salt; (C) SaPI-PLC activity toward PI (8 mM)/PC (8 
mM) SUVs in the absence of salt; and (D) V44C (r) and V44W (▲) compared with the 
WT SaPI-PLC () toward 4 mM PI SUVs.  
 
 
 
 
 
 
  
	  	  113 
4.5 Effect of PC on SaPI-PLC Vesicle Binding 
    For BtPI-PLC, increasing XPC up to 0.8 also increases the affinity of the enzyme for 
SUVs, and tight binding (Kd<10 µM) sequesters the enzyme on the vesicles inhibiting 
enzyme activity [145]. SaPI-PLC behaves quite differently. SaPI-PLC binds well, with 
mM Kd values, to either PG or PG/PC (1:1) SUVs at acidic pH, but binding at pH 7.5 is 
much weaker (Fig. 4-7A), indicating that the primary interaction is electrostatic. At pH 
6.5, where optimal activity is observed, the enzyme has high affinity for anionic 
phospholipid-rich bilayers (XPC=0.5), with fairly low affinity for PC-rich bilayers (Fig. 4-
7B). Indeed, binding to pure PC SUVs could not be measured. The apparent Kd for pure 
PG vesicles is 0.38±0.14 mM at pH 6.5, and this value corresponds well with the 
apparent Km value (0.23±0.03 mM) for cleavage of PI in pure PI SUVs (Fig. 4-7C). For 
XPC=0.5, again the apparent Kd determined by FCS (2.5±0.5 mM) is approximately the 
same as the kinetic apparent Km for PI/PC SUVs (1.9±0.5 mM). SaPI-PLC apparent Kd 
values increase with PC content and the enzyme binds much less tightly at high PC. For 
these compositions, and in the absence of salt, the Km reflects the Kd for vesicle binding 
as measured by FCS. 
    Added salt reduces the affinity for PG-rich SUVs to such an extent that the apparent Kd 
for pure PG SUVs could not be measured. To explore this further we examined the 
fraction of protein bound to a large excess of vesicles (18 mM PG) in the absence and 
presence of NaCl (Fig. 4-7A, inset). Without salt, all of the protein partitioned onto the 
vesicles, whereas increasing the ionic strength dramatically reduced protein binding. 
With ~130 mM NaCl, only ~20% of the protein was bound. Given the high bulk 
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phospholipid concentration (18 mM), in the presence of salt the apparent Kd for PG 
vesicles must be very high (>50 mM). This result suggests that SaPI-PLC binding to pure 
PG vesicles is almost entirely mediated by electrostatic interactions. However, with PC in 
the vesicle, the much higher residual activity indicates that binding of the enzyme to the 
bilayer now has a more substantial hydrophobic component. 
4.6 Perturbing Hydrophobic Interactions with the Membrane 
    In the Bacillus enzymes, a number of aromatic residues are critical for tight binding to 
PC-rich membranes, including Trp242, which partitions into the bilayer [28,31], and a 
strip of four surface Tyr residues in helix G [30]. In SaPI-PLC, Trp242 is replaced by 
Phe249 and this enzyme has only two of the four tyrsoine residues (Tyr253 and Tyr255) 
in helix G. It is also unclear if Phe249 interacts with the membrane because it is tucked 
into the protein and away from the surface in the monomeric acidic SaPI-PLC crystal 
structure and in the dimer structure. To test whether these residues interact with the 
membrane in SaPI-PLC, we constructed the following variants: F249W and F249I, 
Y253S, and Y253S/Y255S. Tyr290, a single Tyr residue that is unlikely to interact with 
the membrane, was also mutated to serine as a control. The activity of the control, 
Y290S, is similar to WT (Fig. 4-8). However, both Y253S and the double Tyr mutant 
enzyme are much less active under all conditions. Increasing PC content has a very 
modest effect on PI cleavage by Y253S, whereas Y253S/Y255S is virtually insensitive to 
the presence of PC. In contrast, mutating Phe249 to a tryptophan significantly enhanced 
enzyme activity for XPC=0.5, whereas the activity of F249I is equivalent to that of the 
WT. The pH dependence was varied for several of these variants, and whereas F249I and 
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Y290S still behave essentially like WT, Y253S exhibits much lower activity regardless of 
pH (Fig. 4-9). The loss of activity and PC activation for Y253S and Y253S/Y255S 
suggest that these residues play a role in the conformational changes that activate the 
protein in the presence of PC. 
    Because both F249W and Y253S/Y255S have activities that are significantly different 
from WT, protein binding to PG/PC SUVs was measured by FCS (Fig. 4-7B). The Kd 
values for F249W are comparable with WT at XPC=0 and 0.2 but significantly smaller at 
0.8 XPC, indicative of enhanced interactions with the membrane as might be expected 
when the larger tryptophan side chain replaces a phenyalanine that inserts into the 
membrane. However, this higher affinity for PC-rich SUVs does not translate into 
significantly higher activity. For comparison, Y253S/Y255S has similar affinities to WT 
up to 0.7 XPC, but much lower activity. For higher PC content, the fraction of mutant 
protein bound was small and linear up to 50 mM phospholipid, and the apparent Kd could 
not be estimated. These surface tyrosine residues are important for PC enhancement of 
activity; however, except at 0.8 XPC, the loss of activity is not a result of reduced binding. 
Thus, unlike Bacillus PI-PLC where Kd values for SUVs vary by orders of magnitude 
(from µM to >100 mM), as a function of XPC and/or enzyme mutations, the range of Kd 
for SaPI-PLC is much more limited and less easily perturbed. 
4.7 Occupation of the Anion Binding Pocket versus Dimerization 
    Compared with WT, Y253S has little activation by PC but similar membrane affinity. 
This behavior can be explained by the structure of Y253S solved by Rebecca Goldstein. 
The monomer structure of Y253S is essentialy identical to WT, but in an in silico Y253S 
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homodimer structure, the anion binding pocket is empty. Tyr253 aids in formation of a 
lid for the pocket in the opposing monomer of the homodimer structure (Fig. 4-4D). 
Replacement of the Tyr side chain with a serine leaves an opening in the adjacent 
monomer, thus increasing anion access to the anion-binding pocket in any Y253S 
homodimer (Fig. 4-4E). This increased accessibility could facilitate soluble anion or 
interfacial anionic phospholipid binding to the site, which in turn would destabilize the 
dimer interface by shifting helix B slightly away from the surface and separating valine 
residues. 
    To further explore the role of the anion-binding pocket and activity, two other mutant 
enzymes were generated: Y253W, where the “lid” for the pocket is now considerably 
larger, likely preventing anion binding and favoring dimerization, and Y253K, where the 
positive charge might increase and enhance anion binding electrostatically, although this 
could be balanced by the methylene chain occluding the pocket. As seen in the inset of 
Fig. 4-8A, Y253W has specific activity much higher than Y253S and comparable with 
WT. Y253K has lower activity than Y253W at all XPC examined. However, it is not as 
compromised as Y253S, suggesting that the bulk of the lysine alkyl chain may be 
blocking access to the anion site. 
    As a further test of how modulating the anion-binding pocket can affect activity we 
also prepared H86Y and H86E. The His86 imidazole forms part of the anion-binding 
pocket. H86Y will remove the side chain positive charge but will keep the lid in place in 
the dimer. H86E should antagonize anion binding because we are replacing a positive 
charge with a negative one. As shown in Fig. 4-8B, H86Y exhibits higher activity toward 
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pure PI SUVs (14.1±1.0 versus 9.8±0.3 µmol min-1 mg-1 for WT) and activity comparable 
with WT with PI/PC SUVs. In contrast, H86E has very low activity toward pure PI SUVs 
(electrostatic repulsion would impede strong binding to SUVs), but is dramatically 
enhanced with PC present (a 135-fold increase compared with the more typical 10–15-
fold for H86Y and WT). Consistent with the low activity toward PI SUVs, H86E showed 
only a small increase in activity with enzyme concentration compared with the other 
proteins, reflecting its difficulty in binding to the target membrane (Fig. 4-8C). With 
XPC=0.5 SUVs, the relative loss of activity for H86E in the presence of salt (29% residual 
activity) was also less than WT (21% residual activity). This behavior also suggests that 
the anion-binding pocket is intertwined with dimer formation. 
    These results suggest a very intriguing proposal: SaPI-PLC is optimally active as a 
dimer, but an appropriate phospholipid interface and/or high protein concentration is 
needed to at least transiently stabilize this structure. Soluble anions, such as the 
physiological anions, phosphate (PO43-) or chloride (Cl-), can compete for the anion-
binding pocket, and prevent dimer formation as well as weakening interfacial binding. An 
anionic phospholipid might interact with this site, but in doing so, it would also 
destabilize the dimer, leading to lower activity while aiding in binding the protein to the 
bilayer. The observation that the double mutant Y253S/Y255S behaves similarly to 
Y253S supports the importance of this single aromatic group in indirectly promoting 
interfacial dimerization. 
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Figure 4-7. SaPI-PLC binding affinity, measured by FCS, increases with pH and PC 
content and is similar to the apparent Km for the enzyme. Variation of the PI-PLC 
apparent dissociation constant, Kd, for SUVs as a function of: (A) pH for PG () and 
PG/PC (XPC=0.5) (), and (B) mole fraction PC, XPC, at pH 6.5, for WT (), F249W 
(£), and Y253S/Y255S (r). The inset in (A) shows the fraction of WT protein bound to 
pure PG (18 mM) SUVs at pH 6.5 as the concentration of salt is increased. (C) Relative 
specific activity of SaPI-PLC as a function of total phospholipid concentration 
([PI]+[PC]) at XPC=0 () and 0.5 () at pH 6.5. The amount of enzyme used was 0.1 
µg/mL for pure PI SUVs and 0.2 µg/mL for experiments with PI/PC SUVs. For each 
system the observed activity was normalized to the maximum observed activity, 11.2 
µmol min-1 mg-1 for pure PI SUVs and 282 µmol min-1 mg-1 for the PI/PC SUVs. The 
error bars are the S.D. from independent experiments. 
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Figure 4-8. Specific activities of SaPI-PLC variants as a function of XPC at pH 6.5. (A) 
The specific activities for WT (■), F249W (▨), F249I ( ), Y253S (□), Y290S (▤), and 
Y253S/Y255S (▥). The inset shows the activity of Y253 variants: Y253S (□), Y253K 
(▨), and Y253W ( ). (B) The specific activities for H86 variants toward pure PI SUVs 
and PI/PC (1:1) SUVs in the absence and presence of added salt: H86Y (□) and H86E 
(▨) are compared with WT (■). The kinetic experiments in (A) and (B) kept the PI 
concentration at 4 mM and increased the PC to yield the indicated XPC. (C) The 
dependence of PI-PLC specific activity on protein concentration: WT (), H86Y (), 
and H86E (¢). Error bars are the S.D. of activities measured in triplicate. 
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Figure 4-9. pH dependence of SaPI-PLC variants specific activity (µmol min-1 mg-1) 
towards PI/PC SUVs (XPC=0.5): WT (■), F249I (□), Y253S ( ), and Y290S (▨). The 
concentration of PI was fixed at 4 mM with increasing amounts of PC added. PC 
activation is only reduced for Y253S. 	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4.8 Discussion 
4.8.1 SaPI-PLC Activity, Dimer Formation and the Membrane PC Content 
    The kinetic and structural data strongly suggest that SaPI-PLC is optimally active as a 
dimer, and that this dimer is transiently stabilized by the membrane surface. The small 
dimer interface in the crystal structure suggests that dimers are likely to be transient, 
making them difficult to observe. SaPI-PLC might aggregate to a small extent in solution, 
but obtaining accurate sizes for bacterial PI-PLCs in solution is difficult because they 
have an affinity for carbohydrates. At the protein concentrations required for gel filtration 
or analytical ultracentrifugation, these PI-PLCs interact with the resin or sucrose leading 
to aberrant sizes [172]. Furthermore, increased ionic strength, which suppresses 
interaction of the B. thuringiensis enzyme with resins [10], would favor monomeric SaPI-
PLC. However, the simple membrane-induced dimer model does not explain why SaPI-
PLC activity increases with increasing PC content despite its lower affinity for PC-rich 
membranes. The presence of PC in the vesicle also rescues activity lost by the enzyme in 
moderate concentrations of salt (Fig. 4-5B), consistent with a switch from electrostatic to 
hydrophobic interactions. 
    A better understanding of SaPI-PLC might be gained by comparing it to the well-
studied PI-PLC from B. thuringiensis, which has a specific binding site for PC near 
helices F and G [34]. For B. thuringiensis PI-PLC, apparent Kds range from ~4 mM for 
anionic SUVs to ~2 µM at XPC=0.75 with apparent Kds of 200-30 µM from 0.2 to 0.5 XPC 
where enzyme activity is optimal [146]. SaPI-PLC binds more weakly to PC containing 
SUVs with apparent Kds of 0.3 to 50 mM for 0 to 0.8 XPC, likely due to its lack of a PC 
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specific binding site near the F and G helices [34].  
    Why then does SaPI-PLC activity increase with PC content when the affinity for 
vesicles is decreasing? Incorporation of PC may dilute the surface concentration of the 
anionic phospholipids in vesicles, and that in turn could enhance SaPI-PLC dimer 
formation. This mechanism is consistent with the observation that much lower enzyme 
concentrations are required to increase PI-PLC specific activity in the presence of PC 
(Fig. 4-6C) even though the apparent Km increases as PC is increased. Alternatively, 
there are a number of aromatic residues in loops and N-terminal portions of helices 
around the barrel rim that could form transient cation-π interactions with the choline 
headgroup. This could alter the conformation of loops or side chains and facilitate 
transient protein dimerization. It should also be noted that the cation-π latch is still 
observed in the dimer structure (obtained at pH 4.6), and its presence is likely to aid in 
soluble cIP release, at least at acidic pH. However, the altered pH profile in the presence 
of PC might suggest that the zwitterionic phospholipid leads to alterations of pKa values 
for the many histidine residues in and around the active site. This could be the result of a 
conformational change or change in the surface charge of the membrane. Additionally, 
interactions with PC and transient dimerization could better orient SaPI-PLC relative to 
the membrane surface, facilitating enzyme activity by increasing substrate access. 
4.8.2 The Anion-binding Pocket – A Key to Inhibiting Dimer Formation  
    One of the unusual features of SaPI-PLC is the very electropositive anion-binding 
pocket just below the rim of the barrel, adjacent to helix B. Neither the Bacillus enzymes 
nor L. monocytogenes PI-PLC have such a pocket and those enzymes cannot form the 
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helix B mediated dimer. In SaPI-PLC the anion pocket is composed of the backbone 
amides of Lys38 and Asp39, as well as the cationic side chains of Lys42 and His86. 
Anion binding leads to a shift in the pocket residues, as well as pull the entirety of helix 
B (Val41 to Ala46) down, closer to the anion binding pocket, and thus away from the 
dimer interface. The shift in helix B would in turn increase the distance of valine pairs 
thus destabilize the dimer interface. Thus anion binding, probable at high salt 
concentrations, and dimer formation appear mutually exclusive. 
4.9 Conclusions 
    We hypothesize that competition between anion binding and dimer formation is the 
key regulator of SaPI-PLC activity (Fig. 4-10). Soluble anion binding weakens protein 
affinity for PI-rich vesicles, inhibiting SaPI-PLC even at moderate salt concentrations. 
An anionic phospholipid might also bind to the pocket electrostatically, and thus aid in 
anchoring the protein to the surface. However, the presence of an anionic phospholipid 
such as PI near this site would favor the monomer and lead to low specific activity. High 
protein concentrations allow dimerization to compete with anionic lipid binding to the 
pocket leading to some dimers on the membrane, but activities are still low. PC then 
activates SaPI-PLC, not by specific interactions, but by lowering the interfacial anionic 
lipid concentration and emptying the anion binding pocket, facilitating dimer formation. 
Occlusion of the pocket by the dimer interface makes the membrane-bound dimer much 
less sensitive to physiological salt concentrations. However, there is a trade-off: dimers 
have higher activity, likely because of a conformational change that enhances catalysis 
and/or because they optimize the protein orientation on the membrane for catalysis, but
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Figure 4-10. A model for SaPI-PLC-membrane interactions. Monomeric PI-PLC 
partitions from solution to the membrane via electrostatic interactions, and a molecule of 
PI diffuses to the active site (step 1). The enzyme then either binds a soluble anion, and 
falls off the membrane, or may bind an auxiliary anionic lipid in/near the anion binding 
pocket (step 2). PI-PLC dimerization is promoted by PC, which dilutes the interfacial 
concentration of the auxiliary anionic lipid, and releases it from the enzyme (step 3). 
Finally, in step 4, the dimer dissociates into monomers or dissociates from the membrane. 
PI-PLC is represented in semi-transparent space filling view, with the active site 
highlighted in red, and the anion binding pocket highlighted in cyan. PI lipids are 
modeled as blue spheres, the membrane is shown as a blue gradient, and a water-soluble 
anion is shown as a purple sphere. 
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they bind more weakly than monomers. On PC-rich bilayers they have lost the 
electrostatic interactions of the regulatory site.     
    S. aureus is known to cause a broad range of diseases in humans and is commonly 
found in skin infections and abscesses which can lead to toxemia and lethal bacteremia 
[20,22]. The association of an auxiliary anion binding site with SaPI-PLC but not with 
homologues from other Gram-positive bacterial species would argue that it is related to 
the biology of S. aureus. Since abscesses are acidic [24], the slightly more acidic 
optimum of SaPI-PLC enzymatic activity would make it more effective. In a study of 
methicillin-resistant S. aureus, expression of the PI-PLC, as well as other exoproteins and 
cytoplasmic proteins, was significantly increased [23]. Although this protein has a 
moderate affinity for anionic surfaces in the absence of salt, once the enzyme is secreted 
into the moderate ionic strength of the extracellular milieu, it will not interact with other 
S. aureus organisms. It is then poised to interact with the PC or sphingomyelin-
containing membranes of eukaryotic target cells via the valine box of the dimer. The still 
weak interaction with pure PC surfaces may allow it to hone in on negatively charged 
regions (the cationic character of the anion binding pocket is still available), which 
include GPI-anchors, the targets of this exoprotein. Clearly, this small soluble 
phospholipase has evolved a complex, apparently unique way to control its access to the 
phosphatidylinositol moieties that are its substrates: (i) A cation-π latch allows it to work 
on membranes under acidic conditions and more easily release soluble product without 
dissociating from the surface. (ii) An anion-binding pocket near the region that binds to 
the membrane likely modulates the location of the protein, whether it is bound to a 
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negatively charged surface, one with significant zwitterionic lipid content, or in solution. 
(iii) High activity requires dimerization of the enzyme and dimerization is enhanced by 
PC content similar to that found in the external leaflet of mammalian plasma membranes. 
This interplay between protein dimerization and an anion sensing site could be a way of 
regulating other peripheral (or even integral) membrane enzymes. Juxtamembrane 
cationic regions, while favoring anionic membrane regions, could prohibit protein/protein 
interactions. However, an appropriately modified bilayer composition might change this 
balance. 
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Chapter 5 
Defining Cation-π Binding in Peripheral Membrane Proteins 
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5.1 Introduction 
    Peripheral membrane proteins often initially recognize specific lipids of their target 
membrane by the stereospecific features of phosphoinositide headgroups [45,46]. This 
interaction may be further modulated by insertion of hydrophobic and aromatic amino 
acids into the bilayer [31,48,49] and/or multivalent interactions [46]. Although there are 
numerous examples of specific binding to anionic lipids, less is known about specificity 
for zwitterionic lipids such as phosphatidylethanolamine (PE) and phosphatidylcholine 
(PC). The trimethylammonium moiety of PC headgroups has been observed in the 
structures of various proteins [52-59] to have cation-π interactions with the aromatic 
residues. However, it is unclear whether the cation-π interaction by itself would provide 
sufficient binding energy to transiently bind a protein to the membrane. 
    To test the hypothesis that such a cation-π box might allow specific, but transient 
binding to a PC-rich membrane, I engineered such a box into S. aureus PI-PLC (SaPI-
PLC). Both B. thuringiensis PI-PLC (BtPI-PLC) and SaPI-PLC can target GPI-anchored 
proteins in the PC-rich outer membrane of eukaryotic cells [17,173]. Although BtPI-PLC 
has a high affinity for PC vesicles [31], the similar PI-PLC from S. aureus has virtually 
no affinity for PC vesicles (refer to Chapter 4). High resolution field-cycling NMR 
experiments on BtPI-PLC identified a discrete binding site for PC that is consistent with 
Tyr residues forming a cation-π box or sandwich [34]. However, this motif is not present 
in the SaPI-PLC, which displays much weaker binding to PC-rich vesicles and virtually 
no binding to pure PC vesicles. Interestingly, unlike most other cation-π boxes, which are 
often made up of aromatic residues located on β strands and/or on loops with the 
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separation required to sandwich a methyl ammonium between at least two π systems, the 
putative BtPI-PLC cation-π box is proposed to be located on adjacent α helices on the 
outside of a β-barrel. Therefore, I added two more tyrosine residues to SaPI-PLC to 
introduce a specific PC binding site and characterize this with several biophysical 
techniques including fluorescence correlation spectroscopy, high resolution field cycling 
NMR, as well X-ray crystallography.  
5.2 Comparing B. thuringiensis and S. aureus PI-PLC 
    BtPI-PLC binds to PC-rich vesicles with the residues located on the loop connecting 
helices F and G (notably Trp242), as well several tyrosine residues located on helix G 
(Tyr246, Tyr247, Tyr248, Tyr251) [30,34]. Sequence and structural alignments of BtPI-
PLC and SaPI-PLC show that whereas Tyr246 and Tyr248 in the Bacillus enzyme 
correspond to Tyr253 and Tyr255 in S. aureus, the other two tyrosine residues (247 and 
251) in the Bacillus enzyme have been replaced with Asn254 and His258 in the S. aureus 
enzyme (Fig. 5-1A). SaPI-PLC binds to PC-rich membranes with much lower affinity 
than does BtPI-PLC and has virtually no affinity for pure PC vesicles (refer to Chapter 4). 
This fact suggests that the higher affinity of BtPI-PLC for PC is associated with the 
presence of an aromatic box that creates a binding site for the choline. We hypothesized 
that mutating Asn254 and His258 to tyrosines (N254Y/H258Y) could introduce a 
specific PC binding site in SaPI-PLC. This expectation was based on the observation that 
the site could utilize cation-π interactions to bind the PC headgroup. 
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5.3 Vesicle Binding of N254Y/H258Y SaPI-PLC 
5.3.1 Vesicle Binding Comparison of WT and Mutated Enzymes by FCS 
   FCS was used to measure binding of the WT and mutated enzymes to SUVs. All three 
proteins (WT, Y253S/Y255S, N254Y/H258Y) have similar affinities for XPC≤0.2 
vesicles, but both WT and Y253S/Y255S have poor affinities once XPC≥0.5, whereas 
N254Y/H258Y still has a millimolar affinity for these PC-rich vesicles (Fig. 5-1B). As 
the PC content increases the difference in binding between the double mutant protein and 
WT is quite pronounced. N254Y/H258Y has a 50-fold lower apparent Kd than WT for 
XPC = 0.8 vesicles. Although WT shows virtually no binding (<8% is bound with 55 mM 
PC) to pure PC SUVs, N254Y/H258Y binds with an apparent Kd of 3.3±0.4 mM. 
5.3.2 Testing PC Binding with a Filtration Assay 
    Moderate salt concentrations dramatically reduce SaPI-PLC binding to vesicles (refer 
to Chapter 4), providing a simple assay to demonstrate whether PC is binding via one or 
both of the tyrosines that were introduced into the PI-PLC variant. Wild-type SaPI-PLC, 
N254Y, H258Y, and N254Y/H258Y (0.2 mg/mL) were each incubated with 1 mM 
PG/PC (0.2 mM/0.8 mM) SUVs in 50 mM MES, pH 7.5, with 140 mM salt, followed by 
centrifugation to separate free protein from vesicle bound protein. The total phospholipid 
concentration of 1 mM was chosen to be close to the Kd for N254Y/H258Y measured by 
FCS. Under these conditions, no WT or N254Y protein was bound to the vesicles; 
however, 12% of H258Y and 59% of N254Y/H258Y were bound to the vesicles. This 
suggests that a tyrosine at residue 258 is required, and that a tyrosine at 254 significantly 
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increases PC binding in the H258Y background. This same binding assay carried out with 
1 mM PG/PE (0.2 mM/0.8 mM) to examine if N254Y/H258Y exhibited a preference for 
PC compared with PE. When N254Y/H258Y was incubated with either the PC or PE 
containing SUVs, 68% of the protein was bound to the PG/PC SUVs, whereas only 36% 
of the protein was bound to the PG/PE SUVs. The interactions of the protein with PC 
appear significantly stronger than with PE. 
5.3.3 PC Binding Specificity by 31P NMR Line Broadening and Intrinsic Fluorescence 
Changes 
    Additionally, binding of SaPI-PLC enzymes to PC micelles was explored by 
monitoring the 31P line width of diC7PC in the presence of the protein (Fig. 5-1C).  BtPI-
PLC induces formation of large protein-micelle complexes right around the critical 
micelle concentration (CMC), and mutations that weaken association with PC reduce this 
change in 31P line width [30]. SaPI-PLC and the Y253S/Y255S variant had little or no 
effect on the diC7PC line width, consistent with poor binding to a PC interface. However, 
N254Y/H258Y mimicked the behavior of the B. thuringiensis PI-PLC with a large 
increase in line width at the critical micelle concentration. The intrinsic fluorescence 
associated with the presence of aromatic residues in N254Y/H258Y also increased with 
the addition of micellar diC7PC; this effect was not observed with the WT protein (Fig. 5-
1C, inset). 
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Figure 5-1. Inserting the two missing Tyr residues generates PC specificity. (A) 
Alignment of the F/G helix region of Bt (PDB 1PTD) and Sa (PDB 3V18) PI-PLC. The 
secondary structure is shown above the alignment and the residues important for 
membrane binding are highlighted. (B) Apparent binding constants at pH 6.5 for WT 
(▲), Y253S/Y255S (), and N254Y/H258Y () partitioning to SUVs as a function of 
mole fraction PC (XPC). (C) 31P linewidth of diC7PC in the absence (solid line) and 
presence of 3 mg/mL of BtPI-PLC () and SaPI-PLC variants: WT (▲) and 
N254Y/H258Y (). The inset shows the relative change in intrinsic fluorescence of WT 
(▲) and N254Y/H258Y () as a function of the amount of micellar diC7PC added (CMC 
of diC7PC is ∼1.5 mM at 25 °C). The line is a hyperbolic fit to the data. 
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5.4 Effect of the Added PC Site on Enzymatic Activity 
    The addition of two tyrosines to helix G in SaPI-PLC has apparently created a site on 
this enzyme that can bind one or more PC molecules. The question arises whether this 
enhanced PC binding influences enzyme activity. SaPI-PLC enzymatic activity toward PI 
in vesicles is sensitive to both pH and salt concentration, and PC in the interface both 
alters the optimal pH for activity and ameliorates the salt sensitivity of the WT enzyme. 
These kinetic effects are not due to specific PC binding but rather result from competition 
between anion binding to a specific pocket in SaPI-PLC and formation of a more active 
homodimer that occludes the anion binding site (Chapter 4). Like WT, N254Y/H258Y 
specific activity increases with increasing enzyme concentration indicating the active 
form is still a dimer. At pH 6.5 in the absence of salt, specific activity shows a large 
increase with PC content for both N254Y/H258Y and WT (Fig. 5-2A). If salt is present 
neither WT nor N254Y/H258Y exhibits much activity toward pure PI SUVs, and salt 
reduces the activity of WT SaPI-PLC even toward SUVs containing PC. However, once 
PC is present in the SUVs, the salt sensitivity of N254Y/H258Y enzyme is virtually 
abolished and the engineered enzyme exhibits activities in the presence of salt that are 
close to the values obtained without salt, whereas the activities of the WT are much lower 
in the presence of salt. 
    Specific activity toward PI in vesicles partially reflects how efficiently the protein 
partitions onto vesicles. For WT, the tightest binding is observed at pH 5.5, and added 
salt dramatically weakens binding to both pure PG and PG/PC (1:1) SUVs (Fig. 5-2, B 
and C). At pH>5.5 in the absence of PC (Fig. 5-2B), the binding of both WT and 
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N254Y/H258Y proteins are similarly inhibited by salt. However, once PC is present in 
the SUVs, N254Y/H258Y binding is not significantly affected by salt (Fig. 5-2C). The 
apparent Kd values for binding to XPC = 0.5 SUVs, at pH 6.5 in the presence of 140 mM 
salt, were ∼70 mM for WT and 2.6 ± 0.6 mM for N254Y/H258Y. Similarly, WT binding 
to pure PC SUVs was too low to measure, whereas N254Y/H258Y exhibited an apparent 
Kd of 5.4 ± 0.9 mM in the presence of salt (only about 50% higher than the apparent Kd 
in the absence of salt). Salt screens electrostatic interactions preventing WT SaPI-PLC 
binding to these vesicles, but the engineered PC site in N254Y/H258Y allows binding to 
PC-containing interfaces even in the presence of salt. 
5.5 Defining the PC Binding Site on a Molecular Level 
    Two experimental approaches were used to confirm the expectation that PC binds in 
direct proximity to the two introduced tyrosines (N254Y/H258Y): (i) high-resolution 
field cycling 31P NMR analysis of the effect of spin-labeled protein on a mixed PC/PMe 
bilayer and (ii) X-ray crystallography structure determination for the N254Y/H258Y and 
H258Y SaPI-PLC variants by Rebecca Goldstein. Comparisons with the WT structure 
that has been described previously (Chapter 4) offer insight not only into the 
conformational adaptability of the protein but also demonstrate that increased PC affinity 
results from PC binding mediated by the introduced tyrosine residues. 
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Figure 5-2. In the presence of PC, N254Y/H258Y SaPI-PLC is less salt-sensitive than 
WT. (A) Specific activity of S. aureus WT (triangles) and N254Y/H258Y (circles) PI-
PLC at pH 6.5 toward different vesicle compositions (XPC = mole fraction PC) in the 
absence (filled symbols) and presence (open symbols) of 140 mM salt. The concentration 
of PI was kept at 4 mM with increasing amounts of PC. B and C, the apparent fraction of 
protein bound to (B) pure PG (6.2 mM) or (C) PG/PC (8.2:8.2 mM) SUVs (extracted 
from FCS data) is shown as a function of pH: WT in the absence (■) or presence (▨) of 
140 mM salt; N254Y/H258Y in the absence (□) or presence (▥) of salt. Error bars 
represent the variation in parameters from experiments using different protein and SUV 
preparations. 
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5.5.1 NMR Field Cycling Experiments with SUVs 
     Because the chemical shifts of different phospholipids are distinct, 31P field cycling 
NMR is useful for identifying specific phospholipid interactions with a spin-labeled 
protein in multicomponent vesicles [34]. In these experiments, differences in 
phospholipid 31P relaxation rates provide a direct measure of the proximity of different 
phospholipid species to the spin label site. In particular, we have shown that for PC/PMe 
SUVs, BtPI-PLC spin labeled at D205C has a large effect on the 31P relaxation rate of PC 
with a much smaller effect on PMe consistent with a PC site near the spin label and a 
bound PC lifetime between 1 µs and 1 ms. PMe, an anionic lipid that also competes with 
PI substrate, was used in these experiments, because over the course of 24 h there is some 
hydrolysis of PG by the enzyme and generation of diacylglycerol that causes vesicle 
fusion. Asp205 in BtPI-PLC aligns with Asp213 in SaPI-PLC, and spin labeling at 
D213C has little effect on the PMe or PC resonances (Fig. 5-3A) under conditions (140 
mM salt and 0.5 mg/mL of protein and 5 mM each phospholipid) where ∼15–20% of this 
labeled WT protein is associated with the SUVs in the presence of salt. The field 
dependence data for D213C in the WT SaPI-PLC background appears equivalent to what 
is seen for the SUVs in the absence of protein [34]. 
    However, a very different profile is observed for spin-labeled D213C/N254Y/H258Y 
under the same conditions, and the results for this variant resemble those for BtPI-PLC 
(Fig. 5-3). A potential complication to the average distance determination arises from the 
fact that SaPI-PLC forms transient dimers on vesicle surfaces via helix B side chains. 
However, based on the dimer X-ray crystal structure, a spin label at residue 213 should 
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be >35 Å from the active site of the opposing monomer, and 34–35 Å from H258Y on 
the opposing monomer. Because the distance dependence of the spin label falls off as 
1/r6, the field cycling NMR should only report on an intramonomer PC site. The stronger 
effect exerted by the spin-labeled protein on the PC NMR relaxation rate compared with 
PMe therefore indicates that in the engineered protein (i) PC has a discrete binding site 
and (ii) it is near the region identified in the B. thuringiensis enzyme [34]. 
    If we assume a single PC binds to the protein for the observed correlation time of the 
low field dispersion, then we can further use the ratio τP-e/ΔRP-e(0) to estimate a distance 
for each of these phospholipids to the spin label at residue 213. These parameters are 
obtained from fitting the relaxation as a function of field that is specifically due to the 
introduction of the spin label on N254Y/H258Y at D213C (Fig. 5-3, inset). The 
correlation time for the 31P-electron dipolar interaction is 2±1 µs and the extrapolated 
ΔRP-e(0) values for the two phospholipids are 8.5±1.3 s−1 (PC) and 0.7±0.6 s−1 (PMe). 
Although τP-e is not known precisely, what is relevant in determining rP-e is the ratio τP-
e/ΔRP-e(0), and this is very similar when fitting the data at 1 to 3 µs. For PC with τP-e = 2 
µs, this yields rP-e = 15.2 ± 0.4 Å. If the plot of ΔR1 versus field is fit at 1- or 3-µs 
correlation times, there is at most a 0.5-Å variation in the estimated rP-e. Interestingly, this 
value is a little longer than the rP-e extrapolated for the BtPI-PLC with a spin label 
attached at the same site (13.5±0.2 Å [34]). The difference in rP-e for PC binding to the 
two PI-PLC proteins may look small, however, it is real because τP-e/ΔRP-e(0) (which 
differs by a factor of two for the two proteins) is proportional to rP-e6. There is a small 
effect on PMe, which should only occupy the active site with this amount of salt in the 
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buffer. If one uses the fit with 2 µs rP-e, bound PMe must be ∼22–24 Å away, roughly 
about where the active would be from the spin label on residue 213. The key result is that 
the PC binding site we introduced in S. aureus N254Y/H258Y is located in the same 
general area of the protein as it is in the BtPI-PLC. 
5.5.2 Crystal Structures of N254Y/H258Y with Choline and diC4PC 
     To further explore the location of the introduced PC site, Rebecca Goldstein (a 
graduate student in the laboratory) obtained crystal structures of the N254Y/H258Y 
double mutant. The overall structure of N254Y/H258Y closely resembles that of the 
Bacillus enzyme and differs only slightly from that of the SaPI-PLC WT. Further 
evidence for the existence and the location of the binding site for a choline moiety was 
provided by crystal structures of N254Y/H258Y with choline and diC4PC (Fig. 5-4). The 
structures revealed two discrete binding pockets – one between tyrosines on helix F and 
helix G and the second between helix G and a loop, which are formed by cation-π 
interaction of choline quaternary amines and the aromatic side chains of H258Y, Tyr212, 
Trp287 and Tyr290.   
5.5.3 Do Both Choline Sites in N254Y/H258Y Bind PC? 
   A comparison of N254Y/H258Y structures in the absence or presence of trimethyl-
ammonium ligands provides insights into the nature of the specific choline and PC sites. 
To accommodate the cationic ligand there are clear rotations of side chains in choline 
binding site 1, relative to the unliganded enzyme (Fig. 5-4A). However, we only see 
soluble diC4PC binding in choline site 2 and not in choline site 1. This could be the result 
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of weak PC binding, at least in the absence of a bilayer (which could locally increase the 
choline headgroup concentration so that binding occurs more readily), or it could be 
attributed to the difficulty in moving side chains in site 1 to accommodate a choline 
moiety, which might be more difficult when the choline is part of a phospholipid 
molecule. 
    The field cycling 31P NMR experiments provide insight into where PC presented in a 
bilayer binds on the protein, for at least 2 µs [34]. For the same amount of protein and 
phospholipids, τP-e/ΔRP-e(0), which is proportional to rP-e6, is 2.35×10−7 s2 for 
N254Y/H258Y, and 1.48×10−7 s2 for BtPI-PLC, consistent with PC binding closer to the 
spin label site in BtPI-PLC than in the engineered S. aureus protein. The Bacillus protein 
only has choline site 1 available for PC binding. Furthermore, if a PC molecule occupied 
both choline sites when N254Y/H258Y was bound to PC/PMe SUVs, there should be a 
considerably stronger relaxation of the 31P nucleus that is roughly twice as effective as 
when a single PC binds to the protein. Because τP-e/ΔRP-e(0) is larger for the S. aureus 
N254Y/H258Y (meaning further away), only one PC binds well with a ≥2 µs lifetime. In 
turn, the observation that the averaged distance of the spin label to the bound PC 31P is 
larger in N254Y/H258Y than in BtPI-PLC is consistent with PC binding to the S. aureus 
protein in choline site 2. Energy minimization of the crystal structure placed the isolated 
chains of diC4PC against the protein, but the same orientation of the choline moiety could 
easily be occupied with a longer chain phospholipid anchored in a bilayer (Fig. 5-4B). 
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Figure 5-3. The spin label at D213C perturbs lipid signals for the N254Y/H258Y mutant 
but not WT. Effect of spin-labeled SaPI-PLC (0.5 mg/mL) on PMe/PC (5:5 mM) SUVs: 
control PMe (☐) and PC () mixed with spin-labeled D213C; PMe (¢) and PC () 
with the spin-labeled D213C/N254Y/H258Y. The inset shows the difference in R1 for 
each phospholipid 31P specifically attributed to the spin label on D213C/N254Y/H258Y; 
the data are fit with τP-e = 2 µs. 
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Figure 5-4. SaPI-PLC structures with and without choline bound. (A) Overlay of the 
SaPI-PLC N254Y/H258Y structure without choline (dark blue, PDB 4I8Y) and with 
choline bound (teal, PDB 4I90) showing that choline site 2 (orange) is preformed, 
whereas site 1 (yellow) requires rotamer changes in side chains. (B) In silico models of 
PC and PI binding to discrete sites on SaPI-PLC N254Y/H258Y. The S. aureus mutant 
structure is shown as a dimer (mediated through helix B) with one molecules of diC7PC 
in site 2 (orange) and one molecule of PI (dark gray) in the active site in views with the 
membrane interface at the top. 
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    As further evidence for occupation of a single PC site in N254Y/H258Y, we generated 
Y211A/N254Y/H258Y/Y290A. Mutation of Tyr-290 to alanine should abolish choline 
affinity for site 2. Tyr-211 is not conserved in B. thuringiensis PI-PLC and must rotate by 
77° to accommodate the choline cation. Its removal might be expected to enhance PC 
binding, if site 1 is significantly populated by a PC molecule. Using the centrifugation 
assay for partitioning of Y211A/N254Y/H258Y/Y290A onto PG/PC (0.2 mM/0.8 mM) 
SUVs, we found little protein associated with the SUVs with 1 mM total phospholipid. 
With 8 mM total phospholipid 7.7 ± 3.8% of the protein was bound. In essence, 
abolishing choline site 2 prevents S. aureus N254Y/H258Y from binding to PC-
containing SUVs. This confirms that although two choline sites were introduced into S. 
aureus N254Y/H258Y, only preformed site 2 interacts significantly with a PC 
headgroup. 
5.6 Discussion 
    Sandwiches, cages, or boxes composed of aromatic amino acid π systems of aromatic 
amino acids are a facile way to bind trimethylammonium moieties via cation-π 
interactions. In so doing they provide a specific recognition motif for the headgroups of 
zwitterioinic phospholipids. Bacillus PI-PLC is activated by PC [10], in large part by 
enhancing vesicle binding [146]. The G helix region of Bacillus PI-PLCs has several Tyr 
residues that could form a sandwich or cage around a choline group [30,34], but how and 
whether PC binds to this box was unclear. Attempts to transplant this box into S. aureus 
PI-PLC by introducing two “missing” tyrosine side chains in helix G generated 
catalytically active protein that binds much more tightly to PC-rich interfaces. Field 
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cycling NMR suggest there are similarities in the position of PC bound to BtPI-PLC and 
to S. aureus N254Y/H258Y protein when the protein is transiently anchored on a vesicle. 
Although X-ray crystallography reveals two spatially close choline binding sites on the 
engineered protein, only choline site 2 between helix G and a loop is occupied by a PC 
molecule in the S. aureus protein. BtPI-PLC does not have the key tryptophan residue 
needed for choline site 2. However, all the side chains are correctly oriented for binding a 
choline (or PC) in what is analogous to S. aureus N254Y/H258Y site 1. 
    Although the specific cation-π PC binding site in BtPI-PLC (equivalent of choline site 
1) and that in S. aureus PI-PLC (choline site 2) are different, the energetic contribution of 
these aromatic π-choline cation interactions to PC binding should be similar and different 
from values for partitioning a tyrosine side chain into a bilayer [174]. We can use the 
apparent Kd values as a way to assess this. The relative change in vesicle binding affinity 
when the cation-π site is abolished, Kd(no PC site)/Kd(intact PC site), should be similar 
for both enzymes. Data for XPC = 0.8 SUVs were chosen for the comparison, because no 
Kd could be obtained for S. aureus WT binding to pure PC SUVs (refer to Chapter 4). For 
SaPI-PLC, Kd(WT)/Kd(N254Y/H258Y) = 48. For BtPI-PLC, the Y251A mutant was 
selected as one where the site analogous to choline site 1 should be abolished (Tyr251 is 
the equivalent of S. aureus H258Y). Binding data at the same mole fraction PC [175] 
yielded Kd(Y251A)/Kd(WT) = 45. Thus, the absence of a PC site, whether it is analogous 
to choline site 1 or choline site 2 in the S. aureus mutant, has essentially equivalent 
effects on vesicle binding. This translates to a change in free energy (at 22 °C, the 
temperature of the FCS experiments) of 9.5 and 9.3 kJ/mol for losing this cation-π 
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interaction. For comparison, partitioning of a tyrosine or a tryptophan side chain from the 
interior of a bilayer to water is estimated as 3.9 or 7.7 kJ/mol, respectively [174]. Clearly, 
cation-π interactions between proteins and the PC headgroup can stabilize the transient 
membrane binding needed for peripheral proteins. Invoking these interactions provides 
an explanation for why SaPI-PLC N254Y/H258Y binds to pure PC bilayers with 
significantly weaker affinity than BtPI-PLC. Tallying up the tyrosine residues around the 
rim of the αβ-barrel it is clear that the BtPI-PLC has far more aromatic residues that could 
either (i) insert into the bilayer or (ii) form transient cation-π complexes. 
5.7 Conclusions 
    These results, combined with structural studies of proteins that bind methyl-Lys, 
methyl-Arg, or choline using similar cation-π cages/boxes suggest that this cation-π motif 
has evolved in a variety of secondary structural contexts ranging from β barrels to β 
propellers to α helices and loops, anywhere that aromatic side chains can be separated by 
8–10 Å to allow space for binding a methylammonium moiety. In the case of membranes, 
such π system motifs could provide a general way to introduce specific yet transient 
interactions of peripheral membrane proteins with PC headgroups. 
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Chapter 6 
Identification of a Novel Mammalian cis-Aconitate 
Decarboxylase 
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6.1 Introduction 
    ITA was first discovered as a product of pyrolytic distillation of citric acid in an 
osmophilic strain of green Aspergillus species [79]. It was postulated to be synthesized 
via aconitase and cis-aconitate decarboxylase (cADC) activities [81,82]. As an important 
step in the clarification of ITA biosynthesis, a 55 kDa protein was purified from the high 
ITA producing strain A. terreus TN484-M1 [87]. The corresponding cADC gene was 
then identified to further verify the ability of this enzyme to produce ITA [85,88]. This 
cADC enzyme contains a conserved domain of the MmgE/PrpD family of proteins of 
bacteria and fungi [85], which include several 2-methylcitrate dehydratases of bacteria 
that are involved in propionate catabolism.  
     Very recently, itaconic acid (ITA) was detected in mammalian cells including a 
macrophage-like tumor cell line (VM-M3) [114]. The ITA was shown to be synthesized 
via decarboxylation of cis-aconitate, indicative of a novel mammalian cADC [114]. This 
unusual solute is secreted by a variety of mammalian cells [115-118]. However, up to the 
beginning of our project, there was no specific gene encoding the mammalian cADC. The 
discovery of ITA metabolite in a metastatic tumor cell line [114] hints that it may also 
have a role in tumor biology. Thus, identification of this novel mammalian cADC will 
help to clarify the physiological function of ITA in the mammalian immune system and 
in cancer. 
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6.2 Optimization of ITA Production in the Macrophage Stimulation   
    The optimal working pH value for the mammalian cADC activity in protein extracts of 
RAW264.7 cells was determined to be pH 7.5 (Fig. 6-1A). Macrophage stimulation 
conditions, including time after LPS addition (1 to 24 h) as well as LPS concentration 
(0.5 ng/mL to 50 µg/mL), were optimized. Relative cADC activities were calculated by 
the following equation: 
Er=(Pn/A280,n)/(Pmax/A280,max) 
where Er, is the relative activity at a specific condition determined by ITA production 
ratio and the estimated total protein concentration. The ITA production ratio, Pn, is 
determined by integrals of 1H NMR peaks for both –C=CH2 protons in ITA (either of the 
two separate peaks, at 5.82 and 5.34 ppm, can be used) and –C=CH– proton in cis-
aconitic acid (at 5.61 ppm). The highest ratio of ITA production was chosen as the 
maximum, Pmax. The absorbance at 280 nm (A280, n) was used to estimate the total protein 
concentration of cell lysates in order to minimize the differences in the amount of cells 
between samples. The mammalian cADC activity was detected ~1 h after adding LPS to 
the cells and reached half of the maximum value in ~4 h. The cADC activity in the 
extracts was constant after 8 h of stimulation and maintained up to 24 h post-LPS 
stimulation (Fig. 6-1B). The optimal LPS concentration range was determined to be from 
2 ng/mL to 10 µg/mL (Fig. 6-1C); use of higher LPS concentrations (>10 µg/mL) did not 
generate more cADC activity in the cells. Thus, for the following cell culture 
experiments, the stimulation time was always fixed at 8 h and LPS concentration was 10 
ng/mL unless specifically mentioned.  
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Figure 6-1. Optimization of ITA production in RAW264.7 cell extracts. The relative 
enzymatic activity was monitored as a function of (A) pH, (B) time course after 
stimulation, and (C) LPS concentration.  
 
 
 
 
 
 	    
6.0 6.5 7.0 7.5 8.0 8.5
0.0
0.2
0.4
0.6
0.8
1.0
pH
R
el
at
iv
e 
ac
tiv
ity
A
0 5 10 15 20 25
0.0
0.2
0.4
0.6
0.8
1.0 B
Time (h)
R
el
at
iv
e 
ac
tiv
ity
10-1 100 101 102 103 104 105
0.2
0.4
0.6
0.8
1.0
1.2
C
CLPS (ng/mL)
R
el
at
iv
e 
ac
tiv
ity
2 ng/mL                               10 μg/mL
	  	  149 
6.3 RAW264.7 Cell Stimulation by Toll-like Receptor (TLR) Agonists 
     LPS is a common used reagent in macrophage stimulations. It activates immune cell 
responses by binding to Toll-like receptors (TLRs). Since ITA production and the amount 
of target mammalian cADC were highly enhanced in macrophage stimulations by LPS, it 
is important to elucidate the molecular mechanism involved in TLR signaling. TLRs are a 
class of receptors that share common structures and signaling that leads to NF-κB 
activation. Stimulation with every agonist except for ssRNA40 (TLR7 agonist) resulted 
in ITA production (Fig. 6-2). By comparison, there was no detectable ITA production for 
the unstimulated cells. The cell lysate after LPS (TLR4 agonist) stimulation exhibited the 
highest cADC activity toward substrate cis-aconitic acid and was used as the standard. 
Polyinosinic-polycytidylic acid (Poly(I:C)), a TLR3 agonist, showed a comparable 
stimulation effect of cADC activity. At the concentration used, the agonists, Pam3CSK4 
(a synthetic lipopeptide (LP) that targets TLR1/2) and FSL-1 (a synthetic LP that targets 
TLR6/2), generated ~60% of the cADC activity observed in LPS stimulation. HKLM 
(bacterial L. monocytogenes, a TLR2 agonist) and FLA (S. typhimurium flagellin, a TLR5 
agonist) were slightly less effective in inducing cADC activity producing <40% of the 
activity generated with LPS. These results show that mammalian cADC production is 
involved in TLR signaling pathways. It is noteworthy that all the material used to engage 
TLRs were based on bacterial triggers except for ssRNA40, which is associated with 
viruses. This target enzyme may be a product under the synergistic effect of various TLR 
signaling pathways excluding TLR7. The level of target cADC expression is closely 
related to TLR4 signaling pathway considering the highest activity in LPS stimulation.  
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Figure 6-2. Toll-like receptor (TLR) agonists stimulate cADC enzymatic activity in the 
RAW264.7 cells. The specific target TLR for each TLR agonist is shown on the top of 
each bar. The control is the sample without any stimulation. The error bars are the S.D. 
determined from three independent agonist stimulation tests. 
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6.4 Actinomycin D Assay Differentiates de novo Synthesis of cADC Activity from Post-
Translational Modification 
    The basic strategy for identification of the enzyme exhibiting cADC activity was to 
compare the proteins profiles of unstimulated and stimulated cell lysates. However, prior 
to trying to fish out the enzyme, I first explored the source of cADC activity upon 
stimulation. It was unknown whether the increased activity was due to post-translational 
modification of an enzyme pool already in cells or caused by de novo protein synthesis. 
Actinomycin D (ActD) inhibits transcription in cells by binding to DNA at the 
transcription initiation complex and preventing elongation of RNA chain by RNA 
polymerase. However, ActD also shows toxicity to mammalian cells. Thus, after co-
incubating LPS and ActD in the samples, the RAW264.7 cells were monitored under a 
light microscope from 1 h to 8 h to check cell viability. A time point of 6 h was chosen as 
the co-incubation time for LPS and ActD since at this time point there is no obvious cell 
death. Different ActD concentrations (from 10 ng/mL to 1 µg/mL) and pre-incubation 
times (from 0 to 1 h) were used. Without pre-incubation with ActD, the cADC activity 
decreased as the ActD concentration increased (Fig. 6-3 No. 1-3 and 6) but the cell death 
ratio also increased when ActD concentration reached 1 µg/mL. An ActD concentration 
of 100 ng/mL was optimal since it led to less than 5% cell death. There was no difference 
in the inhibitory effect of ActD toward cADC activity for 20 min and 1 h (Fig. 6-3 No. 4 
and 5). But the pre-incubation of ActD before LPS stimulation caused a further 20% 
reduction of cADC activity at the same ActD concentration (Fig. 6-3 No. 3-5). Increasing 
the ActD pre-incubation time to 1 h had about the same effect in reducing cADC activity. 
	  	  152 
These results indicate that in stimulated RAW264.7 cells, the cADC enzyme is produced 
by de novo protein synthesis, which means the comparison of unstimulated protein 
profile to stimulated one can be utilized to identify the target enzyme. 
6.5 Enrichment of Target Enzyme from the Stimulated Cell Extract 
    Several experiments were designed to simplify the proteins backgrounds and maximize 
the target enzyme concentration in the matrix, in order to finally identify the target 
enzyme. The designed identification scheme of mammalian cADC is shown in Fig. 6-4. 
After the LPS stimulation, the cells were harvested and disrupted by sonication for better 
separation of the proteins from other organelles for use of centrifugation techniques later. 
One of the various purification methods, ion-exchange column was tried first. Fractions 
eluted with different salt gradients were assayed for cADC activity. The fractions that 
exhibited the highest relative cADC activity were collected, as well as the same salt 
fractions generated by chromatography of unstimulated cell extracts. These two samples 
could then be examined by MS proteomics methods to identify a group of proteins that 
only existed or were significantly overexpressed in the stimulated sample. Based on the 
further sequence alignment to fungal cADC, the potential mammalian cADC enzyme 
could be identified. Taking this one step further, possible cADC candidate proteins can 
be tested by siRNA knockdown experiment of specific genes and then assaying for 
cADC activity once these cells were stimulated with LPS.  
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Figure 6-3. Actinomycin D differentiates post-translational modification from de novo 
protein synthesis of mammalian cADC activity. Conditions are listed the Table (right). 
The error bars are the S.D. determined from three independent tests. 
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Figure 6-4. Scheme for identification of mammalian cADC. 
 
 	    
S"mulated*RAW264.7*cells*
Harvest*cell*
*
Resuspend*in**
lysis*buﬀer*
Sonica"on*
*
Ultracentrifuge*
*
Apply*supernatant**
to*ionBexchange**
puriﬁca"on*
2D*
SDS
BPA
GE*
****************Concentrate*
Trypsin*digest*
Apply*par"ally*puriﬁed**
uns"mulated*and*s"mulated**
protein*samples*to*Mass*Spec*
cADC*actvity*test*
Elute*
0"
0.2"
0.4"
0.6"
0.8"
1"
1.2"
Frac%ons)
Re
la
%v
e)
va
lu
es
)
Csalt"(M)"
"
UV"signal"
"
"
"
"
Ac8vity"
Csalt"=0.09=0.2"M"
-O O-
O OH
O -O
O-
O
O
O cADC
cis-aconitate itaconate
H+
Sa
lt%g
ra
die
nt
%in
cre
as
e%
InBgel*diges"on*
1**
2**
Proteomics*study******************
siRNA*knockdown*
*
Iden"fy*target*gene*
	  	  155 
6.5.1 Centrifugation 
    The crude cell lysate after sonication was further separated by centrifugation (14,000 
rpm, 30 min) and both the supernatant and pellet were assayed for cADC activity. Over 
95% of the activity was found in the supernatant, indicating that the enzyme was a 
soluble protein. Ultracentrifugation was also used for better separation of the soluble 
proteins from those associated with small membrane fragments of other large complexes. 
The sample was centrifuged at 100,000×g for 90 min. Since >90% of enzyme activity 
was in the supernatant, this was the fraction used for different purification techniques.  
6.5.2 Ion Exchange, Hydrophobic, and Gel-filtration Chromatography 
   Several protein purification methods were used to further separate the most active 
fractions from the soluble fraction obtained from stimulated RAW264.7 cells. An ion-
exchange column (QFF) was used along with a NaCl gradient from 0 to 0.6 M (in 20 mM 
Tris-HCl, pH 8.0). Protein, monitored by A280, was compared to cADC enzymatic 
activity (Fig. 6-5A). The mammalian cADC was eluted at the beginning of the salt 
gradient in a broad peak. This indicates that the mammalian cADC is negatively charged 
at this specific pH value since it can bind well with the cationic matrix of the QFF resin 
(the functional group is quaternary amine). It also indicates that the isoelectric point (pI) 
value for the cADC protein should be slightly lower than 8. Based on multiple 
characterizations of cADC activity in several stimulated cell extract samples from 
different preparations, the most active fractions was eluted from 0.09 to 0.24 M salt (Fig. 
6-5B). These fractions were collected for further purification. 
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    Hydrophobic interaction chromatography (HIC) separation is based on the reversible 
interaction between a protein and the hydrophobic ligand attached to the chromatography 
matrix. Several HIC resins with different hydrophobic characteristics were used, 
including phenyl sepharose, butyl sepharose and octyl sepharose. However, all of the 
active proteins accumulated on the resin since the cADC activity was only detected after 
mixing the resin after elution with the cis-aconitic acid substrate. This indicates that this 
mammalian cADC has rather high hydrophobicity and HIC purification is not useful.  
    Gel-filtration was the last method that we used to further purify the cADC protein (Fig. 
6-6). With two different types of gel-filtration matrix, Superdex 75 and 200, the most 
active fractions were associated with proteins that have a molecular weight around 67 kD 
(by comparing with standard gel-filtration curve), which also give the estimated 
molecular weight range of the target cADC protein.  
6.6 1D and 2D SDS-PAGE for Comparison of Stimulated and Unstimulated Samples 
    The stimulated and unstimulated protein mixtures after same steps of purification were 
further concentrated and lyophilized for 1D and 2D SDS-PAGE. However, the large 
number of proteins remaining made it impossible to identify the extra bands (1D SDS-
PAGE) or spots (2D SDS-PAGE) in the stimulated compared to the unstimulated protein 
samples. This procedure was abandoned. 
 
 
 
	  	  157 
Figure 6-5. Partially purification of stimulated RAW264.7 cell extracts by QFF. (A) A 
typical QFF purification plot for () salt gradient, (▲) UV signal and (£) relative cADC 
activity versus fraction number. (B) The dependence of cADC activity on the salt 
gradient. The highlighted region represents the salt gradient chosen for the fraction 
collection. The data were collected from six discrete purification processes. 
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Figure 6-6. Gel-filtration purification of protein mixtures after QFF by using (A) 
Superdex 200 and (B) Superdex 75. Inset: the activity profiles of each fraction. The 
highlighted area by dashed lines indicated where the most active fractions are.  	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6.7 Mass Spectrometry Proteomics Analysis of Stimulated and Unstimulated Samples 	  	  	  	  The same amount of stimulated and unstimulated cell extracts subjected to the same 
steps of purification (sonication, centrifugation, ion-exchange purification with collection 
of fractions from 0.09-0.24 M NaCl), were concentrated for the MS proteomics analysis. 
By comparing the protein profiles of stimulated and unstimulated samples, the 
immunoresponsive gene 1 (IRG1) appeared to be the most likely candidate since it was 
not found in the unstimulated sample but was the major component in the stimulated one 
(Table 6-1). The protein encoded from IRG1 was reported to be involved in the immune 
system, which is also consistent with the finding that mammalian cADC only appears 
during the macrophage stimulation. 
6.8 siRNA Transfection to Confirm IRG1 as a Mammalian cADC 
    In order to further confirm the cADC activity of IRG1 protein, the siRNA transfections 
(using ON-TARGETplus SMARTpool of mouse IRG1 genes) of RAW264.7 cells were 
carried out. Changes in the cADC activity between cells untransfected, cells transfected 
with control siRNA and cells transfected with targeting siRNA of various concentrations 
were monitored. As higher concentration of IRG1 siRNA were used, cADC activity in 
cell extracts was decreased. At 90 nM siRNA transfection, the residual cADC activity 
was ~20% of extracts from the untreated cells or cells transfected with scrambled siRNA 
(Fig. 6-8). This provides another strong evidence that IRG1 codes for the cADC in 
mammalian cells. 
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Table 6-1. Relative increase in proteins in partially purified RAW264.7 extracts of LPS- 
stimulated and unstimulated cells as identified by MS proteomics analyses. 
 
No	   Protein	   Un.	   Sti.	   Ratio	  
1	   IPI00111285	  -­‐	  Irg1	  -­‐	  immunoresponsive	  gene	  1	  	   0	   338	   -­‐	  
2	   IPI00221614	  -­‐	  Arf3	  -­‐	  ADP-­‐ribosylation	  factor	  3	  	   0	   196	   -­‐	  
3	   IPI00667787	  -­‐	  LOC545592	  -­‐	  similar	  to	  heterogeneous	  nuclear	  ribonucleoprotein	  A3	   0	   114	   -­‐	  
4	   IPI00466185	  -­‐	  33	  kDa	  protein	  	   0	   114	   -­‐	  
5	   IPI00409405	  -­‐	  EG620772	  -­‐	  similar	  to	  cofilin-­‐1	  isoform	  1	  	   0	   35	   -­‐	  
6	  
	  
IPI00853668	  -­‐	  LOC100040634;LOC100046224	  -­‐	  similar	  to	  glyceraldehyde-­‐3-­‐	  
phosphate	  dehydrogenase	  (GAPDH)	  isoform	  1	  	   0	   34	   -­‐	  
7	  
	  
IPI00622795	  -­‐	  LOC100042427	  -­‐	  similar	  to	  glyceraldehyde-­‐3-­‐phosphate	  	  	  
dehydrogenase	  (GAPDH)	  isoform	  1	  	   0	   34	   -­‐	  
8	   IPI00828490	  -­‐	  Hcfc1	  -­‐	  host	  cell	  factor	  C1	  	   0	   18	   -­‐	  
9	   IPI00761442	  -­‐	  12	  kDa	  protein	  	   0	   16	   -­‐	  
10	   IPI00114065	  -­‐	  Cfb	  -­‐	  complement	  factor	  B	  precursor	  (fragment)	  	   0	   16	   -­‐	  
11	   IPI00117379	  -­‐	  Atox1	  -­‐	  copper	  transport	  protein	  ATOX1	  	   0	   13	   -­‐	  
12	   IPI00754445	  -­‐	  OTTMUSG00000016644	  -­‐	  hypothetical	  protein	  LOC667373	  isoform	  1	  	   0	   13	   -­‐	  
13	   IPI00109142	  -­‐	  Esd	  -­‐	  S-­‐formylglutathione	  hydrolase	  	   0	   12	   -­‐	  
14	   IPI00129180	  -­‐	  Slfn1	  -­‐	  Schlafen1	  	   0	   12	   -­‐	  
15	   IPI00117730	  -­‐	  Gbp3	  -­‐	  guanylate-­‐binding	  protein	  4	  	   2	   51	   25.5	  
16	   IPI00226188	  -­‐	  Camk1d	  -­‐	  calcium/calmodulin-­‐dependent	  protein	  kinase	  isoform	  1	   2	   25	   12.5	  
17	   IPI00120113	  –	  Tyki	  -­‐	  thymidylate	  kinase	  family	  	   53	   508	   9.6	  
18	   IPI00130624	  -­‐	  Pld3	  -­‐	  phospholipase	  D3	  	   2	   17	   8.5	  
19	   IPI00319509	  -­‐	  Anpep	  -­‐	  aminopeptidase	  N	  	   2	   15	   7.5	  
20	   IPI00136858	  -­‐	  Il1rn	  -­‐	  Interleukin-­‐1	  receptor	  antagonist	  protein	  precursor	  isoform	  1	   16	   118	   7.4	  
21	   IPI00224740	  -­‐	  Pfn1	  -­‐	  profilin-­‐1	  	   4	   27	   6.8	  
22	   IPI00776096	  -­‐	  Ifit1	  -­‐	  bone	  marrow	  macrophage	  cDNA	  	   8	   52	   6.5	  
23	   IPI00123570	  -­‐	  Ifi47	  -­‐	  activated	  spleen	  cDNA	  	   29	   180	   6.2	  
24	   IPI00187512	  -­‐	  Nt5c3	  -­‐	  isoform	  2	  of	  cytosolic	  5'-­‐nucleotidase	  3	  	   5	   31	   6.2	  
25	   IPI00130118	  -­‐	  Rab10	  -­‐	  Ras-­‐related	  protein	  Rab-­‐10	  	   5	   30	   6.0	  
26	   IPI00169925	  -­‐	  Ndufv2	  -­‐	  isoform	  1	  of	  NADH	  dehydrogenase	  	   2	   12	   6.0	  
27	   IPI00263863	  -­‐	  Hspe1	  -­‐	  10	  kDa	  heat	  shock	  protein,	  mitochondrial	  	   23	   136	   5.9	  
28	   IPI00113992	  -­‐	  Gmppb	  -­‐	  mannose-­‐1-­‐phosphate	  guanyltransferase	  subunit	  β	   2	   11	   5.5	  
29	   IPI00229517	  -­‐	  Lgals1	  -­‐	  galectin-­‐1	  	   5	   23	   4.6	  
30	   IPI00225634	  -­‐	  LOC672959;Rps12	  -­‐	  40S	  ribosomal	  protein	  S12	  	   8	   35	   4.4	  
31	   IPI00127501	  -­‐	  Grcc10	  -­‐	  protein	  C10	  	   6	   26	   4.3	  
32	   IPI00124223	  -­‐	  Psme1	  -­‐	  proteasome	  activator	  complex	  subunit	  1	  	   3	   13	   4.3	  
33	   IPI00653158	  -­‐	  Acaa2	  -­‐	  14	  days	  embryo	  liver	  cDNA	  	   9	   37	   4.1	  
34	   IPI00222515	  -­‐	  Psmd11	  -­‐	  26S	  proteasome	  non-­‐ATPase	  regulatory	  	   3	   12	   4.0	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Figure 6-7. Effect of IRG1 siRNA transfection on cADC activity. Controls are from 
either untransfected cells (left) and cells transfected with control (scrambled) siRNA 
(right). IRG1 siRNAa concentration are 30 nM, 60 nM and 90 nM from left to right. The 
error bars are the S.D. determined from three independent siRNA transfection tests. 
 
aThe IRG1 siRNA is ON-TARGETplus SMARTpool (Mouse IRG1), a mixture of 4 
siRNA, provided by Dharmacon with undisclosed sequence information.  
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6.9 Discussion 
    The ITA biosynthetic pathway in fungi occurs via decarboxylation of cis-aconitate by 
cADC [81,82]. The ITA detected as a novel metabolite in mammalian cells, especially in 
macrophage-derived cells, was also attributed to decarboxylation of cis-aconitate by a 
specific decarboxylase [114]. Fungal cells secrete large amounts of ITA (presumably as 
an antibacterial agent); ITA is also secreted in significant amounts by stimulated 
RAW264.7 cells and by the metastatic mouse VM-M3 tumor cells. However, the role of 
ITA in these mammalian cells is not clear. The speculation that ITA may act as an 
antibacterial agent [120,121] suggests a relationship between ITA and the immune 
response. Macrophage activation processes usually stimulate numerous gene products 
that are significant to the immune response, some of which may be highly related to the 
ITA production and its biological roles. 
    In my work, the observation that actinomycin D (ActD) can highly inhibit the cADC 
activity eliminated the possibility of post-translational modification (PTM) of an existing 
protein and showed that mammalian cADC was produced by de novo protein synthesis 
during macrophage stimulation. The expression of mammalian cADC is induced by 
immune response, which also addressed the significance of ITA and the related enzyme 
in this process. 
     Knowing that the protein is synthesized upon cell stimulation provides a way to purify 
the increased cADC protein from all the background proteins in cells. Classical 
biochemistry approaches would be tried to purify the protein based on its unique 
biophysical properties, such as relatively low or high pI values, hydrophobicity or 
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different molecular weight. Various purification techniques can assist in enriching cADC 
activity and potentially yielding the protein responsible. However, after several 
purification steps the cADC activity was sufficiently diluted as to be almost undetectable 
by our 1H NMR assy. Furthermore, the high hydrophobicity of mammalian cADC made 
it impossible to find an optimal hydrophobic resin for further purification. Gel-filtration 
did not separate the protein sufficiently to determine its identification, but it did provide a 
native mass range of target enzyme (around 67 kDa, near the BSA protein eluting 
position according to the standard gel-filtration curve). 
    Proteomics using mass spectrometry can provide global analyses of proteins in a 
proteome, as well as focus on post-translational modification of proteins. For us, this 
technique identified which soluble mammalian proteins were overexpressed when 
RAW264.7 cells were stimulated. This led to the hypothesis that IRG1 was the source of 
the cADC activity. 
    Recently, the IRG1 gene was identified from an LPS-activated RAW264.7 cell line [91] 
and suggested to be one of mammalian cADC candidates. In macrophages, IRG1 gene is 
highly involved in the regulation of immune responses, and closely related to the TLR 
signaling pathways [135-137]. In our TLR agonists experiments, the target mammalian 
cADC was also synthesized in response to specific engagement of various Toll-like 
receptors. TLRs are a type of non-catalytic receptors that are expressed in macrophages 
and usually activate the immune response by recognizing structurally conserved 
molecules in microbes. One of the major signals for TLR is the MyD88(myeloid 
differentiation factor-88)-dependent response that activates NF-κB and mitogen-activated 
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protein kinase. The fact that the IRG1 gene is highly related with MyD88 [135-137] 
further links IRG1 production to TLR signaling. 
    The subcellular localization of IRG1 in murine macrophages, as a prototypic TNF- and 
IFN-γ-coregulated gene, is associated with mitochondria, which are known to play 
crucial roles in the regulation of cellular processes, such as apoptosis and innate immune 
activation [140,141]. Clearly, further study on the localization of mammalian cADC is 
important in understanding its roles in mitochondrial functions as well as in the entire 
immune system.  
    What my work shows is that the recombinant protein encoded by IRG1 is 54 kDa, a 13 
kDa difference from the ~67 kDa molecular weight range from the gel-filtration result. 
The native protein may have an unusual shape, or it could be interacting with a smaller 
binding partner. Alternatively, the protein could have some post-translation modifications 
that alter it significantly. The identification of the IRG1 protein from RAW264.7 cell 
lysate via the specific antibody targeting is a possible way to prove the existence of post-
translation modification. MS-based proteomics may also be used to identify any 
modification sites on cADC. Such modifications could provide insights into how this 
protein catalyzes the unique decarboxylation reaction of cis-aconitate.  
6.10 Conclusions 
    Itaconic acid (ITA) is a metabolite produced by primary macrophages and cell lines 
derived from macrophages that is dramatically increased upon stimulation. ITA is 
synthesized by a cis-aconitate decarboxylase (cADC) enzyme. Sequence searches with a 
known fungal cADC show little homology to ORFs in mammalian cells. The macrophage 
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cell line RAW264.7 was studied to show that cADC activity upon stimulation is 
dependent on de novo protein synthesis. MS analyses of partially purified RAW 264.7 
protein extracts from stimulated cells show a large increase for immunoresponsive gene 1 
protein (IRG1). IRG1 synthesis follows the time course of ITA generation (measured by 
1H NMR) and siRNA knockdown of the IRG1 reduces cADC activity upon stimulation. 
However, the function of IRG1 is still worthy of further investigation in macrophages and 
its up-regulation in stimulated macrophages. 
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Chapter 7 
Expression of IRG1 and Comparison to Fungal cADC 
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7.1 Introduction 
    The IRG1 cDNA was first identified by screening a cDNA library from an LPS-
activated RAW264.7 cell line by Lee G. G., et. al (1995) [91]. This gene was identified as 
a marker and target for many cellular processes. In primary macrophages, the IRG1 gene 
was also identified and found to be highly involved in regulating innate and adaptive 
immune responses. The function of the IRG1 gene is related to the myeloid 
differentiation factor-88 (MyD88), the key adaptor molecule of the Toll-like receptor 
(TLR) signaling pathway [135-137]. The subcellular localization of IRG1 in murine 
macrophages, as a prototypic TNF- and IFN-γ-coregulated gene, is associated with 
mitochondria, which are known to play crucial roles in the regulation of cellular 
processes, such as apoptosis and innate immune activation [140,141]. Clearly, the 
function of IRG1 and its upregulation in stimulated macrophages are worth studying in 
detail. 
    Generation of recombinant cADC can help to clarify the unique decarboxylation 
mechanism. It also opens up an array of future studies in the mammalian immune system 
and cancers. To that end I cloned IRG1 into an E. coli expression system, purified and 
characterized the enzyme and compared it to the fungal cADC. Suspected active site 
residues were identified by mutagenesis studies based on a homology structure model of 
fungal cADC.  
7.2 Secondary Structure and Thermostability of IRG1 and Fungal cADC  
    The secondary structure content and thermal stability of IRG1 and fungal cADC were 
measured using far-UV circular dichroism (CD). The CD spectrum for IRG1 protein is 
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typical of a protein with mixed secondary structure (Fig. 7-1A). The analysis of 
secondary structure content with the CDNN program is shown in Table 7-1; it matches 
the CD spectrum and hence secondary structure content of the fungal cADC. 
    The loss of secondary structure with increasing temperature defines an operational 
melting temperature (Tm) of around 50.5 oC for the mammalian cADC (Fig. 7-1B). This 
indicates that in normal cells at 37 oC, the IRG1 protein is well folded and has no 
tendency to unfold. Interestingly, the MBP-tagged fungal cADC protein shows a plot 
with two distinct transitions (Fig. 7-1C), one with a mid-point of 37.9 oC and the other at 
57.4 oC. By testing the thermal stabilities of both cleaved MBP tag and cADC tag-off 
protein, these two temperatures were attributed to each of the two components. The 
melting temperature (Tm) was 38.2 oC for WT fungal cADC with the MBP tagged 
removed, significantly lower than the mammalian enzyme. Mutant proteins of the fungal 
cADC showed little change in this effective Tm (the range was 35.7-39.3 oC). These 
mutant proteins also exhibited the same secondary structures as the WT fungal cADC 
(Table 7-1, the data are shown for MBP tagged mutant proteins). Similar behavior was 
observed for mammalian IRG1 mutants. Compared with WT IRG1 protein, there were no 
significant changes in structure and thermal stability (Tm is within 3 °C of the Tm for WT) 
for enzymes bearing a single altered amino acid (data not shown). Therefore, any 
difference in activity of both IRG1 and fungal cADC variants is not due to significant 
alterations in protein structure or stability.  
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Figure 7-1. Comparison of CD spectra and thermostability for IRG1 and fungal cADC. 
(A) CD spectra of () IRG1 and (£) fungal cADC. (B) The ellipticity of  () IRG1 
(solid line) and (£) fungal cADC (dashed line) at 222 nm as a function of temperature. 
(C) The ellipticity of () MBP tagged fungal cADC (solid line), (£) tag-off fungal 
cADC (dashed line) and (r) MBP tag (dotted line) as a function of temperature. 
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Table 7-1. Comparison of secondary structure content and Tm values of IRG1 and fungal 
cADC. 
 
 
Protein	  
Secondary	  Structure	  
Tm	  (oC)	  
α-­‐Helix	   β-­‐Sheet	   β-­‐Turn	   Random	  Coil	  
	   %	   	  
IRG1	   23.7	   24.1	   17.2	   35.1	   50.5	  
Fungal	  cADC	   21.6	   26.5	   17.5	   34.4	   38.2	  
MBP	  tagged	  fungal	  cADC	  mutant	  	  
WT	   23.7	   24.7	   17.5	   34.1	   37.9	  
	  E100A 25.4	   23.5	   17.4	   33.7	   	  37.7
	  Y104A 22.0	   26.1	   17.4	   34.4	   	  37.9
	  H111A 22.1	   25.7	   17.5	   34.7	   	  38.1
	  H168A 22.6	   25.6	   17.5	   34.3	   	  36.4
	  K217A 22.7	   25.6	   17.5	   34.1	   	  36.2
	  K288A 21.5	   26.3	   17.4	   34.6	   	  39.1
H396A	   26.1	   23.2	   17.6	   33.0	   39.3	  
K428A	   24.9	   24.2	   17.6	   33.4	   35.7	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7.3 Cofactors 
    Decarboxylation reactions are usually catalyzed by enzymes with the assistant of 
various cofactors [98] such as biotin, flavin, NAD+/NADP+, pyridoxal 5’-phosphate 
(PLP), thiamine diphosphate (TPP), metal ions (Fe2+, Mg2+, Mn2+). The active sites of 
decarboxylases can bind these cofactors to stabilize the carbanion upon elimination of 
carbon dioxide from the substrate. However, there is also one type of decarboxylase, 
which can activate the decarboxylation that does not use an exogenous cofactor [98]. 
Orotidine 5’-monophosphate decarboxylase (OMPDC) and malonate semialdehyde 
decarboxylase (MSAD) are examples of this type of decarboxylase enzyme. To that end, 
we added a series of cofactor candidates to both the fungal cADC and IRG1 
decarboxylation reaction system to test for any activation. No obvious enhancement of 
activity was observed, and some metal ions cofactors, like Fe2+ and Mn2+ had an 
inhibitory effect on the cADC activity (Fig. 7-2). This indicates that cis-aconitate 
decarboxylase might share the enzymatic mechanism with OMPDC or MSAD, which 
catalyze decarboxylation reactions without any cofactors. 
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Figure 7-2. Effect of exogenous cofactors on the activity of (■) IRG1 and (□) fungal 
cADC. The error bars are the S.D. from independent experiments. 
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7.4 Kinetic Behavior of IRG1 and Fungal cADC 
     The pH optimum of these two enzymes was determined. The fungal cADC showed 
optimal activity between pH 5.8-6.2 while for IRG1 the pH optimum was pH 7.5. This 
indicates that this mammalian cADC works under physiological conditions but the fungal 
cADC prefers slightly acidic environment. This is consistent with the result in the cADC 
activity evaluation of RAW264.7 cell lysate (see Chapter 6), which also exhibited the 
highest activity around pH 7.5.  
    From the measurements of the cADC activity versus substrate (cis-aconitic acid) 
concentration, the Km for cis-aconitate was determined to be 2.8±0.6 mM for fungal 
cADC at pH 6.0 (Fig. 7-3B). The equation used for fitting the kinetic curve, v = 
Vmax[S]n/(Kmn + [S]n), tries to account for any cooperativity. However, neither enzyme 
showed significant cooperativity (n = 1.3±0.4 for the fungal enzyme and 0.8±0.2 for 
IRG1) indicates that the cADC enzymes are active as monomers. The Vmax for the fungal 
enzyme was 17±2 µmol min-1 mg-1 (Fig. 7-3B). IRG1 exhibited a two-fold lower Vmax 
(8.2±0.1 µmol min-1 mg-1) with a Km of 0.38±0.08 mM. It should be noted that the data 
for both IRG1 and fungal cADC were each normalized to the highest observed activity in 
this plot (Fig. 7-3B). Enzyme efficiency, kcat/Km, was 5.5±0.6 mM-1 s-1 for the fungal 
enzyme and 20±1 mM-1 s-1 for IRG1. Thus, the cis-aconitic acid is more efficiently 
converted to itaconate by IRG1 than by the fungal cADC, at least as measured at the pH 
optimum for each enzyme.  
    The high value of Km for fungal cADC might suggest the possibility of other better 
substrates for this enzyme. According to the sequence alignment result, the fungal cADC 
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contains a conserved domain of the MmgE/PrpD family of proteins that includes several 
2-methylcitrate dehydratases. Trisodium (2RS, 3RS)-2-methylcitrate was used as the 
substrate to test the 2-methylcitrate dehydratase activities for both IRG1 and fungal 
cADC. Since a carbon-carbon double bond is formed in this specific reaction, the 
comparison of UV-vis spectra between substrate and product was used to monitor activity 
[176]. However, no obvious 2-methylcitrate dehydration activity was observed either by 
IRG1 or by fungal cADC. Therefore, both the fungal and mammalian cADC are specific 
catalysts for the decarboxylation of cis-aconitic acid. The Km values reflect only a 
moderate affinity for the substrate. Working at Vmax would require a cis-aconitate 
concentration of over 3 mM (IRG1) or 15 mM (fungal cADC). However, enzyme activity 
at a lower rate could occur producing a basal level of ITA. Interestingly, in previous 
studies of VM-M3 and RAW264.7 cell extracts using NMR did not detect any cis-
aconitate. However, metabolites would need intracellular concentrations of >0.5 mM to 
be detected by this method. 13C-labeled cis-aconitate was detected but not quantified by 
mass spectrometry. IRG1 is rapidly produced upon activation of RAW264.7 cells 
(Chapter 6) and it is possible that other factors affect the activity of this enzyme.  
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Figure 7-3. Comparison of kinetic behaviors of IRG1 and fungal cADC. (A) pH 
dependence for () IRG1 and (£) fungal cADC. (B) Relative specific activity of () 
IRG1 at pH 7.5 and (£) fungal cADC at pH 6 as a function of total substrate 
concentration. For each system the observed activity was normalized to the maximum 
observed activity, 8.2±0.1 µmol min-1 mg-1 for IRG1 and 17±2 µmol min-1 mg-1 for 
fungal cADC. The error bars are the S.D. from independent experiments. 
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7.5 Inhibitor Screening for Both IRG1 and Fungal cADC 
    cADC catalyzes an unusual decarboxylation reaction without a cofactor. Presumably 
the cis-aconitate structure is optimized for decarboxylation. If so, investigation of a 
variety of related compounds might provide hints as to what is critical for binding. To 
that end, we screened a variety of substrate analogues (di- and tri-carboxylates) as 
inhibitors of ITA production. As shown in Fig. 7-3, with 1:1 ratio of cis-aconitic acid to 
added compound, most di- and tri-carboxylates were not inhibitory. The two inhibitory 
compounds for both fungal cADC and IRG1 protein were maleic acid and citraconic acid. 
Under these conditions, maleic acid showed around 25% inhibition on the activities of 
both fungal cADC and IRG1, and itaconic acid (product) and citraconic acid showed 
more significant inhibition of IRG1 (~65%) when mixed 1:1 with substrate. Interestingly, 
itaconic acid is not an inhibitor of the fungal cADC activity. As for citraconic acid, by 
pre-incubating this substrate analogue with substrate 30 min (at room temperature) prior 
to reaction, the cADC activity of IRG1 can be reduced less than 20% of original value. 
This compound has the highest structure similarity to cis-aconitic acid. The citraconic 
acid can be further employed as a stabilizing reagent in the crystallization of IRG1 
protein. 
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Figure 7-4. Inhibitor screening for IRG1 and fungal cADC. (A) The chemical structures 
of di- and tricarboxylates used in the inhibitor screen compared with itaconic acid and 
cis-aconitic acid. (B) The inhibition effect of maleic acid, itaconic acid, citraconic acid on 
(■) IRG1 and (□) fungal cADC. The error bars are the S.D. from independent 
experiments. *Citraconic acid: pre-incubate citraconic acid with IRG1 enzyme for 30 min 
(r.t.). 
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7.6 Mutagenesis Study Based on a Homology Model of Fungal cADC 
   In a structure similarity search for fungal cADC, several proteins were found (Fig. 7-5), 
including a HUMAN Immunoresponsive gene 1 protein homolog, which is the HUMAN 
homolog of the IRG1 that was identified in murine macrophage stimulation. Based on the 
structure and active site composition of iminodisuccinate epimerase (PDB ID: 2HP0) 
[90], the only protein with known crystal structure, a predicted model structure (assisted 
by Boguslaw Stec, Sanford-Burnham Medical Research Institute, La Jolla, CA) for the 
fungal cADC was generated and several mutants (E100A, Y104A, H111A, H168A, 
K217A, K288A) were designed (Fig. 7-6A, highlighted in red). These residues are highly 
conserved among the proteins found in the structure similarity search (Fig. 7-5, 
highlighted in yellow and cyan). The only exception is Tyr104, which was replaced by 
serine, threonine or cysteine in other proteins. However, considering that the side chain 
may act as a hydrogen bonding donor for Ser92 in iminodisuccinate epimerase, these 
residues with hydroxyl or thiol side chains (tyrosine, threonine, cysteine) are also worth 
replacing to assess their function in forming active site.  
    In enzymatic assays of mutant protein, using longer reaction time (100 min compared 
to the regular 20 min) and higher protein concentration (200 µg/mL compared to the 
regular around 10 µg/mL), no production of ITA was observed for all of these predicted 
active site mutant proteins. This indicates that mutating these residues to alanine totally 
deactivates the cADC enzyme and these residues play important roles in the active site. 
As controls, His396 and Lys428 were converted to alanine to test the effect of deleting a 
specific residue on enzyme function. These residues in the cADC model are located far 
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away from proposed active site (Fig. 7-6, highlighted in blue). These two mutant proteins 
(H396A and K428A) showed the same kinetic behavior as WT fungal cADC.  
     Based on the sequence alignment of IRG1 with fungal cADC (Fig. 7-6B), the 
homologous residues (D93A, H103A, H159A, K207A, K272A) were chosen to verify the 
same active site composition of these two cADCs. These mutant proteins were also 
inactive (Table 7-2), which suggests that IRG1 protein might share the same enzymatic 
mechanism for the decarboxylation of cis-aconitic acid with fungal cADC. 
7.7 Discussion 
    The recombinant mammalian cADC exhibits slightly different properties compared to 
fungal cADC. However, both of them have a conserved domain of the MmgE/PrpD 
family of proteins. There is one type of MmgE/PrpD proteins that only has less than 25% 
sequence identities compared to E.coli PrpD. Most of these proteins are of unclassified 
functions. Both the IDS epimerase that was used to build up the fungal cADC structure 
model and the IRG1 protein are included in this minimal sequence similarity subgroup of 
MmgE/PrpD family. The typical fold of IDS epimerase can be used as the representative 
structure for the whole MmgE/PrpD family, which is conserved for most of the 
MmgE/PrpD proteins even though they only have limited sequence similarity. Thus, this 
structure can be utilized as a scaffold to support different enzymatic functions, such as 
dehydration, epimerization, and so on. This may also provide some structural based 
evidence on how the IRG1 and fungal cADC catalyze the decarboxylation reaction to 
produce ITA.  
    The epimerization of IDS under IDS epimerase is cofactor-independent. Similar to 
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other epimerases, the IDS epimerization of IDS was shown to catalyze by IDS epimerase 
via a single or two-base mechanism (Fig. 7-7, Scheme I, II and III) [90]. Based on the 
crystal structure and in silico docking models of IDS epimerase, His99 (conserved resides 
are His103 in IRG1 and His111 in fungal cADC) and Tyr145 (this residue is less 
conserved) are identified as possible candidates that act as a general base or acid in 
deprotonation/reprotonation of IDS [90]. By using one or two histidine residues for IRG1 
or fungal cADC, the decarboxylation of cis-aconitic acid may also be catalyzed by a 
similar one or two-base mechanism as IDS epimerization (Fig. 7-7, Scheme IV). 
Abstraction of the α-proton, facilitated by the adjacent carboxyl group, could result in an 
enolic intermediate that may be stabilized by interactions with electrophilic groups of the 
enzyme [90]. This could be facilitated by His150 (His159 in IRG1 and His168 in fungal 
cADC), Lys198 (K207 in IRG1 and K217 in fungal cADC) or Lys266 (K272 in fungal 
cADC and K288 in fungal cADC). The loss of decarboxylation activity of both IRG1 and 
fungal cADC variants by mutating these predicted key active site residues to alanine 
strongly suggests that the cis-aconitate decarboxylase shares mechanistic similarity with 
the catalytic mechanism of IDS epimerase. However, the missing of Tyr145 counterpart 
in the decarboxylases and the more complicated features of cis-aconitate decarboxylation 
imply that the two mechanisms are still quite different.  
     According to the enzymatic mechanisms of other cofactor-independent 
decarboxylases that catalyze non-oxidative decarboxylation, the reactions of substrate are 
either via bimolecular electrophilic substitution or stepwise decarboxylation and 
protonation [98]. However, none of these decarboxylation reactions can remove a 
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carboxyl group and produce a carbon-carbon double bond simultaneously. Thus, this 
unique decarboxylation mechanism of cADC needs to be clarified based on the further 
structure alignment of IRG1 (or fungal cADC) with the other types of decarboxylases to 
prove the possibility of similar active site shape and space arrangement of key residues. 
However, considering that the non-oxidative decarboxylases only cleave the bond 
between leaving carboxyl group and the other parts of the substrate molecules while 
cADCs cleave this bond by introducing a C=C bond, these decarboxylases may share a 
very different catalytic mechanism. 
    The inhibitor screen found a substrate analogue – citraconic acid – that may prove 
useful in stabilizing IRG1 for crystal formation. To date, we only tried crystallization of 
the fungal cADC. Unfortunately, no crystals were obtained. The difficulty in the 
crystallization of this decarboxylase may be due to its low stability or structural 
flexibility. Thus, by adding an inhibitor in the active site, the structure may be more 
organized. If crystals are obtained, the interactions between substrate analogue and 
proposed active site residues should provide strong evidence for the decarboxylation 
mechanism. Further docking model of substrate into the structure in silico should also 
help to elucidate this unique mechanism. By trapping the carbanion-like intermediate in 
to the structure, it can be verified whether the decarboxylation is via carbanion 
intermediate or not.  
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Figure 7-5. Sequence alignment of fungal cADC with most similar proteins: (1) Fungal 
cis-aconitate decarboxylase [Aspergillus terreus]; (2) Iminodisuccinate epimerase 
[Agrobacterium tumefaciens BY6, PDB 2HP0]; (3) 2-Methylcitrate dehydratase [Bacillus 
anthracis Ames: BA-2349]; (4) 2-Methylcitrate dehydratase [Escherichia coli str. K-12 
substr. MG1655]; (5) Pdh1p [Saccharomyces cerevisiae S288c]; (6) Possible 
methylcitrate dehydratase PrpD [Mycobacterium tuberculosis H37Rv]; (7) HUMAN 
immunoresponsive gene 1 protein homolog [Homo sapiens]. The highlighted residuces 
are the predicted active site based on the crystal structure of (2) iminodisuccinate 
epimerase with the conserved ones in yellow and the less conserved one in cyan. 
 
 	  
  
                  100  104      111  
[1] …………MTNSAFIQATELDDYHSEAPLHSASIVLPAVFAASEVLAEQ--------GKTISGIDVIL 141 
[2] …………FVNGMAAHAIDFDDSFPVMRGHPSSSLVPAIFAVGEHVGAN-------------GHNCLK 124 
[3] …………FNIGCMIRWLDYNDTWLAAEWGHPSDNLGGILAVADYISRV-RISEGK--EPLKVREVLE 144 
[4] …………FNIGAMIRWLDFNDTWLAAEWGHPSDNLGGILATADWLSRN-AVASGK--APLTMKQVLT 146 
[5] …………FAIGTLIRWLDYNDCWLAAEWGHPSDNLGGILAVADHLSRLNKATHGKNGKQFLVKDVLE 174 
[6] …………WANGVAARELDFHDTFLAADYSHPADNIPPLVAVAQQLGVC-------------GAELIR 166 
[7] …………FVNGVAIHSMDFDDTWHPAT-HPSGAVLPVLTALAEALPRS---------PKFSGLDLLL 132 
           .   :  : .*          .  :  : * .: :                  : :  
 
                                  168 
[1]     AAIVGFESGPRIGKAIYGSDLLNNGWHCGAVYGAPAGALATGKLLGLTPDSMEDALGIAC 201 
[2]     SYVLGIEVVATLG-RAVGKGHYLAGWHPTSTLGVFGATTAAALLLGADEEQLRNAWGIAA 183 
[3]     MMIKAHEIQG----VLALENSLNRVGLDHVLYVKVATTAVVAKMLGGTREEIFNALSHAW 200 
[4]     AMIKAHEIQG----CIALENSFNRVGLDHVLLVKVASTAVVAEMLGLTREEILNAVSLAW 202 
[5]     AMIKAHEIQG----IIALENSFNKVGLDHVVLVKVATAGVVSKMLGLSQEQTIEALSQAF 230 
[6]     GLVTAYEIHI----DLTRGICLHEHKIDHVAHLGPAVAAGIGTMLRLDQETIYHAIGQAL 222 
[7]     AFNVGIEVQGRLLHFAKEANDMPKRFHPPSVVGTLGSAAAASKFLGLSSTKCREALAIAV 192 
            . *                            . :   . :*        .* . *  
 
                          217 
[1]     TQACGLMS---AQYGGMVKRVQHGFAARNGLLGGLLAYGGYEA-MKGVLERSYGGFLKMF 257 
[2]     SNSCGIIKN----FGTMTKPMHTGSAARNGVLSAWLSMQSFTG--CQTVFDDAEGILAMY 237 
[3]     IDNSSLRTYRHAPNTGSRKSWAAGDATSRGVHLAMTALKGEMG-YPTALSAPGWGFQDVL 259 
[4]     VDGQSLRTYRHAPNTGTRKSWAAGDATSRAVRLALMAKTGEMG-YPSALTAPVWGFYDVS 261 
[5]     VDGQSLRTYRHAPNTGSRKSWAAGDAVSRAVNLAYLVKNANVGTIPSVLTARTWGFYDVL 290 
[6]     HLTTSTRQSRKG-AISSWKAFAPAHAGKVGIEAVDRAMRGEGS--PAPIWEGEDGVIAWL 279 
[7]     SHAGAP----MANAATQTKPLHIGNAAKHGIEAAFLAMLGLQG--NKQVLDLEAGFGAFY 246 
            .             *    . *   .:        .  .     :     *.   
   
                                      288 
[1]     TKGNGREPPYKEEEVVAGLGSFWHTFTIRIKLYACCGLVHGPVEAIEKLQRRYPEL………… 313 
[2]     GAQPGPE--LFNAMQKFGTPWAIIAPGLYKKSWPSCYANHKPLAGLFAIMKEHGLT………… 291 
[3]     FNKQE-----LKLAR--PLESYVMENVLFKVSYPAEFHAQTAAECAVKLHPEIKER………… 308 
[4]     FKGES-----FRFQR--PYGSYVMENVLFKISFPAEFHSQTAVEAAMTLYEQMQAA………… 310 
[5]     FKGKP-----FSFQQRSKYDSYVMENVLFKISFPAEFHAQTAVEAAVKAYRILAKQ………… 341 
[6]     LAGPE-----HTYRV--PLPAPGEPKRAILDSYTKQHSAEYQSQAPIDLACRLRER………… 328 
[7]     ANYSP-----KVLPSIASYSWLLDQQDVAFKRFPAHLSTHWVADAAASVRKHLVAE………… 297 
                                        :.     .                     
!!
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Figure 7-6. Mutagenesis design for IRG1 and fungal cADC. (A) The active site residues 
chosen based on the protein structure predicted by Boguslaw Stec on the crystal structure 
of iminodisuccinate epimerase (2HP0). The active site is highlighted in red and the 
control residues are in blue. (B) Sequence alignment between IRG1 and fungal cADC. 
The active site residues are highlighted in red and the control residues are in cyan.  	  
	  	  	  
	  
Ac#ve&site&
Control&residues&
A 
Glu100!
Tyr104!
His111!
His168!
Lys217!
Lys288!
His396!
Lys428!
Ala!
                       10        20        30        40        50        60        70   
IRG1           MMLKSVTESFAGMIHGLKVNHLTDGIIRRSKRMILDSLGVGFLGTGTEVFHKVTQYSKIYSSNTSSTVWGRP 
                    ::  .     .: .. . . ...:.: .:::... ...:. .   .: .: .  .    .  : :   
AtcADC MTKQSADSNAKSGVTAEICHWASNLATDDIPSDVLERAKYLILDGIACAWVGARVPWSEKYVQATMSFEPPGACRVIGYG 
               10        20        30        40        50        60        70        80 
 
             80        90       100        110       120        130       140       150 
IRG1   DFRLPPTYAAFVNGVAVHSMDFDDTWHPAT-HPSGAVLPVLTALSEALPQTPK-FSGLDLLLAFNVGIEVQGRLMHFSKE 
       . .: :. ::..:.. ... ..::    :  : .. :::.. : ::.: .  : .::.:..::  ::.:   :. .     
AtcADC Q-KLGPVAAAMTNSAFIQATELDDYHSEAPLHSASIVLPAVFAASEVLAEQGKTISGIDVILAAIVGFESGPRIGKAIYG 
                90       100       110       120       130       140       150          
 
              160       170       180       190        200       210       220          
IRG1   AKDIPKRFHPPSVVGTLGSAAAASKFLGLSLTKCREALAIAVSHA-GAPIANAATQTKPLHIGNAAKHGMEATFLAMLGL 
       .  . . .:  .: :. ..: :..:.:::.  . ..::.:: ..: :   :. . ..: .. : ::..:. . .::. :  
AtcADC SDLLNNGWHCGAVYGAPAGALATGKLLGLTPDSMEDALGIACTQACGLMSAQYGGMVKRVQHGFAARNGLLGGLLAYGGY 
     160       170       180       190       200       210       220       230          
 
     230        240              250       260       270       280       290            
IRG1   QGNKQILDLG-SGFGAFYAN-------YSPEDLPSLDSHIWLLDQQDVAFKSFPAHLATHWVADAAAAVRKHLVTPE--- 
       .. : .:. . .::  ....       :. :.. .  . .:      . .: .     .:  ..:   ....   ::    
AtcADC EAMKGVLERSYGGFLKMFTKGNGREPPYKEEEVVAGLGSFW--HTFTIRIKLYACCGLVHGPVEAIEKLQRRY--PELLN 
     240       250       260       270       280         290       300       310        
 
      300       310            320       330       340       350         360       370  
IRG1   RALFPADHIERIVLRIPDVQ-----YVNRPFPDSEHEARHSFQYVACASLLDGSITVPSFH--SQQVNRPQVRELLKKVK 
       :: .  ..:... ...  ..     .. .  : :   .. :  :.  ..:.: .  . .:   .....::.: .: .::  
AtcADC RANL--SNIRHVYVQLSTASNSHCGWIPEERPISSIAGQMSVAYILAVQLVDQQCLLAQFSEFDDNLERPEVWDLARKVT 
           320       330       340       350       360       370       380       390    
 
             380        390       400       410       420       430       440       450 
IRG1   LEHPPDNPPSFDTLYC-EISITLKDGTTFTERSDTFYGHWRKPLSQEDLRNKFRANASKMLCRDTVESLITVVEKLEDLE 
         :  .   . . :   .. : ..::.. ::  .   :  ..:. .: . .:.:. :...  .. :. .  .: .:. :  
AtcADC PSHSEEFDQDGNCLSAGRVRIEFNDGSSVTETVEKPLG-VKEPMPNERILHKYRTLAGSVTDESRVKEIEDLVLSLDRLT 
           400       410       420       430        440       450       460       470   
 
              460       470       480         
IRG1   DCSVLTRLLKGPSVQDEASKLSSMSSFDHTTLPRFTNI 
       : . : .::. :                           
AtcADC DITPLLELLNCPVKSPLV                     
            480       490                     
B 
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Table 7-2. Activity table for active site residues mutant protein compared with WT IRG1 
and fungal cADC. 
 
Protein	   [Protein]
	  	  
(μg/mL)	  
[cis-­‐Aconitic	  acid]	  
(mM)	  
Reaction	  time	  
(min)	  
Product	  
(%)	  	  
IRG1	  mutant	   	   	   	   	  
WT	   12.5	   10	   20	   20%	  
D93A	   	  200 	  10 	  100 	  <2%
H103A	   	  200 	  10 	  100 	  <2%
H159A	   	  200 	  10 	  100 	  <2%
K207A	   	  200 	  10 	  100 	  <2%
K272A	   	  200 	  10 	  100 	  <2%
	  Fungal	  cADC	  mutant
	  WT 	  10 	  10 	  20 	  20%
	  E100A 	  200 	  10 	  100 	  <2%
	  Y104A 	  200 	  10 	  100 	  <2%
	  H111A 	  200 	  10 	  100 	  <2%
	  H168A 	  200 	  10 	  100 	  <2%
	  K217A 	  200 	  10 	  100 	  <2%
	  K288A 	  200 	  10 	  100 	  <2%
H396A	   10	   10	   20	   23%	  
K428A	   10	   10	   20	   18%	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Figure 7-7. The proposed cADC decarboxylation mechanism based on epimerization 
mechanism of minodisuccinate (IDS). (I) Epimerization of the stereoisomers of 
iminodisuccinate catalyzed by IDS epimerase; (II) One-base mechanisms for IDS 
epimerisation; (III) Two-base mechanism for IDS epimerization; (IV) Proposed 
decarboxylation mechanism of cis-aconitic acid to produce itaconic acid based on the 
two-base mechanism of (III).  	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7.8 Conclusions 
    The IRG1 was cloned into the E. coli expression system for further purification. The 
pH profile and kinetic properties of this recombinant enzyme were characterized and 
compared to the fungal enzyme. This unique decarboxylase does not use cofactors and 
was strongly inhibited by citraconic acid. Suspected active site residues were identified 
by mutagenesis studies based on a homology structure model built from fungal cADC. 
The identification of this enzyme can help to clarify the unique decarboxylation 
mechanism and also open up future studies into the specific role of ITA in the 
mammalian immune system and cancers. 	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Chapter 8 
Future Directions 
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    The first aim of my thesis was to understand the membrane modulation of one type of 
peripheral protein, bacterial PI-PLC, using recombinant enzymes from tow different 
types of bacteria (BtPI-PLC and SaPI-PLC). Most of my effort was focused on defining 
membrane interactions of SaPI-PLC. Different techniques were applied to study the 
interaction of this protein with vesicles composed of both the substrate lipid PI (or 
substrate analogues PG or PMe) and the activator lipid PC. Based on these results, a 
surface dimerization and activation mechanism was proposed for this PI-PLC (Chapter 4, 
Fig. 4-10). The enzyme activity is modulated by competition between binding of soluble 
anions or anionic lipids to the cationic sensor and transient dimerization on the membrane 
depleted in anionic phospholipids.  
     As part of the proof for an active dimer, I tried to construct a disulfide linked dimer 
based on the V44C SaPI-PLC variant. However, no active dimer was obtained, 
presumably because of a misaligned arrangement of the dimer interface residues. A 
possible explanation is that the dimer interface was disrupted by the hydrogen bonding of 
cysteine side chains (DTT was initially present to keep the protein reduced). It would be 
interesting to see if we can find a better position to introduce cysteine resides and form a 
disulfide-linked dimer. The prediction is that it would possess higher PI cleavage rates, 
particularly towards low substrate concentrations at high XPC. Since the conformation of 
the covalent dimers may be different from the WT SaPI-PLC dimer crystal structure 
(PDB ID: 4F2B), it is also worth crystallizing this protein assuming we can separate 
disulfide-linked from monomeric protein. A detailed view of this artificial dimer interface 
may help explain the unique membrane modulation of SaPI-PLC enzymatic activity.  
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    Both BtPI-PLC and SaPI-PLC can target GPI-anchored proteins in the PC-rich outer 
membrane of eukaryotic cells. However, unlike to BtPI-PLC that has a high PC binding 
affinity, SaPI-PLC has virtually no affinity for PC vesicles (Chapter 4). In order to verify 
the cation-π box in BtPI-PLC to be a specific PC recognition motif, we engineered such a 
box into SaPI-PLC by adding two more tyrosine residues. This generated a catalytically 
active protein that binds much more tightly to PC-rich interfaces (N254Y/H258Y variant, 
Chapter 5). However, the binding affinity of SaPI-PLC N254Y/H258Y towards pure PC 
bilayers is still significantly weaker than BtPI-PLC, which may be due to the fact that 
BtPI-PLC has more aromatic residues around the αβ-rim facing the membrane and these 
can either form other transient cation-π complexes with PC or insert into the bilayer. How 
can we experimentally distinguish cation-π complex formation from membrane insertion 
of aromatic side chains in both BtPI-PLC and SaPI-PLC? One option is the application of 
fluorinated tyrosine and phenylalanine. Fluorine substitutions can deactivate cation-π 
interactions due to the diminished negative electrostatic potential of the aromatic ring 
caused by the high electronegativity of fluorine [177]. By incorporating this kind of 
unnatural amino acid into the PI-PLCs and measuring the energetic contributions of the 
two types of interactions (aromatic π-choline cation of PC interaction versus aromatic 
residues side chain partitioning into a bilayer) based on apparent Kd values, we should be 
able to identify which protein aromatic groups form complexes with the PC cation. This 
would complement a molecular dynamics simulation of BtPI-PLC docking to a bilayer 
where quite a few cation-π complexes could be distinguished. Added to the biochemical 
work is the need to generate crystal structures for the fluorinated proteins. These are 
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important to rule out changes in side chain orientations that might affect PC binding and 
activation. This would be most critical for incorporation of di-3,5-fluorotyrosine where 
the hydroxyl pKa is significant reduced (to ~pH 6.5) [178].   
     Bacterial PI-PLCs are known to target GPI-anchored proteins in the external leaflet of 
a host cell. Release of the tethered protein and generation of diacylglycerol in the 
membrane is thought to contribute to the pathogenicity of the bacterium. Future studies 
on the binding affinity of these proteins to membranes need to use membrane vesicles 
containing GPI anchors. While recombinant generation of specific GPI-anchored proteins 
is not feasible at the moment, one can often enrich membrane preparations with GPI-
anchored proteins. To that end, we should be able to directly observe how PC 
composition or other factors affects the enzymatic cleavage of the PI moiety from the rest 
of the carbohydrate tether plus protein. Understanding how the different bacterial PI-
PLCs interact with target membranes may provide specific ways to selectively inhibit 
them, and hence provide insights into novel methods to control the bacterial infections. 
     Endoplasmic reticulum (ER) membranes are continuous with the nuclear envelope 
outer membrane in eukaryotic cells. These kinds of membranes are also rich in PC with 
an even higher ratio of it compared to the outer cell membrane phospholipid composition. 
The ER provides a site for lipid and protein biosynthesis. Along with the major 
phospholipid PC, ER membranes also have phosphatidylethanolamine (PE) and 
phosphatidylserine (PS), as well as smaller amounts of PI. Bacterial PI-PLCs are usually 
extracellular proteins, but some are secreted from intracellular pathogens. Listeria 
monocytogenes produces a PI-PLC that among other things contributes to escape from 
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primary and secondary vacuoles [179,180]. This might be the best candidate to explore 
binding to ER-like membranes. 
     The second part of my thesis was to identify and characterize a novel mammalian 
cADC. Based on the structural model of fungal cADC, a possible active site was 
proposed. However, this unique mechanism suggested for this enzyme is worth further 
investigation. The enzyme appears to simultaneously remove a carboxyl group and 
introduce an unsaturated bond. What is the spacial arrangement of key active site 
residues? These questions would be answered by the crystallization of mammalian or/and 
fungal cADC with or/and without a substrate analogue (e.g., citraconic acid).  
    The biological role of ITA is also unknown. Based on our experiments to identify the 
mammalian cADC, ITA production is shown to be highly related to the TLR signaling 
pathway. The accumulation of ITA upon macrophage stimulation indicates its significant 
role in protecting the host organism. ITA does inhibit some bacterial TCA enzymes, but it 
is not a very strong inhibitor [120,121]. Since so much of it is secreted by the RAW264.7 
cells, perhaps it has another function. It is also possible that the mammalian cADC carries 
out another activity as well. IRG1 has been implicated in a wide variety of immune 
responses, not all involving bacteria. Could the molecule be an extracellular signal? 
Perhaps intracellular pools of ITA modulate host TCA activity in a way useful. The 
cADC could also form complexes with other proteins and these might be relevant in the 
immune response. Certainly the function of ITA in immune system is still worth of 
further studies.  
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Appendix I 
Phosphatidylcholine Activation Varies on the Changes of 
Surface Cationic Residues in B. thuringiensis PI-PLC 
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AI.1 Introduction 
    There are several types of noncovalent interactions that play critical roles in 
maintaining cell membrane functions and facilitating protein-membrane interactions. 
These include hydrogen bonding, van der Waals contacts, electrostatic attractions, and 
ion-dipole interactions. For interfacial interactions electrostatic forces often initiate the 
binding of many soluble proteins to the membrane surface. This occurs from the 
attraction between the anionic lipid head groups and cationic amino acids on the protein 
surface. Once the protein is in the vicinity of the membrane, other interactions enhance 
protein binding via more specific contacts (hydrophobic partitioning, hydrogen bonding, 
or cation-π interactions) of key residue side-chains. Specific electrostatic driving forces 
are crucial for phospholipases such as the human group IIa secreted phospholipase A2 
(PLA2) to bind to phospholipid membranes [37]. The importance of these electrostatic 
interactions for PLA2 binding to anionic membranes was shown by charge-reversal 
mutants.  
     For a peripheral protein, such as BtPI-PLC, interfacial interactions usually influence 
the enzymatic activity of the protein. A recent model of BtPI-PLC membrane binding and 
activity indicated the importance of some key residues around protein surface. The 
membrane binding is mediated by the electrostatic interactions between Lys44 in helix B 
and anionic phospholipids as well as the hydrophobic plug containing two tryptophan 
residues (Trp47 in helix B and Trp242 on an adjacent 240s’loop). This initial interaction 
correctly orients the protein to the membrane and could induce a transient dimerization if 
it occurred. A previous crystal structure of the W47A/W242A protein exhibited a dimer 
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formed by the Tyr zipper involving Tyr residues 246-248 and 251, which will activate PI-
PLC toward both membrane-bound (PI) and soluble substrates (cIP) [44]. 
In this work, several cationic residues identified by MD simulation as aiding in 
electrostatic interactions of the protein to the anionic lipids bilayer, Lys44, Lys38, Arg71, 
Lys 201 and Lys 279, were changed to alanine to measure the effect on vesicle binding 
and catalytic activity. Meanwhile, another mutation, V46K was designed to see if an 
additional positive charge could enhance enzymatic activity and vesicle binding. The 
enzymatic activity and membrane binding profile of different mutant proteins were 
measured. It was found that many cationic residues contribute to the binding of BtPI-PLC 
to vesicles with PI and this aids in the hydrolysis of PI in the absence of PC. These 
cationic residues can be fairly distant from the active site. Some of these mutants also 
affected the PC binding affinity. For example, V46K exhibits a totally different behavior 
with no improvement on PI binding but large impairment of PC binding. 
AI.2 Materials and Methods 
     All the chemicals and methods to construct BtPI-PLC mutants, characterize PI-PLC 
enzymatic activity and binding affinity towards SUVs are described in Chapter 2, 2.1-
2.10. 
AI.3 MD Simulations of WT BtPI-PLC and Construction of the Mutant Protein
    In this MD simulations model (done by Prof. Nathalie Reuter, University of Bergen, 
Norway), only three of the six tested orientations of PI-PLC led to binding to the implicit 
model membrane. The anchoring was monitored by calculating the binding energy along 
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the simulation and the result showed that all bound PI-PLC had very similar orientations 
with the same membrane interacting residues. It is possible to further evaluate the energy 
of these residues by using the conformations from the last 1.5 ns of simulation. The 
“energy decomposition” (Fig. AI-1B) plotted for all the involved residues can be 
separated into two groups: (i) one group dominated by hydrophobic interactions and (ii) 
another group with electrostatic interactions. This result can be better visualized by 
anchoring the protein into the implicit membrane, which was composed of two simplified 
layers – the aqueous layer and a gradient of dielectric with overall negative charge as the 
membrane model (Fig. AI-1A). Several cationic residues were identified by MD 
simulation as aiding in electrostatic interactions of the protein to the anionic lipid bilayer: 
Lys44, Lys38, Arg71, Lys 201 and Lys 279. Residues that contributed in the hydrophobic 
component of binding were Pro42, Ile43, Val46 and Trp47, which were already studied 
in our previous work [33]. These residues belong to helix B, one of the two interesting 
features at the barrel rim (helix B and 240s’ loop) that can penetrate into the membrane 
by insertion of Trp47 and Trp242. These hydrophobic amino acids can be clustered 
together to facilitate the Trp47 penetration into membrane. Previous mutagenesis studies 
showed that Pro42 could more or less fix the conformation of helix B (which is really 
flexible). This residue was also found to be involved in the dimer stabilization in the 
crystal structure of W47A/W242A [44]. Ile43 and Val46 were proposed to provide 
hydrophobic contacts that stabilize the outward pointing Trp47 conformation. During the 
interaction with the anionic head group of phospholipids, the electrostatic force is thought 
to orient the protein and thus initiate the binding. Therefore, in my work, the cationic 
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residues Lys38, Lys44, Lys201, Lys279 and Arg71 were mutated to alanine and further 
used to probe their contributions to membrane binding and enzymatic activity. For a 
control, Lys122 was also mutated to alanine since it is not near the active site or 
membrane binding surface. The electrostatic attraction between anionic phospholipids 
and cationic amino acids usually facilitates membrane binding of peripheral membrane 
proteins, as is the case for K44A and K44E [146]. Both of these mutants reduce the 
binding of BtPI-PLC to membranes. They also severely impaired the binding synergy 
provided by the combination of PG and PC in the vesicles. It was proposed that Lys44 
might drive the motion of the protein to the membrane allowing the hydrophobic 
interactions of PI-PLC with anionic phospholipids-rich vesicles.  
AI.4 Secondary Structure and Thermal Stability Characterized by CD Spectroscopy 
   All of the mutant proteins were well-folded as monitored by CD wavelength scanning; 
thermal stabilities were essentially the same during the denaturation assay (Table AI-1). 
The similar secondary structure content indicates that removing or introducing one 
cationic residue did not have a dramatic effect on the protein structure. Thermal stabilities 
were all very similar (average Tm=57.3±1.4 oC), although K44A was even more stable 
than the other proteins (Tm=60.3 oC). Thus, any difference for activity or binding effect 
should not be due to the altered structures of mutant proteins compared to WT BtPI-PLC.  
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Figure AI-1. MD simulation results shown by structural and energy decomposition 
models. (A) View of the insertion of PI-PLC into the implicit membrane. The limit of the 
interior region of the membrane is represented in brown, and the position of the negative 
charge in magenta. A color gradient going from blue to red is used to describe the 
residues having respectively a favorable or an unfavorable hydrophobic contribution to 
binding. (B) Plot representing the same energy decomposition (in kcal/mol), the Gouy-
Chapman terms that account for electrostatic interactions are represented with black bars, 
while boxes represent the hydrophobic contacts. 
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Table AI-1. Comparison of secondary structure contents and Tm values of WT and 
mutant BtPI-PLCs. 
 
Protein	  
Secondary	  Structure	  
Tm	  (oC)	  
α-­‐Helix	   β-­‐Sheet	   β-­‐Turn	   Random	  Coil	  
	   %	   	  
WT	   20.6	   32.2	   17.2	   30.0	   57.1	  
K38A	   20.2	   32.5	   17.1	   30.1	   57.3	  
K44A	   21.6	   30.9	   17.4	   30.1	   60.3	  
R71A	   21.4	   30.9	   17.2	   30.3	   56.8	  
K44A/R71A	   21.9	   30.9	   17.4	   29.8	   58.8	  
K201A	   21.6	   30.9	   17.4	   30.1	   56.6	  
K279A	   20.8	   31.8	   17.2	   30.1	   56.0	  
K122A	   21.3	   31.4	   17.3	   29.9	   57.2	  
V46K	   20.7	   31.6	   17.2	   30.6	   55.4	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AI.5 Enzyme Activities of Different Mutant BtPI-PLCs Compared with WT BtPI-PLCs 
AI.5.1 Phosphotransferase Reaction Activity  
     Long chain lipid PI dispersed in neutral lipid Triton X-100 (TX-100) micelles is a 
good substrate system for BtPI-PLC. The concentration of PI used was 4 mM with 8 mM 
TX-100. Removal of one cationic residue led to reduction of the PI cleavage activity for 
K38A, R71A and K201A, which exhibited 30~50% of the activity of native BtPI-PLC 
(Fig. AI-2A). However, other positional mutants (K44A, K122A and K279A) showed 
more or less the same PI cleavage activity as the control. The double mutant K44A/R71A 
with two surface cationic residues are removed had the lowest activity. V46K with an 
added surface cationic residue exhibited the same specific activity as the control in PI/TX 
micelles, but very little PC activation was observed for this enzyme. Most of the other 
mutant enzymes (K38A, K44A, R71A and K122A) except for V46K, showed higher 
specific activities comparable to the native protein when the PI was dispersed in diC7PC 
micelles. Only the activities of double mutant K44A/R71A, K201A and K279A were 
lower than the WT BtPI-PLC.  
    The activation ratio, specific activity in the presence compared to the absence of PC 
can be used to measure the extent of PC activation. All the mutants except V46K behaved 
comparably to WT with higher activation ratios for K38A, R71A and K44A/R71A. This 
suggests that the PC binding site is undisturbed if removing one or two cationic residues 
from the surface of the protein in micellar lipid aggregates system. The interaction 
between PI-PLC and the anionic lipid in the neutral micelles was impaired since the 
electrostatic attraction between anionic head group of lipids and cationic amino acids was 
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reduced, especially for R71A and K201A, which are near the αβ-barrel rim of the protein 
and could play important roles in helping the substrate bind in the active site.   
     SUVs are a better mimic of the natural target membrane surface that the enzymes 
attack. Pure PI SUVs are not a good substrate for BtPI-PLC – they exhibit less than 10% 
of the PI cleavage obtained in PI/TX micelles [10,31,38,43]. A good part of this is 
impaired binding of the protein to SUVs as shown in Chapter 3. All the mutant PI-PLCs 
with the exception of V46K had low activities towards PI SUVs that were even lower 
than WT enzyme, even the control mutant K122A (Fig. AI-2B, inset). There were two 
classes of lower activity mutants K44A, R71A, K44A/R71A and K122A had only 10-
15% residual activity compared to WT, while K38A, K201A and K279A roughly had 
half of the WT activity. However, all the mutants could be activated by PC. Like WT, 
K44A, R71A, K122A, K201A and K279A show substantial surface dilution inhibition 
comparing activities at XPC = 0.8 to XPC = 0.5, indicating that the tighter binding in PC-
rich vesicles reduces opportunities for the enzyme to dissociate and find the next 
substrate. The only exception is the double mutant K44A/R71A, which did not show any 
surface inhibition at XPC = 0.8. That may be due to weak binding at this mole fraction PC, 
which would make it easier for this mutant enzyme to find substrate PI in another vesicle 
and catalyze its cleavage. However, the most interesting mutant protein is V46K, which 
had very little PC activation in a micellar assay system but was always more active than 
WT in SUVs (2-3 fold). Thus, introducing one more cationic residue can significantly 
increase the activity toward pure PI substrate in vesicles as well as those with PC. This is 
a very different behavior compared to the micellar assay system.  
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AI.5.2 Cyclic Phosphodiesterase Reaction Activity 
    cIP hydrolysis in the absence and presence of diC7PC provides another view of the 
importance of those positive side chains. Therefore, the second step of the BtPI-PLC 
reaction, cIP hydrolysis to I-1-P, was also examined for these mutant enzymes. As a 
water-soluble substrate, cIP will not bind to the lipid micellar surface. All mutant 
enzymes except K38A exhibit similar activity (within a factor of two compared to WT).  
Again V46K is anomalous and is more active than WT). Moreover, all the mutants can be 
activated by diC7PC to approach the specific activity of WT PI-PLC although V46K and 
K44A/R71A show a lower extent of activation (only about 5-6 fold compared to the 20-
fold for WT). That observation suggests that there may be two PC binding regions for 
enzyme activation – one for when the enzyme is processing long chain PI substrate (the 
region on helix G that is involved in cation-π interactions with PC) and the other for 
when cIP is hydrolyzed. For K38A, cIP hydrolysis was really impaired (with specific 
activity only 20% of WT) but could be almost completely recovered when diC7PC was 
added. The large recovery if activity with PC present might suggest that this mutant 
enzyme has weak binding to anionic compounds but that when PC binds to the protein, 
they enzyme works as well as WT. These data indicate that of all the cation residues near 
the membrane surface and around the active site, the position of Lys38 is optimal for 
interacting with the cIP negative charge in the absence of PC. 
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Figure AI-2. Specific activities of BtPI-PLC variants in different systems. (A) Specific 
activities of WT BtPI-PLC and mutant BtPI-PLCs for cleavage of 4 mM PI in 8 mM 
neutral detergent Trion X-100 (black bars) and in 16 mM diC7PC (hatched bars) micelles. 
(B) Specific activities towards 2 mM PI in pure PI SUVs (black bars), PI/PC (4:1) SUVs 
(hatched bars), PI/PC (1:1) SUVs (white bars) and PI/PC (1:1) SUVs (grey hatched bars). 
Inset: Enlarged figure for pure PI SUVs. (C) Specific activities for cleavage of 8 mM cIP 
in the absence (black bars) and presence (hatched bars) of 8 mM diC7PC. Error bars 
reflect S.D. from multiple assays. 
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    Val46 is important for transmitting the PC activation signal in assay systems with 
micelles. In SUVs, it appears less important. Presumably the extra positive charge added 
by V46K overcomes some of the surface dilution inhibition, possibly by enhancing 
vesicle binding. The Val46 side chain is still critical for PC activation since activity for 
PI/diC7PC is the same as PI/TX-100. The kinetic assays suggest that PC activation varies 
depending on which step of the reaction is examined. It was further hypothesized that 
BtPI-PLC might have two (or more than two) PC binding sites since the diC7PC may 
bind close to the active site with cIP as substrate (no acyl chains) but occupies other 
site(s), notably the helix G cation-π in the presence of long-chain PI. 
AI.6 Line Broadening of diC7PC Induced by PI-PLC 
     As suggested in the previous studies, BtPI-PLC can interact with diC7PC micelles and 
induce their aggregation. This can be monitored by the increased 31P line width of 
diC7PC [30]. The phosphodiester resonance width at half-height, Δυ1/2, is broadened in 
the presence of protein when the diC7PC concentration is around and just above the CMC 
(1.5 mM) (Fig. AI-3). This large increase in line width is due to the slower exchange rate 
among the more complex components in the system (monomer diC7PC into the bulk 
micelle or onto the enzyme at a discrete site(s)). After the diC7PC concentration exceeds 
20 mM, the ratio of diC7PC/BtPI-PLC is high enough that the weight averaged 
contribution of protein bound diC7PC should be small and the values of Δυ1/2 should be 
close to the pure diC7PC micelles at the same concentration. The results of these diC7PC 
titrations carried on different mutant proteins together with the enzyme kinetics suggest 
that there are three groups of mutant proteins. All the cationic mutants except K38A 
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caused the same line width broadening of diC7PC, indicating that the PC interaction is 
unaffected by removing the cationic residues at those specific positions. This is consistent 
with the same PC activation ratios between PI/TX and PI/diC7PC, as well as cIP with or 
without diC7PC (Fig. AI-2, A and C). Interestingly, the slightly higher activation rate of 
K38A in both PI micelles and cIP assays was not related to the tighter binding of that 
protein to PC species. This suggests that the micellar aggregate structure is not 
responsible for diC7PC activation of PI cleavage or cIP hydrolysis. As for the opposite 
type of mutant, V46K, removing one of the hydrophobic residues of helix B really 
hinders the interaction of protein with the PC lipids (Fig. AI-3, open circles). This 
correlates with lower activation rates in both PI cleavage and cIP hydrolysis. Not 
surprisingly, the impaired interaction of protein with the PC activator leads to a loss of 
the PC activation. Moreover, this also indicates the importance of hydrophobic residues 
of helix B in the interaction with PC lipids. However, this mutant enzyme exhibits PC 
activation in the SUV assay system. All these results need information of SUV binding of 
the mutant enzymes to generate a complete model for what is involved in initial binding 
of the protein to a surface and what is needed for PC activation. 
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Figure AI-3. The interactions between BtPI-PLC variants (85 µM) and diC7PC by line 
width broadening experiments. 31P line width (Hz) of the diC7PC phosphorus resonance 
by increasing lipid concentration in absence of any protein (solid line) and the presence 
of 3 mg/mL WT (solid square), K38A (open square), K44A (dashed line), R71A (short 
dashed line), K201A (solid circle), K279A (short dotted line), K122A (dotted line) and 
V46K (open circle). Error bars reflect S.D. from multiple readings of the line width. 
Inset: Enlargement of the peak region. The CMC of pure diC7PC is 1.5 mM. 
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AI.7 SUVs Binding of Cationic Residue Mutant Proteins 
AI.7.1 K38A 
     In the crystal structure of B.cereus PI-PLC (PDB ID: 1PTD), Lys38 is in a loop right 
before helix B placing it near the rim of the αβ-barrel and above the active site. In the 
kinetic studies, K38A exhibited lower activity toward pure PI substrate (PI/TX micelle or 
PI SUVs) and also towards cIP (it is the lowest among all the mutants enzymes), which 
indicates that the PI binding site is impaired by substituting that lysine residue with an 
alanine. The kinetic result is consistent with weak binding affinity of this mutant protein 
(Fig. AI-4A, dashed line, open square) towards pure PG SUVs – the apparent Kd is 
around 3-fold higher than that of WT PI-PLC. As for PC activation, all the kinetic studies 
show that with PC species involved, both the PI cleavage and cIP hydrolysis are activated 
to nearly the same specific activity as WT. Moreover, in PI/PC SUVs, when the PC mole 
fraction is above 0.5, K38A has higher activity than WT (Fig. AI-4A). However, based 
on the binding profile and line width broadening assay, the PC binding site is somewhat 
impaired due to the removing of the cationic residue at this position. The Kd values for 
SUVs with PC included are all about 10-fold higher than those for WT protein, which 
suggests a weakened affinity of the mutant protein for PC. However, when the total 
phospholipid concentration used in the kinetic assay is above the Kd values at that XPC, 
the enzymatic activity is the same. 
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AI.7.2 K44A 
    As observed in the surface dilution assay (Fig. AI-4B), the specific activity of K44A 
for pure PI SUVs and PI/PC (4:1) SUVs was very low, only about 10-20% of the WT 
activity. This corresponds to the results reported before [146] and is in agreement with 
the very high apparent Kd of this mutant protein for pure PG SUVs. The dependence of 
the relative activity on XPC is similar to that seen for WT (Fig. AI-4B). The typical 
surface dilution inhibition of enzyme activity was also observed due to the tight binding 
with vesicles at XPC=0.8. As the only charged residue in both helix B and the 240s’ loop, 
Lys44 is nearby but directed away from Trp47 according crystal structure of 
Y247S/Y251S (which is kinetically similar to wild-type PI-PLC). This position should be 
important for electrostatic interactions with anionic membranes according to both the 
reduced activity and weak binding in pure PI (or PG as an analogue) system. However, 
this lysine does not have a large influence on the PC activation since K44A does not 
change the enzyme activity toward PI/diC7PC and PI/PC SUVs (the PC activation ratio is  
>20%), and the binding to pure PC SUVs was just slightly weaker than WT. These 
results confirmed the importance of this cationic residue for protein binding to surfaces 
rich in negatively charged phospholipids. Clearly, PC facilitates the binding of K44A 
protein with lipid aggregates, resulting in activities comparable to wild-type PI-PLC in 
PC-rich assay systems. 
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Figure AI-4. Membrane binding and activity of BtPI-PLC variants towards SUVs. (A) 
Binding of WT BtPI-PLC and mutant proteins (10 nM) to DOPG/POPC SUVs as a 
function of XPC. The bold dashed line indicated the total phospholipid concentration used 
in kinetic assays. (B) Variation of the specific activity of BtPI-PLC variants towards 
PI/POPC SUVs with 2 mM PI and varying XPC. WT (solid square), K38A (open square), 
K44A (solid circle), R71A (open circle), K44A/R71A (solid triangle), K279A (open 
triangle), and V46K (cross). Error bars reflect S.D. from multiple assays.   
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AI.7.3 R71A and K44A/R71A 
    Arg71 is at top of β-strand but away from the membrane binding surface, and this 
arginine as well as Lys44 are conserved in the bacterial PI-PLCs of various species (e.g., 
Staphylococcus aureus, Enterococcus faecalis, Erwinia amylovora). Except for Lys44, 
Arg71 is the only other cationic residue near the barrel rim that is likely to contribute a 
large positive potential for attracting the protein to the negatively charged interface. 
Based on the results of enzymatic activity in various assays and the binding curve of 
R71A compared with WT BtPI-PLC, this arginine was shown to contribute to the total 
electrostatic interaction of the protein with an anionic membrane. The lower activity in 
pure PI dispersed in Triton X-100 or pure PI SUVs for R71A was due to the weaker 
binding effect of the mutant to anionic lipid surface in binding and kinetic assay 
conditions (the physiological salt concentration in the buffer will weaken purely 
electrostatic binding). However, because of unimpaired PC binding, enzyme activities 
were comparable to WT BtPI-PLC in PC-rich assay systems (PI/diC7PC and PI/PC 
SUVs). A similar surface dilution inhibition and the synergistic effects between anionic 
lipids and PC activator are still observed, indicating that PC still facilitates the interaction 
of the R71A mutant protein with lipid aggregates. This can also include promotion of an 
optimized protein conformation for both binding of substrate and subsequent catalysis.  
    The double mutant K44A/R71A had a significantly lower activity and is the only 
mutant that does not exhibit surface dilution inhibition effect. The binding profile of 
K44A/R71A is quite similar to K44A but with the slightly higher Kds from XPC=0.2 to 
1.0. The Kd at XPC=0 (pure PG SUVs) is too high to be estimated indicated the really 
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impaired anionic lipid binding after removing the two important surface cationic residues. 
Meanwhile, the PC binding affinity is much weaker in K44A/R71A compared to WT and 
other mutant BtPI-PLCs, which may cause the absence of surface dilution inhibition in 
this double mutant protein.  
AI.7.4 K279A 
    This lysine is pointed away from the active site and also not near the region previously 
proposed to be important for membrane interaction (helix B and 240’s loop). Except in 
the pure PI substrate system, all the other activities of K279A are nearly the same as WT. 
This is confirmed by the SUV binding profile showing that only the binding to pure 
anionic phospholipid vesicle is hindered. The PC activation of this mutant is comparable 
to WT and the binding synergy between substrate analogue (PG) and activator (PC) is 
unimpaired. This result also shows that not all surface cationic residues have large effects 
on binding or PC activation. However, missing one of these residues will highly weaken 
the PI binding affinity even if these residues are far away from the active site. On the 
other hand, this mutant can work as a control to further verify that the different PC 
activation observed for K44A and K38A is not just due to the reduced positive charge of 
the surface. 
AI.7.5 V46K 
    Val46 is part of the hydrophobic face in helix B and was proposed to stabilize the 
conformation with Trp47 side chain poised to interact with the membrane. As seen in 
kinetic studies, V46K is more active than WT enzyme towards pure PI or PI/PC SUVs 
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but exhibits reduced PC activation in PI/diC7PC micelles and towards cIP. These kinetics 
results along with the line width broadening experiments suggest that Val46 is important 
for mediating the hydrophobic interaction with PC-rich interface. This mutation that 
changes a hydrophobic side chain to a cationic one should reduce PI-PLC affinity for PC 
vesicles. The FCS experiments show that the affinity of V46K for PC SUVs is decreased 
significantly (the apparent Kd = 21.7±0.5 compared to the Kd = 0.0298±0.0034 mM for 
WT binding to pure PC SUVs). However, introducing one more cationic residue did not 
strengthen the binding of protein to the anionic substrate in the buffer used (PBS 
containing 139 mM salt). The apparent Kds at XPC from 0.2 to 0.8 are nearly the same 
(around 1 mM) and are all lower than the Kds for pure PG or pure PC, which indicates 
that PC and PI still exhibit some synergism for V46K, but for this mutant enzyme the 
tightest binding occurs between XPC=0.7 and XPC=0.9. These results confirm the 
importance of this hydrophobic residue for protein binding to surfaces rich in PC lipids. 
Once bound to a vesicle, the relative weak affinity of V46K for PC still facilitates the 
interaction of the protein with lipid aggregates, resulting in activities nearly double of 
wild-type PI-PLC in SUVs. In this system the added positive charge may enhance 
substrate binding into the active site. In PI/diC7PC and cIP/diC7PC assay system, the 
impaired PC binding interaction has a negative effect on the activity that affects PC 
activation. It appears that substitution of this hydrophobic residue with a charged one 
hinders the interaction between the helix B region and the substrate-containing vesicle (or 
micelle) as well as the subsequent promotion of the protein conformation optimization for 
both binding and catalysis.  
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    Since Val46 was not expected to be a key residue (like Trp47) for membrane insertion, 
these results indicate that introducing a second cationic residue into helix B is likely to 
destabilize either the conformation or stability of this small helix. The dependence of the 
relative activity on XPC was, however, similar to that seen for WT PI-PLC (Fig. AI-5A-
C). With fixed PI, increasing PC caused a substantial increase in activity followed by 
surface dilution inhibition at high XPC (e.g., fixing PI = 2 mM and increasing the total 
concentration of PC). However, by increasing the fixed PI to 4 mM, the surface dilution 
inhibition is dramatically reduced (compare the V46K activity at XPC=0.5 and 0.8). This 
strongly suggests that in WT enzyme this surface dilution inhibition is strong binding of 
the protein to PC and perhaps slower dissociation to find another vesicle with substrate. 
V46K shows higher activity towards all PC-containing SUVs because it has a weaker 
interaction with activator-rich domain. If the substrate concentration is high enough in a 
vesicle (way above Kd for that composition SUV), surface dilution is not observed. 
    Recent field cycling 31P NMR studies of wild-type PI-PLC interacting with 
phosphatidylmethanol (PMe)/PC vesicles (Pu) suggest that enzyme-induced demixing of 
PMe (substrate analogue) and PC (activator) leading to sequestration of the enzyme in 
PC-rich regions resulting in reduced accessibility to substrate. Thus, another comparison 
of V46K and WT was tested by fixing total phospholipid concentration at 1 mM (the 
similar values as the Kds at XPC=0.2, 0.5, 0.8 of V46K) but altering XPC (Fig. AI-5). 
V46K activity is still twice that of WT, which likely reflects that weak binding can help 
the protein to easily dissociate from PC-rich region to access the next substrate. 
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AI.8 Effect of Salt on the Enzymatic Activity  
     Since increasing salt partially shields electrostatic interactions, around 100 mM salt 
(137 mM NaCl, 2 mM KCl, mimic the PBS buffer condition) was added into the assay 
buffer to further explore the roles of these cationic residues. K38A was chosen as the 
example of the Lys mutant group and K279A was used as the control. In this specific 
experiment, the SUVs system with different composition of lipids (PI was fixed at 2 mM 
and PC increased from 0, 0.5, 2 to 8 mM) was used. The activity data (Fig. AI-6) with or 
without salt were plotted together to emphasize the salt effect. All the proteins show 
reduced activity (3-4-fold) towards PI SUVs with salt present (Fig. AI-6A, inset). For 
WT and K279A, the PI cleavage rate was about 40% of that without salt, but for K38A 
and V46K, it was less than 20%. Therefore, in the pure anionic phospholipid system, the 
dominant factor is the electrostatic interaction that binds the protein to the SUV. This will 
be weakened by moderate salt concentrations. A similar rate reduction for K279A and 
WT BtPI-PLC suggested that Lys279 was not the key residue contributing to electrostatic 
interactions. Compared with WT BtPI-PLC, the enzyme activity profile for K279A as a 
function of XPC with salt present is not altered by mutating Lys279 to alanine.  
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Figure AI-5. Specific activities of WT BtPI-PLC (black bars) and V46K BtPI-PLC 
(hatched bars) for cleavage of PI in the different SUV system: (A) fixed [PL]=1 mM; (B) 
fixed [PI]=2 mM; (C) fixed [PI]= 4 mM. [PL] stands for total phospholipid concentration. 
The table shows the Kds at different XPC. Error bars reflect S.D. from multiple assays. 
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    For K38A and V46K, there was a higher reduction in activity toward pure PI with salt 
present. Therefore, along with the different electrostatic interactions (K38A is weaker 
and V46K is stronger), the binding of protein to PI substrate is affected by other factors, 
for example the correlated conformation changes as noted in MD simulations of the 
isolated protein (Chapter 3). With PC incorporated into the vesicles, adding salt usually 
activates the enzyme since the dominant interaction between protein and PC-rich surface 
is the hydrophobic partitioning of Trp and Tyr. This effect can be observed for WT (Fig. 
AI-6A, solid bar and Fig. AI-4B, solid square) with the slightly higher activity in the 
presence of salt at XPC=0.2 and 0.5. For XPC=0.8, the surface dilution inhibition is the 
major effect, so the activity with or without salt was similar. As for K38A, in PI/PC 
mixed vesicles (XPC=0.2, 0.5 and 0.8), addition of salt enhanced the activity so that 
specific activities were always higher than WT (Fig. I-6A, solid bar and shaded bar as 
well as in Fig. AI-4B, open square). Removal of that cationic residue weakens vesicle 
binding – but that may promote easy dissociation from one vesicle onto another. V46K 
exhibited a similar activation profile but with even less surface dilution inhibition with 
slat present. 
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Figure AI-6. Effect of salt on PI cleavage activity of selected BtPI-PLC variants in SUVs. 
(A) Salt effect on specific activities of WT (black bars), K38A (hatched bars), K279A 
(white bars) and V46K (grey hatched bars). The SUVs conditions are the same as Fig. I-
2B. (B) The comparison of rates with and without salt among selected BtPI-PLC variants: 
WT (solid square, solid line), K38A (open square, dashed line), K279A (solid circle, 
dotted line) and V46K (solid triangle, dash dotted line). Error bars reflect S.D. from 
multiple assays.  
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AI.9 Conclusions 
    MD simulations of BtPI-PLC docking to an implicit membrane identified several basic 
residues – K38, K44, K201 and K279 – that could contribute to electrostatic attraction of 
enzyme to a target bilayer. In this work, these cationic residues were substituted by 
alanine to assess the effect on enzyme activities and vesicle binding. Another mutant 
protein, V46K, was constructed to see if an additional positive charge in helix B (a region 
that does contact the bilayer) would enhance enzymatic activity or vesicle binding. For 
most of these mutations, the activity towards pure PI vesicles was substantially decreased 
with removal of one of the cationic residues, even if some of them were fairly distant 
from the active site. In terms of the binding profiles of mutant proteins compared with 
WT, Lys38 and Lys44 were found to be particularly important for PC binding. 
Introducing a cationic residue instead of the hydrophobic residue in short helix B 
(V46K), really impaired the PC binding. However, at high lipid concentration, PC could 
still activate the enzyme. Therefore, almost all of surface charges aid in binding to 
negatively charged vesicles, but for PC activation the effect of removing a cationic 
residue is more complex since weaker binding could facilitate exchange of the protein 
among vesicles. 
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